Professional Documents
Culture Documents
The Fauci COVID-19 Dossier
The Fauci COVID-19 Dossier
This work was supported, in part, by a fund-raising effort in which approximately 330 persons contributed funds in support
of the New Earth technology team and Urban Global Health Alliance. It is released under a Creative Commons license CC-
BY-NC-SA. Any derivative use of this dossier must be made public for the benefit of others. All documents, references and
disclosures contained herein are subject to an AS-IS representation. The author does not bear responsibility for errors in
the public record or references therein. Throughout this document, uses of terms commonly accepted in medical and
scientific literature do not imply acceptance or rejection of the dogma that they represent.
Background:
Over the past two decades, my company – M·CAM – has been monitoring possible violations of the 1925 Protocol for
the Prohibition of the Use in War of Asphyxiating, Poisonous, or other Gases, and of Bacteriological Methods of Warfare
(the Geneva Protocol) 1972 Convention on the Prohibition of the Development, Production, and Stockpiling of
Bacteriological and Toxin Weapons and Their Destruction (the BTWC). In our 2003-2004 Global Technology
Assessment: Vector Weaponization M·CAM highlighted China’s growing involvement in Polymerase Chain Reaction
(PCR) technology with respect to joining the world stage in chimeric construction of viral vectors. Since that time, on a
weekly basis, we have monitored the development of research and commercial efforts in this field, including, but not
limited to, the research synergies forming between the United States Centers for Disease Control and Prevention (CDC),
the National Institutes for Allergies and Infectious Diseases (NIAID), the University of North Carolina at Chapel Hill (UNC),
Harvard University, Emory University, Vanderbilt University, Tsinghua University, University of Pennsylvania, many other
research institutions, and their commercial affiliations.
The National Institute of Health’s grant AI23946-08 issued to Dr. Ralph Baric at the University of North Carolina at
Chapel Hill (officially classified as affiliated with Dr. Anthony Fauci’s NIAID by at least 2003) began the work on
synthetically altering the Coronaviridae (the coronavirus family) for the express purpose of general research, pathogenic
enhancement, detection, manipulation, and potential therapeutic interventions targeting the same. As early as May 21,
2000, Dr. Baric and UNC sought to patent critical sections of the coronavirus family for their commercial benefit.1 In one
of the several papers derived from work sponsored by this grant, Dr. Baric published what he reported to be the full
length cDNA of SARS CoV in which it was clearly stated that SAR CoV was based on a composite of DNA segments.
“Using a panel of contiguous cDNAs that span the entire genome, we have assembled a full-length cDNA of
the SARS-CoV Urbani strain, and have rescued molecularly cloned SARS viruses (infectious clone SARS-CoV)
that contained the expected marker mutations inserted into the component clones.”2
On April 19, 2002 – the Spring before the first SARS outbreak in Asia – Christopher M. Curtis, Boyd Yount, and Ralph
Baric filed an application for U.S. Patent 7,279,372 for a method of producing recombinant coronavirus. In the first
public record of the claims, they sought to patent a means of producing, “an infectious, replication defective,
coronavirus.” This work was supported by the NIH grant referenced above and GM63228. In short, the U.S. Department
of Health and Human Services was involved in the funding of amplifying the infectious nature of coronavirus between
1999 and 2002 before SARS was ever detected in humans.
In short, with Baric’s U.S. Patent 6,593,111 (Claims 1 and 5) and CDC’s ‘852 patent (Claim 1), no research in the United
States could be conducted without permission or infringement.
We noted that gain-of-function specialist, Dr. Ralph Baric, was both the recipient of millions of dollars of U.S. research
grants from several federal agencies but also sat on the World Health Organization’s International Committee on
Taxonomy of Viruses (ICTV) and the Coronaviridae Study Group (CSG). In this capacity, he was both responsible for
determining “novelty” of clades of virus species but directly benefitted from determining declarations of novelty in the
form of new research funding authorizations and associated patenting and commercial collaboration. Together with
CDC, NIAID, WHO, academic and commercial parties (including Johnson & Johnson; Sanofi and their several coronavirus
patent holding biotech companies; Moderna; Ridgeback; Gilead; Sherlock Biosciences; and, others), a powerful group of
interests constituted what we would suggest are “interlocking directorates” under U.S. anti-trust laws.
These entities also were affiliated with the WHO’s Global Preparedness Monitoring Board (GPMB) whose members were
instrumental in the Open Philanthropy-funded global coronavirus pandemic “desk-top” exercise EVENT 201 in October
2019. This event, funded by the principal investor in Sherlock Biosciences and linking interlocking funding partner, the
Bill and Melinda Gates Foundation into the GPMB mandate for a respiratory disease global preparedness exercise to be
completed by September 2020 alerted us to anticipate an “epidemic” scenario. We expected to see such a scenario
emerge from Wuhan or Guangdong China, northern Italy, Seattle, New York or a combination thereof, as Dr. Zhengli Shi
and Dr. Baric’s work on zoonotic transmission of coronavirus identified overlapping mutations in coronavirus in bat
populations located in these areas.
This dossier is by no means exhaustive. It is, however, indicative the numerous criminal violations that may be
associated with the COVID-19 terrorism. All source materials are referenced herein. An additional detailed breakdown
of all the of individuals, research institutions, foundations, funding sources, and commercial enterprises can be accessed
upon request.
18 U.S.C. §2339 C et seq. – Funding and Conspiring to Commit Acts of Terror .................................................................... 7
18 U.S.C. § 2331 §§ 802 – Acts of Domestic Terrorism resulting in death of American Citizens ......................................... 10
Section 101 of the Patent Act provides: "Whoever invents or discovers any new and useful ... composition of matter,
or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements
of this title." 35 U.S.C. § 101.
We have "long held that this provision contains an important implicit exception[:] Laws of nature, natural
phenomena, and abstract ideas are not patentable." Mayo, 566 U.S., at ___, 132 S.Ct., at 1293 (internal quotation
marks and brackets omitted). Rather, "`they are the basic tools of scientific and technological work'" that lie beyond
the domain of patent protection. Id., at ___, 132 S.Ct., at 1293. As the Court has explained, without this exception,
there would be considerable danger that the grant of patents would "tie up" the use of such tools and thereby "inhibit
future innovation premised upon them." Id., at ___, 132 S.Ct., at 1301. This would be at odds with the very point of
patents, which exist to promote creation. Diamond v. Chakrabarty, 447 U.S. 303, 309, 100 S.Ct. 2204, 65 L.Ed.2d 144
(1980) (Products of nature are not created, and "`manifestations... of nature [are] free to all men and reserved
exclusively to none'").3
In their majority opinion in 2013, the U.S. Supreme Court made it abundantly clear that the Court had “long held” that
nature was not patentable. Merely isolating DNA does not constitute patentable subject matter. In their patent, the
CDC made false and misleading claims to the United States Patent & Trademark Office by stating that, “A newly isolated
human coronavirus has been identified as the causative agent of SARS, and is termed SARS-CoV.”4 No “causal” data was
provided for this statement.
When they filed their patent application on April 25, 2003 their first claim (and the only one that survived to ultimate
issuance over the objection of the patent examiner in 2006 and 2007) was the genome for SARS CoV.
While this patent is clearly illegal under 35 U.S.C. §101, not only did the CDC insist on its granting over non-final and final
rejections, but they also continued to pay maintenance fees on the patent after the 2013 Supreme Court decision
confirmed that it was illegal.
In addition, the CDC patented the detection of SARS CoV using a number of methods including reverse transcription
polymerase chain reaction (RT-PCR). With this patent, they precluded anyone outside of their licensed or conspiring
interest from legally engaging in independent verification of their claim that they had isolated a virus, that it was a
causative agent for SARS, or that any therapy could be effective against the reported pathogen.
It is important to note that the CDC’s patent applications were also rejected in non-final and final rejections for
ineligibility under 35 U.S.C. § 102 for being publicly disclosed prior to their own filing. In the first non-final rejection, the
USPTO stated that the CDC’s genome was published in four Genbank accession entries on April 14, 18, and 21, 2003 with
identity ranging from 96.8% to 99.9% identical sequences.5 Dr. Fauci knew, and failed to disclose evidence that the CDC
patent was illegal, based on work he had funded in the years leading up to the SARS outbreak.
After seeking an illegal patent, petitioning to override the decision of an examiner to reject it, and ultimately prevailing
with the patent’s grant, the CDC lied to the public by stating they were controlling the patent so that it would be
“publicly available”.6 Tragically, this public statement is falsified by the simple fact that their own publication in
3 Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013)
4 U.S. Patent 7,220,852
5 USPTO Non-Final Rejection File #10822904, September 7, 2006, page 4.
6
https://apnews.com/article/145b4e8d156cddc93e996ae52dc24ec0
Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 5
Genbank had, in fact, made it public domain and thereby unpatentable. This fact, confirmed by patent examiners, was
overridden by CDC in a paid solicitation to override the law.
While not covered under 35 U.S.C. §101, Dr. Fauci’s abuse of the patent law is detailed below. Of note, however, is his
willful and deceptive use of the term “vaccine” in patents and public pronouncements to pervert the meaning of the
term for the manipulation of the public.
In the 1905 Jacobson v. Mass case, the court was clear that a PUBLIC BENEFIT was required for a vaccine to be
mandated. Neither Pfizer nor Moderna have proved a disruption of transmission. In Jacobson v. Massachusetts, 197 U.S.
11 (1905), the court held that the context for their opinion rested on the following principle:
“This court has more than once recognized it as a fundamental principle that 'persons and property are subjected to all
kinds of restraints and burdens in order to secure the general comfort, health, and prosperity of the state…”
The Moderna and Pfizer “alleged vaccine” trials have explicitly acknowledged that their gene therapy technology has no
impact on viral infection or transmission whatsoever and merely conveys to the recipient the capacity to produce an S1
spike protein endogenously by the introduction of a synthetic mRNA sequence. Therefore, the basis for the
Massachusetts statute and the Supreme Court’s determination is moot in this case.
Further, the USPTO, in its REJECTION of Anthony Fauci's HIV vaccine made the following statement supporting their
rejection of his bogus "invention"
By no later than April 11, 2005, Dr. Anthony Fauci was publicly acknowledging the association of SARS with bioterror
potential. Leveraging the fear of the anthrax bioterrorism of 2001, he publicly celebrated the economic boon that
domestic terror had directed towards his budget. He specifically stated that NIAID was actively funding research on a
“SARS Chip” DNA microarray to rapidly detect SARS (something that was not made available during the current
“pandemic”) and two candidate vaccines focused on the SARS CoV spike protein.7 Led by three Chinese researchers
under his employment – Zhi-yong Yang, Wing-pui Kong, and Yue Huang – Fauci had at least one DNA vaccine in animal
trials by 2004.8 This team, part of the Vaccine Research Center at NIAID, was primarily focused on HIV vaccine
development but was tasked to identify SARS vaccine candidates as well. Working in collaboration with Sanofi, Scripps
Institute, Harvard, MIT and NIH, Dr. Fauci’s decision to unilaterally promote vaccines as a primary intervention for
several designated “infectious diseases” precluded proven therapies from being applied to the sick and dying.9
The CDC and NIAID led by Anthony Fauci entered into trade among States (including, but not limited to working with
EcoHealth Alliance Inc.) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy
of Sciences) through the 2014 et seq National Institutes of Health Grant R01AI110964 to exploit their patent rights. This
research was known to involve surface proteins in coronavirus that had the capacity to directly infect human respiratory
systems. In flagrant violation of the NIH moratorium on gain of function research, NIAID and Ralph Baric persisted in
working with chimeric coronavirus components specifically to amplify the pathogenicity of the biologic material.
By October 2013, the Wuhan Institute of Virology 1 coronavirus S1 spike protein was described in NIAID’s funded work
in China. This work involved NIAID, USAID, and Peter Daszak, the head of EcoHealth Alliance. This work, funded under
R01AI079231, was pivotal in isolating and manipulating viral fragments selected from sites across China which contained
high risk for severe human response.10
By March 2015, both the virulence of the S1 spike protein and the ACE II receptor was known to present a considerable
risk to human health. NIAID, EcoHealth Alliance and numerous researchers lamented the fact that the public was not
sufficiently concerned about coronavirus to adequately fund their desired research.11
7 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320336/
8 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095382/
9 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232869/
10 Ge, XY., Li, JL., Yang, XL. et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503, 535–538
(2013).
11 Forum on Medical and Public Health Preparedness for Catastrophic Events; Forum on Drug Discovery, Development, and Translation; Forum on
Microbial Threats; Board on Health Sciences Policy; Board on Global Health; Institute of Medicine; National Academies of Sciences, Engineering,
and Medicine. Rapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and
Private-Sector Partnerships: Workshop Summary. Washington (DC): National Academies Press (US); 2016 Feb 12. 6, Developing MCMs for
Coronaviruses. Available from: https://www.ncbi.nlm.nih.gov/books/NBK349040/
Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 7
“Daszak reiterated that, until an infectious disease crisis is very real, present, and at an emergency threshold, it is often
largely ignored. To sustain the funding base beyond the crisis, he said, we need to increase public understanding of the
need for MCMs such as a pan-influenza or pan-coronavirus vaccine. A key driver is the media, and the economics follow
the hype. We need to use that hype to our advantage to get to the real issues. Investors will respond if they see profit at
the end of process, Daszak stated.”12
The CDC and NIAID entered into trade among States (including, but not limited to working with University of North
Carolina, Chapel Hill) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of
Sciences represented by Zheng-Li Shi) through U19AI109761 (Ralph S. Baric), U19AI107810 (Ralph S. Baric), and National
Natural Science Foundation of China Award 81290341 (Zheng-Li Shi) et al. 2015-2016. These projects took place during
a time when the work being performed was prohibited by the United States National Institutes of Health.
The public was clearly advised of the dangers being presented by NIAID-funded research by 2015 and 2016 when the
Wuhan Institute of Virology material was being manipulated at UNC in Ralph Baric’s lab.
“The only impact of this work is the creation, in a lab, of a new, non-natural risk,” agrees Richard Ebright, a molecular
biologist and biodefence expert at Rutgers University in Piscataway, New Jersey. Both Ebright and Wain-Hobson are
long-standing critics of gain-of-function research.
In their paper, the study authors also concede that funders may think twice about allowing such experiments in the
future. "Scientific review panels may deem similar studies building chimeric viruses based on circulating strains too risky
to pursue," they write, adding that discussion is needed as to "whether these types of chimeric virus studies warrant
further investigation versus the inherent risks involved”.
But Baric and others say the research did have benefits. The study findings “move this virus from a candidate emerging
pathogen to a clear and present danger”, says Peter Daszak, who co-authored the 2013 paper. Daszak is president of the
EcoHealth Alliance, an international network of scientists, headquartered in New York City, that samples viruses from
animals and people in emerging-diseases hotspots across the globe.
Studies testing hybrid viruses in human cell culture and animal models are limited in what they can say about the threat
posed by a wild virus, Daszak agrees. But he argues that they can help indicate which pathogens should be prioritized for
further research attention.”13
Knowing that the U.S. Department of Health and Human Services (through CDC, NIH, NIAID, and their funded
laboratories and commercial partners) had patents on each proposed element of medical counter measures and their
funding, Dr. Fauci, Dr. Gao (China CDC), and Dr. Elias (Bill and Melinda Gates Foundation) conspired to commit acts of
terror on the global population – including the citizens of the United States – when, in September 2019, they published
the following mandate:
“Countries, donors and multilateral institutions must be prepared for the worst. A rapidly spreading pandemic due to a
lethal respiratory pathogen (whether naturally emergent or accidentally or deliberately released) poses additional
preparedness requirements. Donors and multilateral institutions must ensure adequate investment in developing
innovative vaccines and therapeutics, surge manufacturing capacity, broad-spectrum antivirals and appropriate non-
pharmaceutical interventions. All countries must develop a system for immediately sharing genome sequences of any
12 Ibid.
13 https://www.nature.com/news/engineered-bat-virus-stirs-debate-over-risky-research-%201.18787
Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 8
new pathogen for public health purposes along with the means to share limited medical countermeasures across
countries.
• Donors and countries commit and identify timelines for: financing and development of a universal influenza
vaccine, broad spectrum antivirals, and targeted therapeutics. WHO and its Member States develop options for
standard procedures and timelines for sharing of sequence data, specimens, and medical countermeasures for
pathogens other than influenza.
• Donors, countries and multilateral institutions develop a multi-year plan and approach for strengthening R&D
research capacity, in advance of and during an epidemic.
• WHO, the United Nations Children’s Fund, the International Federation of Red Cross and Red Crescent Societies,
academic and other partners identify strategies for increasing capacity and integration of social science
approaches and researchers across the entire preparedness/response continuum.”14
As if to confirm the utility of the September 2019 demand for “financing and development of” vaccine and the fortuitous
SARS CoV-2 alleged outbreak in December of 2019, Dr. Fauci began gloating that his fortunes for additional funding were
likely changing for the better. In a February 2020 interview in STAT, he was quoted as follows:
““The emergence of the new virus is going to change that figure, likely considerably, Fauci said. “I don’t know how much
it’s going to be. But I think it’s going to generate more sustained interest in coronaviruses because it’s very clear that
coronaviruses can do really interesting things.””15
14 https://apps.who.int/gpmb/assets/annual_report/GPMB_annualreport_2019.pdf (page 8)
15 https://www.statnews.com/2020/02/10/fluctuating-funding-and-flagging-interest-hurt-coronavirus-research/
Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 9
18 U.S.C. § 2331 §§ 802 – Acts of Domestic Terrorism resulting in death of
American Citizens
Section 802 of the USA PATRIOT Act (Pub. L. No. 107-52) expanded the definition of terrorism to cover "domestic," as
opposed to international, terrorism. A person engages in domestic terrorism if they do an act "dangerous to human
life" that is a violation of the criminal laws of a state or the United States, if the act appears to be intended to: (i)
intimidate or coerce a civilian population; (ii) influence the policy of a government by intimidation or coercion;
Dr. Anthony Fauci has intimidated and coerced a civilian population and sought to influence the policy of a government
by intimidation and coercion.
With no corroboration, Dr. Anthony Fauci promoted16 Professor Neil Ferguson’s computer simulation derived claims
that,
“The world is facing the most serious public health crisis in generations. Here we provide concrete estimates of the
scale of the threat countries now face.
“We use the latest estimates of severity to show that policy strategies which aim to mitigate the epidemic might
halve deaths and reduce peak healthcare demand by two-thirds, but that this will not be enough to prevent health
systems being overwhelmed. More intensive, and socially disruptive interventions will therefore be required to
suppress transmission to low levels. It is likely such measures – most notably, large scale social distancing – will need
to be in place for many months, perhaps until a vaccine becomes available.” 17
Reporting to the President that as many as 2.2 million deaths may result from a pathogen that had not yet been isolated
and could not be measured with any accuracy, Dr. Fauci intimidated and coerced the population and the government
into reckless, untested, and harmful acts creating irreparable harm to lives and livelihoods.18 Neither the Imperial
College nor the “independent” Institute for Health Metrics and Evaluation (principally funded by the Bill and Melinda
Gates Foundation)19 had any evidence of success in estimating previous burdens from coronavirus but, without
consultation or peer-review, Dr. Fauci adopted their terrifying estimates as the basis for interventions that are explicitly
against medical advice.
The imposition of social distancing was based on computer simulation and environmental models with NO
disease transmission evidence whatsoever.
The imposition of face mask wearing was directly against controlled clinical trial evidence and against the
written policy in the Journal of the American Medical Association.
“Face masks should not be worn by healthy individuals to protect themselves from acquiring respiratory
infection because there is no evidence to suggest that face masks worn by healthy individuals are
effective in preventing people from becoming ill.”20
In both the Imperial College and the IHME simulations, quarantines were modeled for the sick, not the healthy.
16 https://www.cato.org/blog/did-mitigation-save-two-million-lives
17 https://www.imperial.ac.uk/news/196234/covid-19-imperial-researchers-model-likely-impact/
18 https://www.npr.org/2020/03/31/823916343/coronavirus-task-force-set-to-detail-the-data-that-led-to-extension-of-guideline
19 https://www.gatesfoundation.org/Media-Center/Press-Releases/2017/01/IHME-Announcement
20
https://jamanetwork.com/journals/jama/fullarticle/2762694?fbclid=IwAR2RE-c4V-fhUodui0JQRbiHRcgEJuDKG_21N4oL5zAfciQfWCyHAsetJmo
Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 10
Insisting on vaccines while blockading the emergency use of proven pharmaceutical interventions may have contributed
to the death of many patients and otherwise healthy individuals.21
Using the power of NIAID during the alleged pandemic, Dr. Anthony Fauci actively suppressed proven medical
countermeasures used by, and validated in scientific proceedings, that offered alternatives to the products funded by his
conspiring entities for which he had provided direct funding and for whom he would receive tangible and intangible
benefit.
21 https://www.reuters.com/investigates/special-report/health-coronavirus-usa-cost/
Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 11
18 U.S.C. § 1001 – Lying to Congress
(a)Except as otherwise provided in this section, whoever, in any matter within the jurisdiction of the executive,
legislative, or judicial branch of the Government of the United States, knowingly and willfully—
(1) falsifies, conceals, or covers up by any trick, scheme, or device a material fact;
(2) makes any materially false, fictitious, or fraudulent statement or representation; or
(3) makes or uses any false writing or document knowing the same to contain any materially false, fictitious,
or fraudulent statement or entry;
shall be fined under this title, imprisoned not more than 5 years or, if the offense involves international or domestic
terrorism (as defined in section 2331), imprisoned not more than 8 years, or both. If the matter relates to an offense
under chapter 109A, 109B, 110, or 117, or section 1591, then the term of imprisonment imposed under this section
shall be not more than 8 years.
On October 22, 2020, the United States Government Accountability Office (GAO) published a report entitled:
BIOMEDICAL RESEARCH: NIH Should Publicly Report More Information about the Licensing of Its Intellectual Property.
In this document, the authors reported that the National Institutes of Health (NIH) received, “up to $2 billion in royalties
from its contributions to 34 drugs sold from 1991-2019.”22
A casual review of the NIH Office of Technology Transfer report of active licenses23 appears to conflict with the GAO
report on several important facts. Conspicuously absent from the GAO report are over 30 patents associated with active
compounds generating billions of dollars in revenue. Why would it be that the GAO and the NIH couldn’t agree on
something as simple as drugs generating income for NIH?
Since the passage of the Bayh Dole Act (Pub. L. 96-517, December 12, 1980), federally funded research has been an
economic bonanza for U.S. universities, federal agencies, and their selected patronage. For the first decade following
Bayh Dole, NIH funding doubled from $3.4 billion to $7.1 billion. A decade later, it doubled again to $15.6 billion. In the
wake of September 2001, the National Institute for Allergy and Infectious Diseases (NIAID) saw its direct budget increase
over 300% without accounting for DARPA funds of as much as $1.7 billion annually from 2005 forward. In 2020, NIH’s
budget was over $41 billion.
What has become of the $763 billion of taxpayer funds allocated to making America healthier since inventors have been
commercially incentivized? Who has been enriched?
The NIH is the named owner of at least 138 patents since 1980.
The United States Department of Health and Human Services is the named owner of at least 2,600 patents.
NIAID grants or collaboration have resulted in 2,655 patents and patent applications of which only 95 include an
assignment to the Department of Health and Human Services as an owner. Most of these patents are assigned to
universities thereby making the ultimate commercial beneficiaries entirely opaque. One of the largest holders is SIGA
Technologies (NASDAQ: SIGA) who, while publicly reporting close affiliation with NIAID, is not referenced in the NIH GAO
report. SIGA’s CEO, Dr. Phillip L. Gomez spent 9 years at NIAID developing its vaccine program for HIV, SARS, Ebola,
West Nile Virus, and Influenza before exiting to commercial ventures. While their technology is clearly derived from
NIAID science, the company reports revenue from NIAID but no royalty or commercial payments to NIH or any of its
programs.
22 https://www.gao.gov/products/GAO-21-52
23 https://www.ott.nih.gov/reportsstats/hhs-license-based-vaccines-therapeutics
Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 12
NIAID’s Director, Dr. Anthony Fauci is listed as an inventor on 8 granted U.S. patents. None of them are reported in
NIAID, NIH, or GAO reports of active licensing despite the fact that Dr. Fauci reportedly was compelled to get paid for his
interleukin-2 “invention” – payments he reportedly donated to an unnamed charity.24
Of the 21 patents listed in the U.S. Food and Drug Administration’s (FDA) Orange book itemized in the GAO report, none
of Dr. Anthony Fauci’s patents are listed. Furthermore, none of the NIAID patents are listed despite clear evidence that
Gilead Sciences and Janssen Pharmaceuticals (a division of Johnson & Johnson) have generated over $2 billion annually
from sales that were the direct result of NIAID funded science. Missing from the GAO report are 2 patents for Velclade®
which has been generating sales in excess of $2.18 billion annually for several years. None of the patents for Yescarta®
are listed in the GAO report. None of the Lumoxiti® patents are listed in the GAO report. None of the Kepivance®
patents are listed in the GAO report. In violation of 37 USC §410.10 and 35 USC §202(a), over 13 of the 21 patents in the
GAO report fail to disclose government interest despite being the direct result of NIH funding.
US Patent 6,190,656 and 6,548,055 Immunologic enhancement with intermittent interleukin-2 therapy
A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected
intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in
peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows
the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in
peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This
intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-
retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2
administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. By this
approach the cells are first activated in vivo via the aforementioned IL-2 therapy, and transduction then is effected by
delivering a genetically engineered retroviral vector directly to the patient.
This application is a continuation of U.S. patent application Ser. No. 08/487,075, filed Jun. 7, 1995, now abandoned,
which is a continuation in part of U.S. patent application Ser. No. 08/063,315, filed May 19, 1993, now issued as U.S. Pat.
No. 5,419,900, and U.S. patent application Ser. No. 08/452,440, filed May 26, 1995, now issued as U.S. Pat. No.
5,696,079, which is the National Stage filed under 35 USC 371 of PCT/US94/05397, filed May 19, 1994, the contents of
which are incorporated herein by reference.
Issued a Final Rejection January 20, 1998. Rejected after abandonment August 14, 1998 and April 12, 1999. Reduced
and modified claims granted May 8, 2000.
This family of patents was the basis of Fauci’s lie to the British Medical Journal in which he falsely stated:
“Dr Anthony Fauci told the BMJ that as a government employee he was required by law to put his name on the patent for
the development of interleukin 2 and was also required by law to receive part of the payment the government received
for use of the patent. He said that he felt it was inappropiate (sic) to receive payment and donated the entire amount to
charity.”25
He was not “required by law” to commit fraud on the patent office and then get paid for it!
24 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC545012/
25 Ibid.
Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 13
US Patent 6,911,527 HIV related peptides
This invention is the discovery of novel specific epitopes and antibodies associated with long term survival of HIV-1
infections. These epitopes and antibodies have use in preparing vaccines for preventing HIV-1 infection or for controlling
progression to AIDS.
Rejected as unpatentable January 22, 2003. Issued with a final rejection on July 15, 2004 after submitting
reconsideration requests. Modified and restricted claims allowed September 29, 2004.
Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a
portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy
chain. The portion or the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of
the heavy chain of an IgA antibody ara tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed
herein are methods for using these CD4 fusion proteins.
Rejected as unpatentable August 18, 2006. Paid appeal to overturn examiner’s findings February 15, 2007. Rejected
again May 11, 2007. On October 10, 2007 applicants further narrowed the construction of what was clearly not a patent
and the USPTO granted less than half the claims that had been sought in the original filing.
US Patent 9,896,509, 9,193,790 and 9,441,041 Use of antagonists of the interaction between HIV GP120 and
.alpha.4.beta.7 integrin
Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an
HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and .alpha.4
integrin, such as a .alpha.4.beta.1 or .alpha.4.beta.7 integrin antagonist, thereby treating the HIV infection. In several
examples, the .alpha.4 integrin antagonist is a monoclonal antibody that specifically binds to a .alpha.4, .beta.1 or
.beta.7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to
reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that
interferes with the interaction of gp120 and .alpha.4 integrin, such as a .alpha.4.beta.1 or .alpha.4.beta.7 integrin
antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.
Rejected May 22, 2017 as Double Patenting. In their response, the applicants acknowledge the illegal act and seek only
those components of their application that extend beyond the life of the issued patents. On October 11, 2017, the limited
claims were issued.
U.S. Patent 8,999,351 was issued to Tekmira Pharmaceuticals Corporation in Burnaby, British Columbia. In their patent,
they disclose that their research was supported by a grant from the National Institute of Allergy and Infectious Disease
(Grant HHSN266200600012C). Ironically, this $23 million grant was awarded in 2006 to Alnylam Pharmaceuticals, Inc.,
not to Tekmira.26
26
https://www.technologynetworks.com/genomics/news/alnylam-awarded-23-million-us-government-contract-to-develop-rnai-therapeutics-
186097
Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 14
In 2012, Alnylam agreed to pay Tekmira $65 million to settle legal disputes including a $1 billion damages claim for
“relentless and egregious” misappropriation of Tekmira’s trade secrets. From the patent filing’s earliest priority of
November 10, 2008, there is no public record stating Tekmira as the beneficiary of this NIAID grant. Notwithstanding,
the lipid nanoparticle technology developed from this grant is the technology now used in the Moderna COVID-19
intervention. In their 10-Q filing, Alnylam reports to have a license to technology from Arbutus – formerly Tekmira –
which has accused Acuitas of misappropriating trade secrets and licensing them to Moderna and Pfizer’s collaboration
with BioNTech.
https://www.ott.nih.gov/nih-and-its-role-technology-transfer
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/206288Orig1s000TAltr.pdf
https://www.gao.gov/assets/720/710287.pdf
https://grantome.com/search?q=%22National%20Institute%20of%20Allergy%20and%20Infectious%20Diseases%22
The National Institute of Health’s grant AI23946-08 issued to Dr. Ralph Baric at the University of North Carolina at
Chapel Hill (officially classified as affiliated with Dr. Anthony Fauci’s NIAID by at least 2003) began the work on
synthetically altering the Coronaviridae (the coronavirus family) for the express purpose of general research, pathogenic
enhancement, detection, manipulation, and potential therapeutic interventions targeting the same. As early as May 21,
2000, Dr. Baric and UNC sought to patent critical sections of the coronavirus family for their commercial benefit.27 In
one of the several papers derived from work sponsored by this grant, Dr. Baric published what he reported to be the full
length cDNA of SARS CoV in which it was clearly stated that SAR CoV was based on a composite of DNA segments.
“Using a panel of contiguous cDNAs that span the entire genome, we have assembled a full-length cDNA of
the SARS-CoV Urbani strain, and have rescued molecularly cloned SARS viruses (infectious clone SARS-CoV)
that contained the expected marker mutations inserted into the component clones.”28
On April 19, 2002 – the Spring before the first SARS outbreak in Asia – Christopher M. Curtis, Boyd Yount, and Ralph
Baric filed an application for U.S. Patent 7,279,372 for a method of producing recombinant coronavirus. In the first
public record of the claims, they sought to patent a means of producing, “an infectious, replication defective,
coronavirus.” This work was supported by the NIH grant referenced above and GM63228. In short, the U.S. Department
of Health and Human Services was involved in the funding of amplifying the infectious nature of coronavirus between
1999 and 2002 before SARS was ever detected in humans.
Against this backdrop, we noted the unusual patent prosecution efforts of the CDC, when on April 25, 2003 they sought
to patent the SARS coronavirus isolated from humans that had reportedly transferred to humans during the 2002-2003
SARS outbreak in Asia. 35 U.S.C. §101 prohibits patenting nature. This legality did not deter CDC in their efforts. Their
application, updated in 2007, ultimately issued as U.S. Patent 7,220,852 and constrained anyone not licensed by their
patent from manipulating SARS CoV, developing tests or kits to measure SARS coronavirus in humans or working with
their patented virus for therapeutic use. Work associated with this virus by their select collaborators included
considerable amounts of chimeric engineering, gain-of-function studies, viral characterization, detection, treatment
(both vaccine and therapeutic intervention), and weaponization inquiries.
In short, with Baric’s U.S. Patent 6,593,111 (Claims 1 and 5) and CDC’s ‘852 patent (Claim 1), no research in the United
States could be conducted without permission or infringement.
We noted that gain-of-function specialist, Dr. Ralph Baric, was both the recipient of millions of dollars of U.S. research
grants from several federal agencies but also sat on the World Health Organization’s International Committee on
Taxonomy of Viruses (ICTV) and the Coronaviridae Study Group (CSG). In this capacity, he was both responsible for
determining “novelty” of clades of virus species but directly benefitted from determining declarations of novelty in the
form of new research funding authorizations and associated patenting and commercial collaboration. Together with
CDC, NIAID, WHO, academic and commercial parties (including Johnson & Johnson; Sanofi and their several coronavirus
patent holding biotech companies; Moderna; Ridgeback; Gilead; Sherlock Biosciences; and, others), a powerful group of
interests constituted what we would suggest are “interlocking directorates” under U.S. anti-trust laws.
1990 Pfizer files U.S. Patent 6,372,224 on a vaccine for the S-protein on coronavirus November 14, 2000
which was abandoned April 2010 making it public domain.
2000 Ralph Baric AI23946 and GM63228 from the National Institutes of Health actively working recombinant
CoV
2001 National Institute of Health, Allergy and Infectious diseases. “Reverse Genetics with a Coronavirus
Infectious cDNA Construct.” 4/1/2001-3/31/005 $1.0 million total costs/yr. RS Baric, PI
2003 April 25, 2003 CDC Patent filed and ultimately becomes US7,220,852 (the patent on the RNA
sequence) and 7,776,521 (the patent on the testing methodology. These patents give the U.S.
Department of Health and Human Services the ability to control the commercial exploitation of SARS
coronavirus.
Dr. Anthony Fauci appointed to the Bill and Melinda Gates Foundation’s Global Grand Challenges
Scientific Advisory Board (served through 2010).
April 28, 2003 Sequoia Pharmaceuticals $953K for pathogen response and patent US7,151,163
https://www.sbir.gov/node/305319
July 21, 2003 Ralph Baric’s team (using AI23946 and GM63228) file U.S. Patent 7,618,802 which issued
on November 17, 2009. https://patents.google.com/patent/US7618802B2
Dana Farber Cancer Institute files U.S. Patent 7,750,123 on a monoclonal antibody to neutralize SARS
CoV. This research is supported by several NIH grants including National Institutes of Health Grants
A128785, A148436, and A1053822.
2004 January 6, 2004 – SARS and Bioterrorism linked at Bioterrorism and Emerging Infectious Diseases:
antimicrobials, therapeutics and immune modulators.
https://tks.keystonesymposia.org/index.cfm?e=web.meeting.program&meetingid=706
At this conference, the term “The New Normal” was introduced by Merck
FAUCI AND BARIC start making money!!! National Institutes of Health, Allergy and Infectious Diseases.
SARS Reverse Genetics. AI059136-01. $1.7 million total costs, RS Baric, PI. 10% effort. 4/1/04- 3/31/09.
The project develops a SARS-CoV full length infectious cDNA, the development of SARS-CoV replicon
particles expressing heterologous genes, and seeks to adapt SARS-CoV to mice, producing a pathogenic
mouse model for SARS-CoV infection.
Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 17
National Institutes of Health, Allergy and Infectious Diseases. R01. Remodeling the SARS Coronavirus
Genome Regulatory Network. RS Baric, PI 10% effort. 7/1/04-6/30/09. $2.1 million
November 22, 2004 University of Hong Kong patents SARS associated spike protein on CoV and
pursues patent US 7,491,489
2005 DARPA gets in on the game Synthetic Coronaviruses. Biohacking: Biological Warfare Enabling
Technologies, June 2005. Washington, DC. DARPA/MITRE sponsored event. Invited Speaker
2008 Biodefense Grant U54 AI057157 commences with $10,189,682 to UNC Chapel Hill
https://taggs.hhs.gov/Detail/AwardDetail?arg_awardNum=U54AI057157&arg_ProgOfficeCode=104
2009 Biodefense Grant U54 AI057157 continues with $5,448,656 to UNC Chapel Hill (non-competitive grant
from NIAID)
2010 Biodefense Grant U54 AI057157 continues with $8,747,142 to UNC Chapel Hill (non-competitive grant
from NIAID)
Patent issuance for SARS coronavirus patents peak post the Asia outbreak at 391 issued patents.
August 6, 2010, Moderna (prior to its establishment) files U.S. Patent 9,447,164 which attracted the
investment of (and “inventorship” for) venture capitalists at Flagship Ventures. This patent grew out of
the work of Dr. Jason P. Schrum of Harvard Medical School supported by National Science Foundation
Grant #0434507. While the application claims priority to August 2010, the application didn’t get
finalized until October, 2015. On November 4, 2015, the USPTO issued a non-final rejection on this
original patent rejecting all claims.
https://www.nsf.gov/awardsearch/showAward?AWD_ID=0434507 with reference to the grant funding
in
https://molbio.mgh.harvard.edu/szostakweb/publications/Szostak_pdfs/Schrum_et_al_JACS_2009.pdf
2011 Crucell joined the Janssen Pharmaceutical Companies of Johnson & Johnson in February taking with it all
of its SARS technology.
Biodefense Grant U54 AI057157 continues with $7,344,820 to UNC Chapel Hill (non-competitive grant
from NIAID)
Biodefense Grant U54 AI057157 continues with $7,627,657 to UNC Chapel Hill (non-competitive grant
from NIAID)
2013 Biodefense Grant U54 AI057157 continues with $7,226,237 to UNC Chapel Hill (non-competitive grant
from NIAID)
2014 April 23, 2014, Moderna files patent on nucleic acid vaccine with Patents US9872900 and US10022435
2016 NIH through Scripps Institute and Dartmouth College file patent application WO 2018081318A1
“Prefusion Coronavirus Spike Proteins and their Use” disclosing mRNA technology that overlaps (and is
used in tandem with) Moderna’s technology.
https://patents.google.com/patent/WO2018081318A1/en Lead Inventor Barney Scott Graham was well
known to Moderna as he’s the person at NIH that Moderna “e-mailed” to get the sequence for SARS
CoV-2 according to Moderna’s report here (“In January 2020, once it was discovered that the infection in
Wuhan was caused by a novel coronavirus, Bancel quickly emailed Dr. Barney Graham, deputy director
of the Vaccine Research Center at the National Institutes of Health, asking him to send the genetic
sequence for the virus.”) https://www.wsws.org/en/articles/2020/05/26/vacc-m26.html
In addition, co-inventor Jason McLellan worked with Graham on a vaccine patent jointly owned with the
Chinese government filed in Australia in 2013
https://patents.google.com/patent/AU2014231357A1/en?inventor=Jason+MCLELLAN.
2017 August – Sanofi buys Protein Science Corp with considerable SARS patent holdings
2018 June – Sanofi buys Ablynx with considerable SARS patent holdings
Through non-competitive grant awards to UNC Chapel Hill’s Ralph Baric, to selection of the Bio-Safety Level 4 laboratory
locations, to the setting of prices for Remdesivir and mRNA therapies from Moderna and Pfizer, NIAID, CDC, and the U.S.
Department of Health and Human Services have been involved in allocating Federal funds to conspiring parties without
independent review.
Around March 12, 2020, in an effort to enrich their own economic interests by way of securing additional funding from
both Federal and Foundation actors, the CDC and NIAID’s Dr Fauci elected to suspend testing and classify COVID-19 by
capricious symptom presentation alone. Forcing the public to rely on The COVID Tracking Project – funded by the
Bloomberg, Zuckerberg and Gates Foundation and presented by a media outlet (The Atlantic) – not a public health
agency – Dr. Fauci used fraudulent testing technology (RT-PCR) to conflate “COVID cases” with positive PCR tests in the
living while insisting that COVID deaths be counted by symptoms alone. This perpetuated a market demand for his
desired vaccine agenda which was recited by him and his conspiring parties around the world until the present. Not
surprisingly, this was necessitated by the apparent fall in cases that constituted Dr. Fauci’s and others’ criteria for
depriving citizens of their 1st Amendment rights.
Dr. Fauci is on the Leadership Council of the Bill and Malinda Gates Global Vaccine Action Plan
Dr. Fauci while controlling the economic dispensation of Federal research funding, Dr. Fauci has been, and continues to
be, on the World Health Organization’s Global Preparedness Monitoring Board. He is joined on this board by the
conflicted donor from the Bill and Melinda Gates Foundation’s Dr. Chris Elias and the State Council of China’s Dr. George
F. Gao of the Chinese CDC. This GPMB stipulated that all member states must take part in a global simulation of the
release of a respiratory pathogen.
Dr. Baric is one of the primary beneficiaries of U.S. Federal funds, runs a BSL-4 facility and sits on the International
Committee on Taxonomy of Virus Coronaviridae Working Group tasked to confirm the presence of absence of the
pathogen for which he is directly compensated.
As referenced in the section covering violations of 18 U.S.C. § 1001 above, numerous undisclosed commercial
relationships exist between funded researchers, their funding agencies, and commercial interests in which disclosed and
undisclosed commercial terms exist. A complete list of all potential implicated parties is listed in the section below
entitled “The Commercial Actors”.
It appears that, during the period of patent enforcement and after the Supreme Court ruling confirming that patents on
genetic material were illegal, the CDC and National Institute of Allergy and Infectious Diseases led by Anthony Fauci
(hereinafter “NIAID” and "Dr Fauci", respectively) entered into trade among States (including, but not limited to working
with Ecohealth Alliance Inc.) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese
Academy of Sciences) through the 2014 et seq National Institutes of Health Grant R01AI110964 to exploit their patent
rights.
It further appears that, during the period of patent enforcement and after the Supreme Court ruling confirming that
patents on genetic material was illegal, the CDC and National Institute of Allergy and Infectious Diseases (hereinafter
“NIAID”) entered into trade among States (including, but not limited to working with University of North Carolina,
Chapel Hill) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of Sciences
represented by Zheng-Li Shi) through U19AI109761 (Ralph S. Baric), U19AI107810 (Ralph S. Baric), and National Natural
Science Foundation of China Award 81290341 (Zheng-Li Shi) et al. 2015-2016.
It further appears that, during the period of patent enforcement and after the Supreme Court ruling confirming that
patents on generic material was illegal, the CDC and NIAID entered into trade among States (including, but not limited to
working with University of North Carolina, Chapel Hill) and with foreign nations to conduct chimeric construction of
novel coronavirus material with specific virulence properties prior to, during, and following the determination made by
the National Institutes for Health in October 17, 2014 that this work was not sufficiently understood for its biosecurity
and safety standards.
In this inquiry, it is presumed that the CDC and its associates were: a) fully aware of the work being performed using
their patented technology; b) entered into explicit or implicit agreements including licensing, or other consideration;
and, c) willfully engaged one or more foreign interests to carry forward the exploitation of their proprietary technology
Reportedly, in January 2018, the U.S. Embassy in China sent investigators to Wuhan Institute of Virology and found that,
“During interactions with scientists at the WIV laboratory, they noted the new lab has a serious shortage of
appropriately trained technicians and investigators needed to safely operate this high-containment laboratory.” The
Washington Post reported that this information was contained in a cable dated 19 January 2018. Over a year later, in
June 2019, the CDC conducted an inspection of Fort Detrick’s U.S. Army Medical Research Institute of Infectious Diseases
(hereinafter “USAMRIID”) and ordered it closed after alleging that their inspection found biosafety hazards. A report in
the journal Nature in 2003 (423(6936): 103) reported cooperation between CDC and USAMRIID on coronavirus research
followed by considerable subsequent collaboration. The CDC, for what appear to be the same type of concern identified
in Wuhan, elected to continue work with the Chinese government while closing the U.S. Army facility.
The CDC reported the first case of SARS-CoV like illness in the United States in January 2020 with the CDC’s Epidemic
Intelligence Service reporting 650 clinical cases and 210 tests. Given that the suspected pathogen was first implicated in
official reports on December 31, 2019, one can only conclude that CDC: a) had the mechanism and wherewithal to
conduct tests to confirm the existence of a “novel coronavirus”; or, b) did not have said mechanism and falsely reported
the information in January. It tests credulity to suggest that the WHO or the CDC could manufacture and distribute tests
for a “novel” pathogen when their own subsequent record on development and deployment of tests has been shown to
be without reliability
An obligation on the part of the contractor, in the event a United States patent application is filed by or on its behalf
or by any assignee of the contractor, to include within the specification of such application and any patent issuing
thereon, a statement specifying that the invention was made with Government support and that the Government has
certain rights in the invention.
Over 5000 patents and patent applications have included reference to SARS Coronavirus dating back to priority dates of
1998. They are summarized below.
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 total
file 0 0 0 0 0 120 338 290 328 297 256 188 198 207 244 371 407 466 451 416 326 199 9 file 5111
issue 0 0 0 0 0 1 63 135 179 224 275 334 391 61 8 314 431 420 504 513 449 578 231 issue 5111
priority 10 12 29 38 129 506 487 408 335 370 279 256 303 279 322 330 348 342 208 95 25 0 0 priority 5111
total 10 12 29 38 129 627 888 833 842 891 810 778 892 547 574 1015 1186 1228 1163 1024 800 777 240 total 15333
On July 23, 2020, the Patent Trial and Appeal Board of the United States Patent and Trademark Office rejected
Moderna’s efforts to invalidate U.S. Patent 8,058,069. This patent, owned by Arbutus Biopharma Corp (principally
owned by Roivant Science Ltd), covers the lipid nanoparticle (LNP) required to deliver an mRNA vaccine. Some of the
core technology was based on work originally done at the University of British Columbia and was first licensed in 1998.
mRNA-1273 – the experimental vaccine developed by Moderna for COVID-19 – uses the LNP technology that Moderna
thought it had licensed from Acuitas Therapeutics Inc., a firm developed by a former principal of Arbutus’ prior company
Tekmira. That license did not authorize Moderna to use the technology for the COVID-19 vaccine.
M·CAM and Knowledge Ecology International have independently confirmed that Moderna has violated U.S. law in
failing to disclose the U.S. government’s funding interest in their patents and patent applications. While this negligence
impacts all of Moderna’s over 130 granted U.S. patents, it is particularly problematic for U.S. Patent 10,702,600 (‘600)
which is the patent relating to, “a messenger ribonucleic acid (mRNA) comprising an open reading frame encoding a
betacoronavirus (BetaCoV) S protein or S protein subunit formulated in a lipid nanoparticle.” The specific claims
addressing the pivot to the SARS Coronavirus were patented on March 28, 2019 – 9 months before the SARS CoV-2
In 2013, the Autonomous Diagnostics to Enable Prevention and Therapeutics (ADEPT) program awarded grant funding to
Moderna Therapeutics for the development of a new type of vaccine based on messenger RNA. The initial DARPA grant
was W911NF-13-1-0417. The company used that technology to develop its COVID-19 vaccine, currently undergoing
Phase I clinical trials in conjunction with NIH.29
Under the Federal Acquisition Regulation (FAR) rules, contractor to the Federal Government must provide information
regarding intellectual property infringement issues as part of their contract. Under FAR §27.201-1(c) and (d), the
Government both requires a notice of infringement or potential infringement as well as retention of economic liability
for patent infringements. Specifically, in FAR §52.227.3 (a), the “Contractor shall indemnify the Government and its
officers, agents, and employees against liability, including costs for infringement of any United States Patent…”. In
addition to the patents cited by the USPTO in their examination of ‘600, M·CAM has identified fourteen other issued
patents preceding the ‘600 patent which were used by patent examiners to limit patents arising from the same funded
research including patents sought by CureVac.
In short, while Moderna enjoys hundreds of millions of dollars of funding allegiance and advocacy from Anthony Fauci
and his NIAID, since its inception, it has been engaged in illegal patent activity and demonstrated contempt for U.S.
Patent law. To make matters worse, the U.S. Government has given it financial backing in the face of undisclosed
infringement risks potentially contributing to the very infringement for which they are indemnified.
29 https://crsreports.congress.gov/product/pdf/IN/IN11446
Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 24
21 C.F.R. § 50.24 et seq., Illegal Clinical Trial
It is unlawful to conduct medical research (even in the case of emergency) without a series of steps taken to:
a. Establish the research with a duly authorized and independent institutional review board;
b. Secure informed consent of all participants including a statement of risks and benefits; and,
c. Engage in consultation with the community in which the study is to be conducted.
Dr. Anthony Fauci has forced upon the healthy population of the United States an unlawful clinical trial in which the U.S.
Department of Health and Human Services are extrapolating epidemiologic data. No informed consent has been sought
or secured for any of the “medical countermeasures” forced upon the population and no independent review board – as
defined by the statute – has been empaneled.
Through April 2020, the official recommendation by the Journal of the American Medical Association was
unambiguous.
“Face masks should not be worn by healthy individuals to protect themselves from acquiring respiratory infection
because there is no evidence to suggest that face masks worn by healthy individuals are effective in preventing people
from becoming ill.”30
Part of that lack of evidence in fact showed that cloth facemasks actually increased influenza-linked illness.31
In contravention to established science, States, municipalities, and businesses have violated the legal requirements for
the promulgation of medical counter measures during a public health emergency stating a “belief” that face masks limit
the spread of SARS CoV-2. To date, not a single study has confirmed that a mask prevented the transmission of, or the
infection by SARS CoV-2.
All parties mandating the use of facemasks are not only willfully ignoring established science but are engaging in what
amounts to a whole population clinical trial. This conclusion is reached by the fact that facemask use and COVID-19
incidence are being reported in scientific opinion pieces promoted by the United States Centers for Disease Control and
Prevention and others.32
Social distancing of up to 6 feet has been promoted as a means of preventing person-to-person transmission of
influenza-like viruses. While one study hypothesized that infection could happen in a 6 foot range, the study explicitly
states that person-to-person transfer was not tested and viability of the virus at 6 feet was not even a subject of the
investigation.33 That did not stop the misrepresentation of the study to be used as the basis for an unverified medical
counter measure of social distancing. To date, no study has established the efficacy of social distancing to modify the
transmission of SARS CoV-2. Public health officials have referenced:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907354/#CR43
In contravention to established science, States, municipalities, and businesses have violated the legal requirements for
the promulgation of medical counter measures during a public health emergency stating a “belief” that social distancing
of a healthy population limits the spread of SARS CoV-2. To date, not a single study has confirmed that social distancing
of any population prevented the transmission of, or the infection by SARS CoV-2.
30 https://jamanetwork.com/journals/jama/fullarticle/2762694
31 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420971/
32 https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover-guidance.html
33 Werner E. Bischoff, Katrina Swett, Iris Leng, Timothy R. Peters, Exposure to Influenza Virus Aerosols During Routine Patient Care, The Journal of
Infectious Diseases, Volume 207, Issue 7, 1 April 2013, Pages 1037–1046, https://doi.org/10.1093/infdis/jis773
Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 25
It is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product or service can prevent, treat, or cure
human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-
controlled human clinical studies, substantiating that the claims are true at the time they are made. As a result, every
party promoting the use of face masks is violating the FTC Act.
All of these laws have been broken. All relevant authorities in the United States must cease and desist the use of face
masks until the matters above are rectified.
File Issu
d e
Priori Dat Dat
PATENT Title Owner ty e e
25- 30- 12-
US9995706 Amperometric gas sensor Steris Corporation Jun- Sep Jun-
12 -14 18
25- 30- 12-
US9995705 Amperometric gas sensor Steris Corporation Jun- Sep Jun-
12 -14 18
20- 19- 12-
US9994558 Multicyclic compounds and methods of using same Karyopharm Therapeutics Inc. Sep- Sep Jun-
13 -14 18
7- 7- 12-
Heterocyclic modulators of lipid synthesis for use against cancer and
US9994550 3-V Biosciences, Inc. Jan- Jan Jun-
viral infections
14 -15 18
31- 31- 12-
Immunogenic compositions comprising silicified virus and methods
US9993543 Portland State University Jan- Jan Jun-
of use
13 -14 18
12- 29-
13-
US9982257 Chiral control WAVE LIFE SCIENCES LTD. Jul- May
Jul-12
13 -18
14- 1- 29-
US9982241 Recombinant HCMV and RHCMV vectors and uses thereof Oregon Health & Science University May- Oct May
10 -15 -18
5- 5- 29-
The United States of America, as represented by the
US9982025 Monomeric griffithsin tandemers Jun- Jun May
Secretary, Department of Health and Human Services
13 -14 -18
5- 4- 10-
Isothiazolopyrimidinones, pyrazolopyrimidinones, and
US9938300 Forma Therapeutics, Inc. Feb- Feb Apr-
pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
15 -16 18
21- 6- 20-
US9920314 Compositions for and methods of identifying antigens President and Fellows of Harvard College Feb- May Mar
06 -15 -18
28- 20- 20-
US9920128 Synthetic antiserum for rapid-turnaround therapies The Johns Hopkins University Jan- Jan Mar
15 -16 -18
28- 10- 20-
Methods of treating and prophylactically protecting mammalian
US9919034 TAMIR BIOTECHNOLOGY, INC. Mar- Jun Mar
patients infected by viruses classified in Baltimore group V
14 -15 -18
24- 21- 13-
Systems and methods for distinguishing optical signals of different
US9915613 GEN-PROBE INCORPORATED Feb- Mar Mar
modulation frequencies in an optical signal detector
11 -14 -18
25- 27- 13-
FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY
US9914976 Methods and compositions for prostate cancer metastasis Mar- May Mar
(FA
11 -16 -18
15- 15- 13-
Treatment of evolving bacterial resistance diseases including
US9913801 YOUR ENERGY SYSTEMS, LLC Feb- Mar Mar
Klebsiella pneumoniae with liposomally formulated glutathione
13 -13 -18
8- 1- 6-
Efficient deep sequencing and rapid genomic speciation of RNA
US9909176 The Johns Hopkins University Sep- Sep Mar
viruses (vRNAseq)
14 -15 -18
26- 16- 6-
US9908946 Generation of binding molecules Merus N.V. Sep- Sep Mar
11 -15 -18
16- 19- 6-
US9908675 Powdered pouch and method of making same MONOSOL, LLC Apr- Jul- Mar
12 16 -18
29- 5- 30-
Dendrimer like amino amides possessing sodium channel blocker
US9878988 PARION SCIENCES, INC. May- Jan Jan-
activity for the treatment of dry eye and other mucosal diseases
12 -16 18
13- 1- 5-
US9833504 Virus-like particles and process for preparing same Folia Biotech Inc. May- May Dec
11 -12 -17
2- 15- 5-
US9833492 Combinations of a caspase inhibitor and an antiviral agent Centre National de la Recherche Scientifique Nov- May Dec
07 -15 -17
30- 19- 5-
US9832998 Antiviral compositions Long Island University May- Mar Dec
07 -15 -17
18- 10- 28-
US9828382 Pyrimidinone compounds as human neutrophil elastase inhibitors Chiesi Farmaceutici S.p.A. Dec- May Nov
12 -16 -17
1- 28-
Pyrrolo-pyrrole carbamate and related organic compounds, 3-Jul-
US9828379 ABIDE THERAPEUTICS, INC. Jul- Nov
pharmaceutical compositions, and medical uses thereof 13
14 -17
23- 22- 28-
US9828370 Compositions and methods for inhibiting kinases INHIBIKASE THERAPEUTICS, INC. Apr- Apr Nov
15 -16 -17
2- 31- 28-
US9828346 N-myristoyl transferase inhibitors University of Dundee Sep- Aug Nov
08 -15 -17
24- 8- 14-
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-
US9815805 ASTRAZENECA AB Jan- Nov Nov
carboxamides as dipeptidyl peptidase 1 inhibitors
14 -16 -17
4- 22- 14-
US9814777 Targeting lipids Arbutus Biopharma Corporation Dec- Oct Nov
07 -13 -17
6- 25- 7-
Use of live cell inteferometry with reflective floor of observation
US9810683 The Regents of the University of California May- Nov Nov
chamber to determine changes in mass of mammalian cells
09 -13 -17
6- 6- 7-
The United States of America, as represented by the
US9809845 Methods and reagents for amplifying nucleic acids Aug- Aug Nov
Secretary, Department of Health and Human Services
12 -12 -17
29- 18- 7-
US9809796 Animal protein-free media for cultivation of cells Baxalta GmbH Oct- May Nov
04 -17 -17
23- 22- 7-
University of Washington Through its Center for
US9809632 Universal protein tag for double stranded nucleic acid delivery Oct- Oct Nov
Commercialization
13 -14 -17
8- 5- 7-
US9809591 Heterocyclic modulators of lipid synthesis 3-V Biosciences, Inc. Mar- Oct Nov
11 -15 -17
26- 25- 7-
US9808490 Induced hepatocytes and uses thereof ACCELERATED BIOSCIENCES CORP. Nov- Nov Nov
14 -15 -17
6- 6- 31-
Microarray-based assay integrated with particles for analyzing
US9803236 CapitalBio Corporation Aug- Aug Oct-
molecular interactions
10 -10 17
25- 27- 31-
US9803197 Particle-nucleic acid conjugates and therapeutic uses related thereto Emory University Jun- Feb Oct-
12 -13 17
21- 23- 31-
US9802937 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH Apr- Apr Oct-
11 -12 17
31- 26- 31-
US9802919 Compounds CHIESI FARMACEUTICI S.p.A. May- May Oct-
16 -17 17
21- 21- 31-
US9801948 Antimicrobial compositions and methods of use thereof Yale University Sep- Sep Oct-
11 -12 17
10- 6- 31-
US9801947 Methods and compositions for enhancing immune response 3M INNOVATIVE PROPERTIES COMPANY Apr- Oct Oct-
03 -14 17
20- 11- 31-
US9801935 Soluble needle arrays for delivery of influenza vaccines SEQIRUS UK LIMITED Aug- Oct Oct-
10 -16 17
6- 31-
6-Jul-
US9801897 Delivery of RNA to trigger multiple immune pathways GLAXOSMITHKLINE BIOLOGICALS SA Jul- Oct-
10
11 17
1- 30- 24-
Non-target amplification method for detection of RNA splice-forms in
US9797000 QIAGEN GAITHERSBURG INC. May- Apr Oct-
a sample
09 -10 17
3- 28- 24-
US9796979 Oligonucleotide modulators of the toll-like receptor pathway Quark Pharmaceuticals Inc. Mar- Jul- Oct-
11 16 17
2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4-
15- 14- 29-
D]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl) quinazolin-
US9745306 Respivert Limited Mar- Mar Aug
4(3H)-one derivatives and their use as phosphoinositide 3-kinase
13 -14 -17
inhibitors
8- 27- 29-
Quality control methods for oil-in-water emulsions containing
US9744231 NOVARTIS AG Nov- Aug Aug
squalene
06 -13 -17
4- 28- 29-
Vaccines and immunotherapeutics using IL-28 and compositions and
US9744229 THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Apr- Apr Aug
methods of using the same
08 -14 -17
6- 29-
6-Jul-
US9744183 Nucleic acid prodrugs and methods of use thereof WAVE LIFE SCIENCES LTD. Jul- Aug
09
10 -17
21- 28- 22-
US9738894 Short interfering RNA (siRNA) analogues Roche Innovation Center Copenhagen A/S Mar- Mar Aug
03 -16 -17
21- 20- 22-
US9738624 Nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. Jun- Jun Aug
13 -14 -17
30- 20- 22-
Adeno-associated virus (AAV) glades, sequences, vectors containing
US9737618 The Trustees of the University of Pennsylvania Sep- Jul- Aug
same, and uses therefor
03 15 -17
19- 15- 22-
US9737593 Carbon nanotube compositions and methods of use thereof Yale University Mar- Mar Aug
08 -13 -17
21- 20- 15-
US9730997 Alphavirus vectors for respiratory pathogen vaccines Novartis Vaccines and Diagnostics, Inc. May- Aug Aug
04 -14 -17
12- 12- 15-
US9730912 Pharmaceutical compounds ASTEX THERAPEUTICS LIMITED Oct- Oct Aug
06 -07 -17
27- 26- 8-
US9727810 Spatially addressable molecular barcoding Cellular Research, Inc. Feb- Feb Aug
15 -16 -17
10- 3- 8-
US9726607 Systems and methods for detecting multiple optical signals GEN-PROBE INCORPORATED Mar- Mar Aug
05 -14 -17
6- 6- 8-
Methods and compositions for identification of source of microbial
US9725770 The Regents of the University of California Mar- Mar Aug
contamination in a sample
12 -13 -17
4- 13- 8-
US9725487 Compositions and methods for measles virus inhibition Autoimmune Technologies, LLC Nov- May Aug
03 -15 -17
29- 29- 1-
Tissue preferential codon modified expression cassettes, vectors
US9719106 The Trustees of the University of Pennsylvania Apr- Apr Aug
containing same, and uses thereof
13 -14 -17
8- 8- 1-
US9719083 Bioagent detection methods IBIS BIOSCIENCES, INC. Mar- Mar Aug
09 -10 -17
12- 11- 1-
US9718774 Indole carboxamide derivatives as P2X7 receptor antagonist IDORSIA PHARMACEUTICALS LTD Dec- Dec Aug
12 -13 -17
1- 1- 1-
US9717755 Method of treating inflammation Cytosorbents Corporation Apr- Apr Aug
10 -11 -17
16- 16- 1-
US9717749 Production of stable non-polyadenylated RNAs Massachusetts Institute of Technology Oct- Oct Aug
12 -13 -17
15- 17- 1-
US9717732 Drug combination VERONA PHARMA PLC Mar- Mar Aug
13 -14 -17
29- 30- 25-
US9714411 Animal protein-free media for cultivation of cells Baxalta GmbH Oct- Nov Jul-
04 -15 17
28- 2- 25-
US9714283 Compositions and methods for the treatment of immunodeficiency ADMA BIOLOGICS, INC. Oct- Jul- Jul-
14 15 17
13- 25-
29-
US9714226 Hydrazide containing nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. Nov Jul-
Jul-11
-15 17
13- 13- 25-
US9713641 Anti-TIGIT antigen-binding proteins and methods of use thereof Potenza Therapeutics, Inc. Feb- Feb Jul-
17 -17 17
Nucleic acid comprising or coding for a histone stem-loop and a 15- 15- 6-
US9669089 poly(A) sequence or a polyadenylation signal for increasing the CureVac AG Feb- Feb Jun-
expression of an encoded pathogenic antigen 12 -13 17
26- 25- 6-
US9669088 Vaccination with multiple clades of H5 influenza A virus Seqirus UK Limited Nov- Nov Jun-
07 -08 17
24- 26- 30-
The Arizona Board of Regents on Behalf of The University
US9661856 Synergy of plant antimicrobials with silver Aug- Aug May
of Arizona
12 -13 -17
20- 10- 23-
US9657278 Methods to produce bunyavirus replicon particles Stichting Dienst Landbouwkundig Onderzoek Sep- Jul- May
10 15 -17
23- 23- 23-
GM-CSF and IL-4 conjugates, compositions, and methods related
US9657076 Children's Healthcare of Atlanta, Inc. Oct- Oct May
thereto
12 -13 -17
4- 4- 23-
US9657048 Enantiomers of the 1′,6′-isomer of neplanocin A Auburn University Aug- Aug May
14 -15 -17
12- 12- 4-
Double-stranded oligonucleotide molecules to DDIT4 and methods
US9611474 QUARK PHARMACEUTICALS, INC. Sep- Sep Apr-
of use thereof
12 -13 17
24- 15- 28-
US9605276 Replication defective adenovirus vector in vaccination Etubics Corporation Aug- Mar Mar
12 -13 -17
24- 22- 28-
US9603864 Substituted nucleosides, nucleotides and analogs thereof Alios BioPharma, Inc. Jun- Jun Mar
14 -15 -17
11- 3- 28-
US9603850 MerTK-specific pyrazolopyrimidine compounds The University of North Carolina at Chapel Hill Apr- Apr Mar
14 -15 -17
10- 9- 21-
US9599606 ADP-ribose detection reagents The Board of Regents of the University of Texas System Jun- Jun Mar
14 -15 -17
3- 28- 21-
US9598459 Pharmaceutical compositions and methods Pop Test Oncology LLC Aug- Jul- Mar
15 16 -17
31- 7-
31-
US9588069 Methods for performing thermal melt analysis GEN-PROBE INCORPORATED Jul- Mar
Jul-12
13 -17
17- 16- 7-
Adeno-associated virus (AAV) serotype 8 sequences, vectors
US9587250 Trustees of the University of Pennsylvania Dec- Jan Mar
containing same, and uses therefor
01 -15 -17
9- 4- 7-
US9586998 Methods of propagating monkey adenoviral vectors GenVec, Inc. Nov- Aug Mar
09 -15 -17
13- 19- 7-
Arylalkyl- and aryloxyalkyl-substituted epthelial sodium channel
US9586911 Parion Sciences, Inc. Dec- Dec Mar
blocking compounds
13 -14 -17
3- 14- 7-
Hydrazino 1H-imidazoquinolin-4-amines and conjugates made
US9585968 3M Innovative Properties Company Jun- Aug Mar
therefrom
11 -15 -17
22- 22- 7-
Immunogenic compositions in particulate form and methods for
US9585953 MUCOSIS B.V. Mar- Mar Mar
producing the same
11 -12 -17
9- 6- 7-
US9585874 Nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. May- Jan Mar
12 -16 -17
17- 17- 7-
US9585849 Broad spectrum antiviral and methods of use The Burlington HC Research Group, Inc. Apr- Apr Mar
06 -07 -17
8- 8- 28-
US9580474 Polyionic papilloma virus-like particle (VLP) vaccines THE JOHNS HOPKINS UNIVERSITY Sep- Sep Feb
10 -11 -17
CENTRE DE INVESTIGACION BIOMEDICA EN RED 13- 13- 28-
Methods and reagents for efficient and targeted delivery of
US9580468 BIOINGENIERA BIOMATERIALS Y NANOMEDICINA (CIBER Jan- Jan Feb
therapeutic molecules to CXCR4 cells
BBN) 11 -12 -17
6- 15- 28-
US9580429 Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy AstraZeneca AB Dec- Sep Feb
04 -14 -17
1- 1- 21-
US9574189 Enzymatic encoding methods for efficient synthesis of large libraries Nuevolution A/S Dec- Dec Feb
05 -06 -17
21- 24- 21-
US9574181 Influenza virus reassortment method Seqirus UK Limited May- Oct Feb
10 -14 -17
16- 16- 21-
US9573955 Compounds Chiese Farmaceutici S.p.A. Dec- Dec Feb
13 -14 -17
11- 11- 21-
Therapeutic hydroxypyridinones, hydroxypyrimidinones and
US9573938 Rutgers, The State University of New Jersey Sep- Sep Feb
hydroxypyridazinones
12 -13 -17
29- 5- 21-
US9572899 Compositions for enhancing transport of molecules into cells AVI BIOPHARMA, INC. Apr- Nov Feb
03 -08 -17
12- 11- 21-
US9572864 Compositions and uses of lectins Emory University Feb- Dec Feb
10 -15 -17
16- 5- 21-
US9572823 Boron-containing small molecules Anacor Pharmaceuticals, Inc. Feb- Apr Feb
05 -16 -17
19- 15- 14-
US9567336 Conjugated TLR7 and/or TLR8 and TLR2 agonists INVIVOGEN Nov- Mar Feb
12 -13 -17
22- 21- 14-
US9566326 Adjuvanted influenza vaccines for pediatric use Seqirus UK Limited Feb- Jun Feb
08 -13 -17
24- 24- 14-
US9566291 Nutritional composition comprising indigestible oligosaccharides N.V. Nutricia Aug- Aug Feb
04 -05 -17
16- 20- 14-
US9566290 Boron-containing small molecules Anacor Pharmaceuticals, Inc. Feb- Apr Feb
05 -16 -17
13- 8- 17-
US9546184 Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY Aug- Jun Jan-
08 -15 17
2- 29- 17-
Substituted quinazolin-4-ones for inhibiting ubiquitin specific
US9546150 HYBRIGENICS SA Sep- Aug Jan-
protease 7
11 -12 17
12- 23- 17-
US9545440 Methods for preparing squalene NOVARTIS AG May- Oct Jan-
10 -15 17
12- 10- 10-
US9540373 Substituted spirocycles Boehringer Ingelheim International GmbH Sep- Sep Jan-
14 -15 17
9- 10-
27-
US9539321 HMGB1-derived peptides enhance immune response to antigens The Regents of the University of California Mar Jan-
Jul-10
-15 17
3- 3- 10-
US9539217 Nanoparticle compositions Allertein Therapeutics, LLC Apr- Apr Jan-
13 -14 17
21- 26- 3-
Pyrimidine derivatives and their use in the treatment of cancer and
US9533978 Sumitomo Dainippon Pharma Co., Ltd May- Aug Jan-
further diseases
09 -14 17
Methods for designing and preparing vaccines comprising directed 16- 16- 3-
US9533037 sequence polymer compositions via the directed expansion of Declion Holdings LLC Oct- Oct Jan-
epitopes 07 -08 17
6- 6- 18-
US9469876 Circulating biomarkers for metastatic prostate cancer Caris Life Sciences Switzerland Holdings GmbH Apr- Apr Oct-
10 -11 16
23- 11-
11-
US9464276 Highly efficient influenza matrix (M1) proteins Novavax, Inc. Feb Oct-
Jul-03
-15 16
9- 21- 11-
Peptides having activity of inhibiting infections of respiratory viruses
US9464123 XIANGXUE GROUP (HONG KONG) COMPANY LIMITED May- Feb Oct-
and use of the same
13 -14 16
3- 11- 11-
Arranging interaction and back pressure chambers for
US9463240 NOVARTIS AG Dec- Jul- Oct-
microfluidization
09 14 16
29- 29- 4-
Quantitative measurement of nano/micro particle endocytosis with
US9459247 Academia Sinica Mar- Mar Oct-
cell mass spectrometry
10 -11 16
25- 26- 4-
US9459233 Amperometric gas sensor Steris Corporation Jun- Feb Oct-
12 -13 16
25- 23- 4-
US9458492 Methods and cells for identifying RIG-I pathway regulators Kineta, Inc. Feb- Feb Oct-
11 -12 16
21- 23- 4-
Recombinant influenza virus-like particles (VLPs) produced in
US9458470 MEDICAGO INC. Jan- Jan Oct-
transgenic plants expressing hemagglutinin
08 -13 16
15- 15- 4-
US9458184 Compositions of TLR7 and/or TLR8 agonists conjugated to lipids INVIVOGEN Jun- Mar Oct-
12 -13 16
27- 4-
Substituted bicyclic dihydropyrimidinones and their use as inhibitors 31-
US9458113 Boehringer Ingelheim International GmbH Jul- Oct-
of neutrophil elastase activity Jul-14
15 16
24- 23- 4-
Compositions and methods for treating and preventing porcine
US9457074 Ohio State Innovation Foundation Apr- Feb Oct-
reproductive and respiratory syndrome
12 -15 16
2- 22- 27-
US9453043 Nucleic acid chemical modifications ALNYLAM PHARMACEUTICALS, INC. Mar- Jan Sep
09 -15 -16
4- 15- 27-
THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF
US9452973 Modulators of the relaxin receptor 1 May- Mar Sep
TRUSTEES
12 -13 -16
4- 27-
Influenza virus-like particles (VLPS) comprising hemagglutinin 13-
US9452210 MEDICAGO INC. Jan Sep
produced within a plant Jul-07
-13 -16
8- 8- 26-
University of Pittsburgh - Of the Commonwealth System of
US9322827 B-cell antigen presenting cell assay Apr- Apr Apr-
Higher Education
10 -11 16
19- 19- 26-
Compositions for increasing polypeptide stability and activity, and
US9321999 SOLIS BIODYNE OÜ Nov- Nov Apr-
related methods
09 -10 16
20- 22- 26-
Activatable toxin complexes comprising a cleavable inhibitory
US9321847 RAMOT at Tel Aviv University Ltd. Sep- Aug Apr-
peptide
10 -11 16
Device and method for reducing spread of microorganisms and 14- 12-
17-
US9310088 airborne health hazardous matter and/or for protection from Technical University of Denmark Jul- Apr-
Jul-09
microorganisms and airborne health hazardous matter 10 16
7- 4- 12-
US9309325 Antibodies and methods of use thereof The Regents of the University of California May- May Apr-
09 -10 16
30- 27- 5-
D-amino acid derivative-modified peptidoglycan and methods of use
US9303068 The Regents of the University of California Nov- Nov Apr-
thereof
12 -13 16
17- 16- 5-
US9303000 Olefin containing nuclear transport modulators and uses thereof KARYOPHARM THERAPEUTICS INC. Jan- Jan Apr-
11 -12 16
21- 11- 29-
US9297010 Short interfering RNA (siRNA) analogues Roche Innovation Center Copenhagen A/S Mar- Feb Mar
03 -14 -16
22- 22- 29-
US9295732 Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists INVIVOGEN Feb- Feb Mar
13 -13 -16
24- 24- 29-
US9295708 Modified release formulations for oprozomib Onyx Therapeutics, Inc. Oct- Oct Mar
12 -13 -16
18- 29-
6-Jul-
US9295646 Cationic oil-in-water emulsions Novartis AG Sep Mar
10
-11 -16
13- 22-
13-
US9291628 Direct clone analysis and selection technology Dublin City University Jul- Mar
Jul-10
11 -16
1- 22-
2-Jul-
US9291597 Detecting targets using mass tags and mass spectrometry VENTANA MEDICAL SYSTEMS, INC. Jul- Mar
10
11 -16
11- 12- 22-
US9290794 Mutant protease biosensors with enhanced detection characteristics PROMEGA CORPORATION May- Nov Mar
10 -12 -16
26- 25- 22-
US9290786 Monoclonal antibody production by EBV transformation of B cells Institute for Research in Biomedicine Feb- Apr Mar
03 -13 -16
15- 14- 22-
US9290760 Modified iRNA agents ALNYLAM PHARMACEUTICALS, INC. Sep- Sep Mar
10 -11 -16
10- 14- 22-
US9290745 Luciferase biosensor PROMEGA CORPORATION Oct- Feb Mar
03 -14 -16
23- 23- 22-
US9290545 Compositions and methods for the treatment of viral infections Dana-Farber Cancer Institute, Inc. Jan- Jul- Mar
08 10 -16
6- 9- 22-
Substituted bicyclic dihydropyrimidinones and their use as inhibitors
US9290459 Boehringer Ingelheim International GmbH Feb- Nov Mar
of neutrophil elastase activity
13 -15 -16
27- 22-
Substituted dihydropyrimidinones and their use as inhibitors of 31-
US9290457 Boehringer Ingelheim International GmbH Jul- Mar
neutrophil elastase activity Jul-14
15 -16
14- 11- 22-
US9289487 II-key/antigenic epitope hybrid peptide vaccines Antigen Express, Inc. Sep- Jan Mar
99 -05 -16
19- 19- 15-
Application of highly conserved domain sequences from viral
US9284560 Biocross Institute of Molecular Medicine (Nantong) Co., Ltd. Sep- Sep Mar
genome as template to design therapeutic sliRNAs
11 -11 -16
10- 10- 8-
US9278126 Influenza vaccines with reduced amounts of squalene Seqirus UK Limited Feb- Feb Mar
09 -10 -16
12- 11- 1-
Compositions, comprising improved IL-12 genetic constructs and
US9272024 The Trustees of the University of Pennsylvania Dec- Dec Mar
vaccines, immunotherapeutics and methods of using the same
11 -12 -16
30- 30- 1-
Shelf stable, reduced corrosion, ready to use peroxycarboxylic acid
US9271494 Ecolab USA, Inc. Aug- Aug Mar
antimicrobial compositions
07 -07 -16
15- 17- 23-
US9266844 Suppression of SARS replication by SARS helicase inhibitors The Curators of the University of Missouri Jun- Jun Feb
12 -13 -16
29- 9- 16-
Dendrimer like amino amides possessing sodium channel blocker
US9260398 PARION SCIENCES, INC. May- Dec Feb
activity for the treatment of dry eye and other mucosal diseases
12 -14 -16
20- 20- 9-
US9255144 Anti-IL-18 antibodies and their uses MedImmune Limited Dec- Dec Feb
10 -11 -16
15- 23- 9-
Adjuvancy and immune potentiating properties of natural products
US9255140 NEW YORK BLOOD CENTER, INC. Jun- Mar Feb
of Onchocerca volvulus
04 -09 -16
28- 3- 9-
Systems and methods for identifying replikin scaffolds and uses of
US9254315 Not Available Apr- Feb Feb
said replikin scaffolds
04 -10 -16
31- 31- 9-
US9254265 Small liposomes for delivery of immunogen encoding RNA NOVARTIS AG Aug- Aug Feb
10 -11 -16
14- 14- 2-
US9249427 Recombinant HCMV and RHCMV vectors and uses thereof Oregon Health & Science University May- Nov Feb
10 -12 -16
7- 4- 2-
US9249195 Reovirus vaccines and methods of use therefor Vanderbilt University Apr- Apr Feb
10 -11 -16
11- 5- 2-
US9248201 Mutant protease biosensors with enhanced detection characteristics PROMEGA CORPORATION May- May Feb
10 -14 -16
8- 8- 2-
Different serotypes of vesicular stomatitis virus as expression
US9248178 Not Available Jun- Jun Feb
vectors for immunization regimens
09 -10 -16
17- 16- 26-
Lipidated immune response modifier compound compositions,
US9242980 3M Innovative Properties Company Aug- Aug Jan-
formulations, and methods
10 -11 16
24- 5- 19-
Compositions, methods, and kits for isolating and analyzing nucleic
US9238809 QIAGEN GAITHERSBURG, INC. Sep- Aug Jan-
acids using an anion exchange material
09 -10 16
17- 16- 12-
US9234175 Creating bioengineered lymph nodes H. Lee Moffitt Cancer Center and Research Institute, Inc. Nov- Nov Jan-
09 -10 16
9- 16- 12-
Replikin-based compounds for prevention and treatment of influenza
US9233148 Not Available Jan- Oct Jan-
and methods of differentiating infectivity and lethality in influenza
09 -09 16
15- 14- 5-
US9227977 Phosphoinositide 3-kinase inhibitors Respivert Ltd. Mar- Mar Jan-
13 -14 16
29- 2- 29-
US9222075 Animal protein-free media for cultivation of cells Baxalta GmbH Oct- May Dec
04 -14 -15
20- 29-
22-
US9221832 Heterocyclic amide derivatives as P2X7 receptor antagonists ACTELION PHARMACEUTICALS LTD. Jul- Dec
Jul-11
12 -15
21- 12- 29-
Substituted pyridones and pyrazinones and their use as inhibitors of
US9221807 Boehringer Ingelheim International GmbH Feb- Feb Dec
neutrophil elastase activity
14 -15 -15
9- 14- 29-
Decreasing potential iatrogenic risks associated with influenza
US9220768 Novartis AG Sep- Oct Dec
vaccines
04 -11 -15
2- 11- 22-
Arrayed detector system for measurement of influenza immune
US9217745 University of Rochester May- Jul- Dec
response
08 13 -15
27- 22-
27-
US9217157 Recombinant influenza viruses and uses thereof Icahn School of Medicine at Mount Sinai Jul- Dec
Jul-09
10 -15
1- 16- 22-
US9216192 Toll-like receptor agonist formulations and their use VentiRx Pharmaceuticals, Inc. Aug- Jul- Dec
08 12 -15
1- 15-
Lipoparticles comprising proteins, methods of making, and using the 30-
US9213027 Integral Molecular, Inc. Nov Dec
same Jul-03
-13 -15
1- 7- 15-
Biological specimen collection and transport system and method of
US9212399 Longhorn Vaccines and Diagnostics, LLC Oct- Jan Dec
use
07 -14 -15
28- 15-
26-
US9212205 Nucleic acid binding compounds and methods of use University of Rochester Jul- Dec
Jul-07
08 -15
16- 16- 8-
US9206396 Methods and devices for quantitative viral assays Wisconsin Alumni Research Foundation Nov- Nov Dec
05 -06 -15
10- 8-
29-
US9206158 Hydrazide containing nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. Jun Dec
Jul-11
-15 -15
19- 18- 1-
US9200329 Rapid epidemiologic typing of bacteria BioFire Diagnostics, LLC May- May Dec
08 -09 -15
7- 24-
Delivery of self-replicating RNA using biodegradable polymer 6-Jul-
US9192661 Novartis AG Jun Nov
particles 10
-11 -15
28- 17-
20-
US9187748 Compositions and methods for silencing ebola virus gene expression Not Available Mar Nov
Jul-09
-14 -15
27- 25- 17-
US9187426 Organic compounds Novartis AG Jun- Jun Nov
08 -09 -15
30- 17- 17-
US9186419 Directed evolution and in vitro panning of virus vectors The University of North Carolina at Chapel Hill Apr- Jan Nov
08 -14 -15
9- 29- 17-
Immune stimulatory oligonucleotide analogs containing modified
US9186399 AdiutTide Pharmaceuticals GmbH Oct- Sep Nov
sugar moieties
07 -08 -15
22- 20- 10-
US9181303 Treatment of bacterial infections with cyclic antimicrobial peptides NovaBiotics Limited Dec- Jun Nov
05 -14 -15
17- 19- 10-
Inhibition of biofilm formation by 1,2,3,4,6-penta-O-galloyl-D-
US9181290 CHANG GUNG UNIVERSITY Jun- Sep Nov
glucopyranose
11 -11 -15
14- 14- 3-
US9175047 Peptidomimetic macrocycles Aileron Therapeutics, Inc. Jan- Jan Nov
09 -10 -15
26- 28- 3-
Phorbol type diterpene compound, pharmaceutical composition for KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND
US9174925 Oct- Sep Nov
treatment or prevention of viral infectious diseases including same BIOTECHNOLOGY
11 -12 -15
14- 11- 7-
Method of using substituted 2-Aza-bicyclo[2.2.2]octane-3-carboxylic
US9073869 Boehringer Ingelheim International GmbH Mar- Sep Jul-
acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C
13 -14 15
27- 27- 7-
Chemically and metabolically stable dipeptide possessing potent
US9072738 PARION SCIENCES, INC. Jun- Jun Jul-
sodium channel blocker activity
11 -12 15
20- 21- 7-
Methods of treating or preventing inflammation and hypersensitivity
US9072726 Oculus Innovative Sciences, Inc. Jan- Dec Jul-
with oxidative reductive potential water solution
06 -09 15
21- 21- 7-
US9072702 Reverse genetics using non-endogenous pol I promoters Novartis AG May- May Jul-
09 -10 15
13- 30-
13-
US9066964 Use of tylvalosin as antiviral agent Cambridge University Technical Services Jul- Jun-
Jul-06
07 15
The United States of America as represented by the 2- 25- 23-
Method for detection of antigen-specific antibodies in biological
US9063150 Secretary of the Department of Health and Human Sep- Aug Jun-
samples
Services, Centers for Disease Control Prevention 08 -09 15
16- 15- 23-
US9061001 Combination adjuvant formulation Dalhousie University Oct- Oct Jun-
08 -09 15
4- 8- 16-
US9056900 Compositions and methods for coronavirus inhibition Autoimmune Technologies, LLC. Nov- Aug Jun-
03 -13 15
20- 22- 16-
US9056898 Attenuated RNA virus and applications thereof Washington University Sep- Sep Jun-
07 -08 15
2- 19- 16-
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
US9056071 Compounds and methods for preventing or treating a viral infection Nov- Jun Jun-
(C.N.R.S.)
07 -13 15
25- 23- 9-
FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY
US9051619 Methods and compositions for prostate cancer metastasis Mar- Mar Jun-
(FAMU)
11 -12 15
21- 21- 9-
US9051564 Compositions for and methods of identifying antigens President and Fellows of Harvard College Feb- Feb Jun-
06 -07 15
20- 24- 9-
US9051353 Crystalline tripeptide epoxy ketone protease inhibitors Onyx Therapeutics, Inc. Mar- Sep Jun-
09 -13 15
25- 1- 12-
Methods of inducing or enhancing an immune response in a subject
US9028823 GITR, Inc. Mar- Mar May
by administering agonistic GITR binding antibodies
05 -13 -15
25- 20- 5-
US9024001 Alphavirus replicon packaging constructs Novartis Vaccines and Diagnostics, Inc. May- May May
04 -05 -15
14- 11- 5-
US9023855 Compounds Chiesi Farmaceutici S.p.A. Sep- Feb May
11 -14 -15
1- 22- 5-
US9023839 Compounds and compositions as c-kit kinase inhibitors IRM LLC Sep- Apr May
11 -14 -15
15- 18- 28-
Adjuvancy and immune potentiating properties of natural products
US9017699 New York Blood Center, Inc. Jun- Feb Apr-
of Onchocerca volvulus
04 -10 15
10- 10- 28-
US9017696 Adenovirus vectors Isis Innovation Limited Apr- Apr Apr-
07 -08 15
31- 31- 21-
Compositions and methods using siRNA molecules and siRNA
US9012622 Not Available Dec- Dec Apr-
cocktails for the treatment of breast cancer
08 -09 15
1- 31- 21-
Transportable vacuum assisted decontamination unit and
US9011767 STERIS Inc. Apr- Mar Apr-
decontamination process
13 -14 15
18- 9- 14-
Substituted imidazoquinolines, imidazopyridines, and
US9006264 3M Innovative Properties Company Jun- Sep Apr-
imidazonaphthyridines
04 -13 15
19- 17- 14-
Compositions and methods for diminishing viral infection and
US9006194 Drexel University Dec- Dec Apr-
inflammation associated with viral infection
08 -09 15
9- 9- 14-
Academish Medisch Centrum Bij de Universiteit van
US9005974 Means and methods for influencing the stability of cells Dec- Dec Apr-
Amsterdam
05 -05 15
24- 24- 14-
Compositions and methods for treating and preventing porcine
US9005665 Ohio State Innovation Foundation Apr- Apr Apr-
reproductive and respiratory syndrome
12 -13 15
21- 20- 14-
Genetically modified human umbilical cord perivascular cells for
US9005599 Tissue Regeneration Therapeutics Inc. Apr- Apr Apr-
prophylaxis against or treatment of biological or chemical agents
08 -09 15
19- 7-
29-
US8999996 Hydrazide containing nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. Mar Apr-
Jul-11
-14 15
Compositions and uses thereof for the treatment of acute 20- 20- 2-
US8822409 respiratory distress syndrome (ARDS) and clinical disorders Phylogica Limited Jun- Jun Sep
associated with therewith 07 -08 -14
24- 2-
9-Jul-
US8821897 Viral adjuvants The University of North Carolina at Chapel Hill Nov Sep
04
-10 -14
Methods for controlling SR protein phosphorylation, and antiviral 26- 19- 26-
US8816089 agents whose active ingredients comprise agents that control SR Masatoshi Hagiwara Dec- Nov Aug
protein activity 03 -12 -14
2- 7- 26-
Methods for treating viral infection using IL-28 and IL-29 cysteine
US8816053 ZymoGenetics, Inc. Apr- Sep Aug
mutants
04 -12 -14
7- 29- 26-
US8815837 Respiratory disease treatment Pulmagen Therapeutics (Inflammation) Limited Aug- Jun Aug
08 -12 -14
3- 3- 26-
US8815831 Treatment of Acinetobacter with alginate oligomers and antibiotics Algipharma AS Jun- Jun Aug
09 -10 -14
10- 3- 26-
US8815611 Surface for label independent detection and method thereof Corning Incorporated Apr- Apr Aug
08 -09 -14
4- 26- 26-
US8815249 Ii-key/antigenic epitope hybrid peptide vaccines Antigen Express, Inc. Sep- Jul- Aug
99 10 -14
29- 16- 26-
US8815244 Method for production of antibody using ostrich Japan Science and Technology Agency Aug- Aug Aug
05 -11 -14
24- 23- 19-
US8809377 Deubiquitinase inhibitors and methods for use of the same The Regents of the University of Michigan Sep- Sep Aug
10 -11 -14
Compounds (cystein based lipopeptides) and compositions as TLR2 23- 23- 19-
US8808703 agonists used for treating infections, inflammations, respiratory Not Available Mar- Mar Aug
diseases etc 10 -11 -14
28- 14- 1-
US8765704 Modified small interfering RNA molecules and methods of use Novartis AG Feb- Dec Jul-
08 -11 14
4- 1- 1-
US8765643 Composition, device and associated method General Electric Company Dec- Mar Jul-
06 -07 14
31- 31- 1-
US8765146 Adenoviral vector-based malaria vaccines GenVec, Inc. Aug- Aug Jul-
05 -06 14
6- 24- 1-
US8765138 Antiviral and antibacterial activity from medicinal mushrooms Not Available Jan- Sep Jul-
04 -08 14
29- 16- 1-
US8765133 Method of producing anti-CD166 antibody in ostrich Japan Science and Technology Agency Aug- Aug Jul-
05 -11 14
24- 25- 24-
Oligonucleotide compound and method for treating nidovirus
US8759307 Sarepta Therapeutics, Inc. Dec- Apr Jun-
infections
03 -08 14
15- 23- 24-
US8758763 Archaeal polar lipid aggregates for administration to animals National Research Council of Canada Dec- Jan Jun-
06 -13 14
29- 27- 24-
US8758680 Method and device for cleaning air Not Available Sep- Sep Jun-
10 -11 14
1- 19- 17-
US8754071 Compounds and compositions as c-kit kinase inhibitors Not Available Sep- Sep Jun-
11 -13 14
21- 20- 17-
Modified phage for displaying post-translationally modified proteins
US8754015 University of Rochester Nov- Nov Jun-
and uses thereof
06 -07 14
22- 22- 10-
US8748567 Method for delivery across the blood brain barrier Children's Medical Center Corporation May- May Jun-
06 -07 14
7- 16- 10-
Use of SIRT1 activators or inhibitors to modulate an immune
US8748464 The J. David Gladstone Institutes Feb- Jul- Jun-
response
08 10 14
26- 9- 10-
Methods and compositions for the treatment of cancer or other
US8748405 City of Hope Jan- Sep Jun-
diseases
07 -11 14
29- 16- 10-
US8748156 Animal protein-free media for cultivation of cells Baxter Healthcare SA Oct- Apr Jun-
04 -13 14
15- 28- 3-
US8741813 Composition, device and associated method General Electric Company Dec- Feb Jun-
05 -07 14
22- 16- 3-
US8741653 Single recombination system and methods of use Emergent Product Development GmbH Dec- Dec Jun-
08 -09 14
7- 14- 3-
US8741604 Nucleic acid molecule encoding a specific IL-1R1 antibody Medimmune Limited Nov- Sep Jun-
08 -12 14
4- 26- 3-
Quantitative nuclease protection assay (QNPA) and sequencing
US8741564 HTG Molecular Diagnostics, Inc. May- Apr Jun-
(QNPS) improvements
11 -12 14
27- 26- 3-
US8741311 Methods and compositions for immunization against virus Academia Sinica Mar- Mar Jun-
09 -10 14
6- 6- 27-
US8735567 Multi-targeted RNAi therapeutics for scarless wound healing of skin Not Available Nov- Nov May
07 -08 -14
11- 11- 27-
US8735559 Mutant protease biosensors with enhanced detection characteristics Promega Corporation May- May May
10 -11 -14
24- 24- 6-
Systems and methods for distinguishing optical signals of different
US8718948 Gen-Probe Incorporated Feb- Feb May
modulation frequencies in an optical signal detector
11 -12 -14
20- 6-
20-
US8716464 Compositions and methods for silencing Ebola virus gene expression Not Available Jul- May
Jul-09
10 -14
24- 24- 6-
US8716461 Human parvovirus Blood Systems, Inc. May- May May
04 -05 -14
24- 13- 29-
US8710224 Heterocyclic compounds as CCR2B antagonists AstraZeneca AB Dec- Sep Apr-
04 -13 14
5- 7- 29-
Methods of preventing and treating viral infections by inhibiting the
US8709730 Icahn School of Medicine at Mount Sinai Apr- Apr Apr-
deISGylation activity of OTU domain-containing viral proteins
07 -08 14
6- 23- 29-
Use of deuterium oxide for the treatment of virus-based diseases of
US8709496 D2 Bioscience Group Ltd. Jan- May Apr-
the respiratory tract
10 -12 14
22- 26- 29-
Compositions and methods for activating innate and allergic
US8709447 ID Biomedical Corporation of Quebec Oct- Apr Apr-
immunity
03 -12 14
18- 6- 29-
US8709441 TC-83-derived alphavirus vectors, particles and methods Alphavax, Inc. May- Jul- Apr-
04 10 14
11- 11- 22-
The United States of America, as represented by the
US8704169 Direct impact ionization (DII) mass spectrometry Oct- Oct Apr-
Secretary, Department of Health and Human Services
11 -11 14
11- 10- 22-
Cleaning composition for treating tissue for transplantation derived
US8703748 CG BIO Co., Ltd. Feb- Feb Apr-
from human/animal
09 -10 14
27- 26- 22-
Inactivation of a pathogen in a sample by a treatment with formalin
US8703467 Baxter Healthcare SA May- May Apr-
and UV light
04 -05 14
3- 31- 22-
Electrochemistry and electrogenerated chemiluminescence with a
US8702958 Board of Regents of the University of Texas System Jun- May Apr-
single faradaic electrode
05 -12 14
24- 24- 15-
Amide substituted imidazopyridines, imidazoquinolines, and
US8697873 3M Innovative Properties Company Mar- Mar Apr-
imidazonaphthyridines
04 -05 14
10- 10- 15-
US8697853 TAL effector-mediated DNA modification Iowa State University Research Foundation, Inc. Dec- Jan Apr-
09 -13 14
12- 10- 15-
US8697659 Analogues of glycolipids useful as immunoadjuvants Luigi Panza Oct- Oct Apr-
07 -08 14
28- 28- 15-
US8697140 Virucidal disinfectant B. Braun Medical AG Jan- May Apr-
05 -09 14
25- 27- 15-
VLPs derived from cells that do not express a viral matrix or core
US8697088 Novavax, Inc. May- May Apr-
protein
07 -08 14
4- 6- 15-
Influenza vaccines including combinations of particulate adjuvants
US8697087 Novartis AG Nov- Nov Apr-
and immunopotentiators
05 -06 14
25- 24- 8-
US8691837 Substituted imidazo ring systems and methods 3M Innovative Properties Company Nov- Nov Apr-
03 -04 14
14- 13- 8-
US8691826 Compounds Chiesi Farmaceutici S.p.A. Sep- Sep Apr-
11 -12 14
5- 4- 8-
US8691781 Compositions for treating respiratory viral infections and their use Sirnaomics, Inc. Nov- Nov Apr-
04 -05 14
1- 19- 11-
Biological specimen collection and transport system and method of
US8669240 Longhorn Vaccines & Diagnostics, LLC Oct- Mar Mar
use
07 -13 -14
11- 30- 4-
US8664218 Pharmaceutical compounds Astex Therapeutics Ltd. Apr- Jan Mar
08 -13 -14
11- 11- 4-
siRNA compositions and methods for potently inhibiting viral
US8664188 Xiangxue Group (Hong Kong) Company Limited Dec- Dec Mar
infection
08 -09 -14
10- 1- 4-
US8663922 Systems and methods for detecting multiple optical signals Gen-Probe Incorporated Mar- Jun Mar
05 -10 -14
15- 15- 25-
US8658767 Lipidated polyepitope vaccines National Health Research Institutes Nov- Nov Feb
10 -11 -14
21- 21- 4-
US8642260 Single quantum-dot based aptameric nanosensors The Research Foundation of the City University of New York Oct- Oct Feb
08 -09 -14
29- 28- 21-
US8633322 Alkynyl derivatives useful as DPP-1 inhibitors Janssen Pharmaceutica NV Oct- Oct Jan-
09 -10 14
28- 27- 21-
Compounds for preventing or treating viral infections and methods
US8633308 The Governors of The University of Alberta Feb- Feb Jan-
of use thereof
07 -08 14
30- 29- 21-
US8632764 Directed evolution and in vivo panning of virus vectors University of North Carolina at Chapel Hill Apr- Apr Jan-
08 -09 14
6- 6- 14-
Compounds that modulate negative-sense, single-stranded RNA
US8629283 Icahn School of Medicine at Mount Sinai Mar- Mar Jan-
virus replication and uses thereof
08 -09 14
6- 2- 14-
US8629271 Compounds AstraZeneca AB Feb- Apr Jan-
08 -12 14
15- 14- 14-
US8629098 Compositions and methods for adoptive and active immunotherapy Yale University Jan- Jan Jan-
08 -09 14
28- 2- 14-
US8628786 Polychlorinated biphenyls and squalene-containing adjuvants Novartis AG Dec- Dec Jan-
07 -11 14
24- 4- 7-
US8623419 Technology for preparation of macromolecular microspheres Ansun Biopharma, Inc. Jan- Nov Jan-
06 -11 14
17- 18- 7-
US8623382 Immunogenic compositions for inducing an immune response to HIV Wyeth LLC Jun- Jan Jan-
04 -11 14
8- 24- 7-
US8623364 Antigenic GM-CSF peptides and antibodies to GM-CSF Morphotek, Inc. Feb- Oct Jan-
06 -12 14
20- 20- 31-
US8617838 Fluorescent proteins and related methods and compounds University of Massachusetts Sep- Sep Dec
04 -05 -13
10- 10- 24-
US8615368 Method for determining the amount of an analyte in a sample Gen-Probe Incorporated Mar- Mar Dec
05 -06 -13
13- 14- 17-
Highly active glycoproteins-process conditions and an efficient
US8609370 Glycotope GmbH Feb- Feb Dec
method for their production
04 -05 -13
23- 23- 17-
Granulocyte-macrophage colony-stimulating factor (GM-CSF)
US8609101 Theraclone Sciences, Inc. Apr- Apr Dec
neutralizing antibodies
09 -10 -13
20- 22- 10-
US8604215 Crystalline tripeptide epoxy ketone protease inhibitors Onyx Therapeutics, Inc. Mar- Mar Dec
09 -10 -13
16- 27- 10-
Methods of treating cancer with human monoclonal antibodies
US8603469 Genmab A/S Dec- Dec Dec
against interleukin 8
02 -11 -13
6- 6- 3-
US8599383 Optical cytometry The Regents of the University of California May- May Dec
09 -09 -13
14- 12- 3-
US8598192 Hydroxylamine substituted imidazoquinolines 3M Innovative Properties Company Nov- Nov Dec
03 -04 -13
22- 23- 3-
RNAi modulation of RSV, PIV and other respiratory viruses and uses
US8598134 South Alabama Medical Science Foundation Oct- Jul- Dec
thereof
04 10 -13
4- 29- 3-
US8598116 Treatment of influenza virus infection Educational Fund and Autoimmune Technologies, LLC Nov- May Dec
03 -12 -13
17- 5- 3-
Anti-microbial composition exhibiting residual anti-microbial
US8598106 Byotrol PLC Sep- Jul- Dec
properties on a surface
07 11 -13
8- 6- 3-
Methods for treating rheumatoid arthritis with anti-bile salt-
US8597650 HERNELL OLLE Apr- Apr Dec
stimulated lipase (BSSL) antibodies
09 -10 -13
23- 22- 3-
Phenoxyacetic acid derivatives useful for treating respiratory
US8524715 Astrazeneca AB Nov- Nov Sep
diseases
04 -05 -13
10- 9- 3-
Methods and devices for determining a cell characteristic, and
US8524488 The Regents of the University of California Sep- Mar Sep
applications employing the same
02 -05 -13
18- 3-
20-
US8524241 Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A The General Hospital Corporation Jul- Sep
Jul-07
08 -13
13- 13- 27-
US8519106 Monoclonal human tumor-specific antibody University of Zurich Mar- Mar Aug
07 -08 -13
8- 7- 13-
National University Corporation, Hamamatsu University
US8507545 Cytotoxic T cell activator comprising EP4 agonist May- May Aug
School of Medicine
07 -08 -13
3- 13-
5-Jul-
US8507544 Bi-aryl amide compounds as CRTh2 receptor modulators Astrazeneca AB Jul- Aug
07
08 -13
4- 4- 13-
US8507455 Folate conjugates Alnylam Pharmaceuticals, Inc. Dec- Dec Aug
07 -08 -13
29- 28- 13-
US8506968 SARS vaccine compositions and methods of making and using them Eli Lilly and Company Jun- Dec Aug
00 -09 -13
22- 20- 13-
US8506966 Adjuvanted influenza vaccines for pediatric use Novartis AG Feb- Feb Aug
08 -09 -13
5- 4- 6-
US8501746 Organic compounds Novartis AG Jun- Jun Aug
06 -07 -13
7- 6-
3-Jul-
US8501699 Bicyclic nucleosides and nucleotides as therapeutic agents Biota Scientific Management Pty Ltd Sep Aug
08
-12 -13
10- 3- 6-
US8501461 System for performing multi-formatted assays Gen-Probe Incorporated Mar- Dec Aug
05 -09 -13
6- 28- 30-
US8497405 Process for dispersing vaporous hydrogen peroxide STERIS Inc. Mar- Feb Jul-
07 -13 13
28- 28- 30-
US8497112 Method for producing viral vaccines Baxter Healthcare SA Aug- Aug Jul-
07 -08 13
6- 10- 23-
Systems and methods for identifying replikin scaffolds and uses of
US8494781 BOGOCH ELENORE S Jun- Dec Jul-
said replikin scaffolds
03 -10 13
11- 23-
12-
US8492329 Bioactive peptides and methods of using same Compugen Ltd. Jul- Jul-
Jul-07
08 13
14- 14- 16-
US8486959 Dibenzo[f,h]isoquinoline derivatives National Health Research Institutes Jan- Jan Jul-
10 -11 13
23- 1- 16-
US8486678 Pharmaceutical compositions for the treatment of virus infection Kineta Two, LLC Nov- Feb Jul-
05 -12 13
21- 20- 2-
US8476288 Salts 756 AstraZeneca AB May- May Jul-
09 -10 13
14- 2-
30-
US8476265 Compounds-801 AstraZeneca AB Sep Jul-
Jul-10
-12 13
14- 18- 25-
Method and medicament for inhibiting the infection of influenza
US8470771 Institute of Microbiology, Chinese Academy of Sciences Nov- Dec Jun-
virus
07 -07 13
18- 30- 25-
Method of treatment of bacterial infection by administration of poly-
US8470769 Novabiotics, Ltd. Aug- Nov Jun-
lysine
04 -11 13
RNA virus infection inhibitor, method for inhibition of infection by 16- 16- 21-
US8444961 RNA virus, RNA virus infection-inhibiting product, and use as RNA Sekisui Chemical Co., Ltd. Jun- Jun May
virus infection inhibitor 09 -10 -13
16- 14-
17-
US8440704 Quercetin-containing compositions Quercegen Pharmaceuticals LLC Dec May
Jul-06
-09 -13
24- 11- 14-
US8440649 Phenanthroindolizidine analogues National Health Research Institutes Feb- Feb May
09 -10 -13
16- 1- 14-
US8440642 Boron-containing small molecules Anacor Pharmaceuticals, Inc. Feb- Sep May
05 -11 -13
10- 22- 14-
US8440432 Tal effector-mediated DNA modification Iowa State University Research Foundation, Inc. Dec- Mar May
09 -12 -13
10- 22- 14-
US8440431 TAL effector-mediated DNA modification Iowa State University Research Foundation, Inc. Dec- Mar May
09 -12 -13
29- 10- 14-
US8440408 Animal protein-free media for cultivation of cells Baxter Healthcare S.A. Oct- Dec May
04 -10 -13
8- 6- 7-
US8436178 Imidazoquinolines with immuno-modulating properties AstraZeneca AB May- May May
07 -08 -13
2- 1- 7-
US8436024 2-pyridone compounds Astrazeneca AB Oct- Oct May
09 -10 -13
24- 24- 30-
Microparticles containing biodegradable polymer and cationic
US8431160 Novartis AG Feb- Feb Apr-
polysaccharide for use in immunogenic compositions
06 -07 13
The United States of America as represented by the 31- 30-
Use of a pneumococcal P4 peptide for enhancing 31-
US8431134 Secretary of the Department of Health and Human Jul- Apr-
opsonophagocytosis in response to a pathogen Jul-08
Services, Centers for Disease Control and Prevention 09 13
30- 29- 23-
US8426565 Dendritic cell marker and uses thereof Walter and Eliza Hall Institute of Medical Research Aug- Aug Apr-
07 -08 13
1- 31- 16-
US8420798 Method for producing nucleic acid probes Ventana Medical Systems, Inc. Sep- Aug Apr-
06 -07 13
8- 6- 2-
2-pyrazinone derivatives for the treatment of disease or condition in
US8410114 AstraZeneca AB May- Jan Apr-
which inhibition of neutrophil elastase activity is beneficial
06 -12 13
21- 14- 2-
US8409589 Mutant forms of streptolysin O Novartis AG Dec- Sep Apr-
07 -11 13
12- 10- 19-
US8399651 Nucleic acids encoding GAS57 mutant antigens Novartis AG Sep- Sep Mar
07 -12 -13
29- 22- 19-
US8398992 Methods and compositions for polytopic vaccination Polytopos LLC Apr- Dec Mar
05 -11 -13
21- 26- 12-
US8394986 Phenoxiacetic acid derivatives AstraZeneca AB Aug- Jul- Mar
03 11 -13
11- 7- 12-
US8394945 Compositions for use in identification of bacteria Ibis Biosciences, Inc. Sep- Mar Mar
03 -07 -13
28- 27- 12-
Sequential delivery of immunogenic molecules via adenovirus and
US8394386 The Trustees of the University of Pennsylvania Apr- Apr Mar
adeno-associated virus-mediated administrations
04 -05 -13
20- 20- 9-
US7829712 Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase Xenon Pharmaceuticals Inc. Sep- Sep Nov
04 -05 -10
6- 5- 9-
US7829707 Pyrrolo [3,2-d]pyrimidin-4-one derivatives and their use in therapy AstraZeneca AB Dec- Dec Nov
04 -05 -10
8- 7- 9-
US7829302 Method for detecting the specificity of activated lymphocyte HU JUN Dec- Dec Nov
03 -04 -10
3- 18- 26-
Methods and apparatus to prevent, treat, and cure the symptoms of
US7820210 Inhalation, Inc. Apr- Mar Oct-
nausea caused by chemotherapy treatments of human cancers
00 -08 10
2- 2- 6-
US7691599 Mammalian genes involved in viral infection and tumor suppression Zirus, Inc. May- May Apr-
02 -03 10
2- 19- 6-
US7691390 Viral protein CHANG MING-FU Mar- Sep Apr-
04 -07 10
27- 25- 30-
US7687535 Substituted 3-sulfur indoles AstraZeneca AB May- May Mar
03 -04 -10
16- 30-
9-Jul-
US7687475 RNA interference in respiratory epithelial cells University of Iowa Research Foundation Oct Mar
04
-07 -10
26- 20- 23-
Microporous materials, methods, and articles for localizing and
US7682688 University of Utah Research Foundation Nov- Nov Mar
quantifying analytes
02 -03 -10
16- 26- 16-
US7678774 Treating severe acute respiratory syndrome Hemispherx Biopharma May- Jan Mar
03 -07 -10
15- 16-
Liposomes coated with selected antibodies that bind to 15-
US7678386 Board of Regents the University of Texas Aug Mar
aminophospholipids Jul-02
-03 -10
19- 14- 9-
Fluorene derivatives, composition containing said derivatives and
US7674795 Aventis Pharma SA May- Nov Mar
the use thereof
05 -07 -10
15- 1-
Cancer treatment methods using selected immunoconjugates for 15-
US7625563 Board of Regents, The University of Texas System Aug Dec
binding to aminophospholipids Jul-02
-03 -09
28- 28- 1-
US7625492 Charge-based water filtration systems The University of Wyoming Research Corporation Jan- Jan Dec
03 -04 -09
28- 28- 1-
US7625428 Bioagent air filtration systems The University of Wyoming Research Corporation Jan- Jan Dec
03 -04 -09
6- 24-
Computer-implemented biological sequence identifier system and The United States of America as represented by the 2-Jul-
US7623997 Jun Nov
method Secretary of the Navy 04
-06 -09
16- 27- 24-
US7622559 Human monoclonal antibodies against interleukin 8 (IL-8) Genmab A/S Dec- Jun Nov
02 -07 -09
5- 5- 24-
US7622125 Polycistronic HIV vector constructs Novartis Vaccines and Diagnostics, Inc. May- May Nov
04 -05 -09
15- 24-
Cancer treatment methods using selected antibodies to 15-
US7622118 Board of Regents, The University of Texas System Aug Nov
aminophospholipids Jul-02
-03 -09
5- 6- 24-
US7622112 Anti-SARS monoclonal antibodies Not Available Dec- Dec Nov
03 -04 -09
18- 17- 17-
US7619067 Evolved interferon-alpha polypeptides Maxygen, Inc. May- May Nov
05 -06 -09
19- 17-
Compositions of coronaviruses with a recombination-resistant 21-
US7618802 The University of North Carolina at Chapel Hill Jan Nov
genome Jul-03
-06 -09
10- 5- 17-
Proteome epitope tags and methods of use thereof in protein
US7618788 Millipore Corporation May- Feb Nov
modification analysis
02 -04 -09
19- 17-
21-
US7618635 Super-antigen fusion proteins and the use thereof Healthbanks Biotech Co., Ltd. Jul- Nov
Jul-04
05 -09
2- 2- 10-
Method and apparatus for detecting estradiol and metabolites
US7615381 BioScale, Inc. May- May Nov
thereof using an acoustic device
05 -06 -09
9- 8- 4-
US7569384 Albumin fusion proteins Human Genome Sciences, Inc. Feb- Aug Aug
04 -06 -09
13- 13- 23-
US7550140 Antibody to the human OX40 receptor Crucell Holland B.V. Jun- Jun Jun-
02 -03 09
20- 20- 16-
Bicyclic heterocyclic derivatives and their use as inhibitors of
US7547698 Xenon Pharmaceuticals Inc. Sep- Sep Jun-
stearoyl-coadesaturase (SCD)
04 -05 09
10- 10- 16-
Method for reducing the presence of amplification inhibitors in a
US7547516 Gen-Probe Incorporated Mar- Mar Jun-
reaction receptacle
05 -06 09
Synthetic peptide targeting critical sites on the SARS-associated 22- 28- 17-
US7491489 coronavirus spike protein responsible for viral infection and method The University of Hong Knog Nov- Oct Feb
of use thereof 04 -05 -09
9- 10- 17-
US7491397 Receptor binding polypeptides National Health Research Institutes Jan- Jan Feb
04 -05 -09
18- 30- 10-
US7488801 Interferon-alpha polypeptides and conjugates Maxygen, Inc. Nov- Oct Feb
02 -06 -09
18- 30- 10-
US7488589 Interferon-alpha polypeptides and conjugates Maxygen, Inc. Nov- Oct Feb
02 -06 -09
18- 30- 10-
US7488473 Interferon-alpha polypeptides and conjugates Maxygen, Inc. Nov- Oct Feb
02 -06 -09
27- 27- 3-
US7485432 Selective modulation of TLR-mediated biological activity 3M Innovative Properties Company Feb- Feb Feb
03 -04 -09
28- 12- 27-
US7482334 Therapeutic treatment methods Hollis-Eden Pharmaceuticals, Inc. Aug- Feb Jan-
02 -07 09
9- 9- 27-
Inhibition of SARS coronavirus infection with clinically approved
US7482149 Genome Institute of Singapore Jun- Jun Jan-
antiviral drugs
03 -04 09
25- 25- 20-
Peptides and peptidomimetics having immune-modulating, anti-
US7479484 Takeda Pharmaceutical Company Limited Jun- Jun Jan-
inflammatory, and anti-viral activity
03 -04 09
26- 25- 30-
Use of Ulinastatin and its pharmaceutical composition for treating
US7470666 Guangdong Techpool Biochem. Pharma. Co., Ltd. May- May Dec
severe acute respiratory syndrome
03 -04 -08
6- 27- 29-
US7405046 Compositions and methods for treatment of rhinovirus The Quigley Corporation Aug- Oct Jul-
01 -06 08
27- 15- 15-
US7399588 Method for detecting SARS coronavirus Eiken Kagaku Kabushiki Kaisha Jun- Jun Jul-
03 -04 08
4- 4- 8-
US7396914 SARS nucleic acids, proteins, antibodies, and uses thereof University of Massachusetts Aug- Aug Jul-
03 -04 08
14- 14- 1-
US7393856 Anti-viral uses of borinic acid complexes Anacor Pharmaceuticals, Inc. Jun- Jun Jul-
04 -05 08
1- 1-
1-Jul-
US7393638 Assay system and methods for detecting SARS-CV AsiaGEN Corporation Jul- Jul-
03
03 08
30- 30- 17-
US7387271 Immunostimulatory combinations 3M Innovative Properties Company Dec- Dec Jun-
02 -03 08
PCR primer set for detecting severe acute respiratory syndrome 12- 24- 20-
US7375210 (SARS)-Coronavirus, method and kit for detecting SARS- Samsung Electronics Co., Ltd. Dec- Nov May
Coronavirus using the same 03 -04 -08
3- 27- 18-
Methods and apparatus to prevent, treat, and cure the symptoms of
US7344740 Inhalation, Inc. Apr- Nov Mar
nausea caused by chemotherapy treatments of human cancers
00 -04 -08
Methods and apparatus to prevent, treat and cure infections of the 3- 2- 23-
US7048953 human respiratory system by pathogens causing severe acute Inhalation, Inc. Apr- May May
respiratory syndrome (SARS) 00 -03 -06
28- 17- 4-
US7023593 Apparatus for forming nano-grating device Industrial Technology Research Institute Nov- Mar Apr-
03 -04 06
24- 30- 20-
US6946291 Mixed cell diagnostic systems Diagnostic Hybrids, Inc. Apr- Mar Sep
98 -04 -05
18- 4-
US20200176 METHODS AND DEVICES FOR NUCLEIC ACID-BASED REAL-TIME 19-
Not Available Jul- Jun-
079 DETERMINATION OF DISEASE STATES Jul-17
18 20
19- 13- 4-
US20200172 COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND
Not Available Nov- Sep Jun-
883 ACTIVITY, AND RELATED METHODS
09 -19 20
3- 2- 4-
US20200172
DHFR TUNABLE PROTEIN REGULATION Not Available Mar- Sep Jun-
879
17 -19 20
16- 4-
US20200172 15-
RSV F PROTEIN COMPOSITIONS AND METHOD FOR MAKING SAME GLAXOSMITHKLINE BIOLOGICALS, SA Aug Jun-
600 Jul-09
-17 20
12- 5- 4-
US20200172
DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS Hoffmann-La Roche Inc. Jun- Feb Jun-
513
16 -20 20
5- 4-
US20200172 CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC 12-
HANGZHOU DAC BIOTECH CO., LTD. Feb Jun-
480 AGENTS Jul-12
-20 20
19- 18- 4-
US20200171
Method of Treating Respiratory Tract Infection Not Available May- May Jun-
085
17 -18 20
26- 4-
US20200171 FLEX-NUCLEOSIDE ANALOGUES, NOVEL THERAPEUTICS AGAINST 31-
Not Available Jan Jun-
060 FILOVIRUSES AND FLAVIVIRUSES Jul-17
-18 20
7- 6- 28-
US20200165 ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR
Spark Therapeutics, Inc. Jun- Jun May
632 rAAV VECTOR PRODUCTION
17 -18 -20
2- 2- 14-
US20200147 COMPOSITIONS AND METHODS FOR TUMOR VACCINATION AND
Not Available Jun- Jun May
193 IMMUNOTHERAPY INVOLVING HER ANTIGENS
17 -18 -20
26- 25- 7-
US20200140 MULTIFUNCTIONAL ANTIBODY-LIGAND TRAPS TO MODULATE
Not Available May- May May
547 IMMUNE TOLERANCE
17 -18 -20
26- 25- 7-
US20200140
Engineering Virus-like Nanocarriers for Biomolecule Delivery Not Available Oct- Oct May
493
18 -19 -20
13- 6- 7-
US20200140
HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS AZIENDA OSPEDALIERA UNIVERSITARIA SENESE Feb- Jan May
398
15 -20 -20
6- 5- 2-
US20200102 TUMOR NECROSIS FACTOR RECEPTOR (TNFR) BINDING PROTEIN
Not Available Apr- Apr Apr-
362 COMPLEX WITH IMPROVED BINDING AND BIOACTIVITY
17 -18 20
10- 2-
US20200102 SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS 3-Jul-
Not Available Jul- Apr-
292 AND USES THEREOF 13
19 20
1- 22- 2-
US20200101 ANTI-TIGIT ANTIGEN-BINDING PROTEINS AND METHODS OF USE
Not Available Oct- Oct Apr-
158 THEREOF
15 -19 20
6- 6- 2-
US20200101
MVA-BN AND AD26.ZEBOV OR AD26.FILO PRIME-BOOST REGIMEN Not Available Apr- Apr Apr-
153
17 -18 20
12- 12- 2-
US20200101
PDE5 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY Not Available Jun- Jun Apr-
142
17 -18 20
11- 3- 26-
US20200093 ENHANCED IMMUNE RESPONSE UPON TREATMENT WITH NITRIC
Not Available Sep- Jun Mar
855 OXIDE
17 -19 -20
17- 30- 26-
US20200093
Broad Spectrum Antiviral and Methods of Use Not Available Apr- Apr Mar
841
06 -19 -20
22- 19-
US20200087 PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM 14-
Not Available Nov Mar
655 OXIDES Jul-15
-19 -20
31- 31- 19-
US20200087 OPTIMIZED HUMAN CLOTTING FACTOR IX GENE EXPRESSION
Not Available May- May Mar
646 CASSETTES AND THEIR USE
17 -18 -20
10- 25- 19-
US20200087
INFLUENZA VIRUS AND TYPE 1 DIABETES Istituto Zooprofilattico Sperimentale delle Venezie Oct- Jul- Mar
630
12 19 -20
10- 27- 19-
US20200087 The United States of America,as represented by the
GRIFFITHSIN MUTANTS Feb- Nov Mar
359 Secretary,Department of Health and Human Services
15 -19 -20
25- 19-
US20200087 29-
NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Not Available Apr Mar
313 Jul-11
-19 -20
1- 27- 19-
US20200087 Imidazo[4,5-c] Ring Compounds Containing Guanidine Substituted
Not Available Mar- Feb Mar
298 Benzamide Groups
17 -18 -20
5- 25- 19-
US20200087 QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-
Not Available Feb- Nov Mar
280 SPECIFIC PROTEASE 7 INHIBITORS
15 -19 -20
30- 27- 19-
US20200086
DEVICES AND METHODS FOR NUCLEIC ACID EXTRACTION Not Available Jun- Dec Mar
324
16 -18 -20
7- 25- 19-
US20200085 APPARATUS, METHOD AND SYSTEM FOR SELECTIVELY AFFECTING THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF
Mar- Nov Mar
984 AND/OR KILLING A VIRUS NEW YORK
11 -19 -20
7- 14- 19-
US20200085
VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER Not Available Sep- May Mar
947
12 -19 -20
1- 1- 12-
US20200078
COMPOSITIONS AND METHODS TO REDUCE PATHOGENESIS Not Available May- May Mar
335
17 -18 -20
5- 2- 5-
US20200072 MEDIA ELABORATED WITH NEWLY SYNTHESIZED ANTIBODIES
Not Available May- Apr Mar
836 (MENSA) AND USES THEREOF
14 -19 -20
30- 29- 5-
US20200071
RNA-BASED DELIVERY SYSTEMS WITH LEVELS OF CONTROL Not Available Aug- Aug Mar
723
18 -19 -20
9- 16- 6-
US20200038
NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Not Available May- May Feb
373
12 -19 -20
6- 14- 30-
US20200033 EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS
Not Available Oct- Oct Jan-
343 INFECTIONS AND DISEASES
08 -19 20
26- 6- 30-
US20200032 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
Not Available Jan- Mar Jan-
255 OR OTHER DISEASES
07 -19 20
4- 30- 30-
US20200031
NOVEL DEPSIPEPTIDES AND USES THEREOF Not Available Apr- Mar Jan-
871
17 -18 20
23- 26- 30-
US20200031
COMPOSITIONS AND METHODS FOR INHIBITING KINASES Not Available Apr- Jun Jan-
819
15 -19 20
17- 8- 30-
US20200030 Lipidated Immune Response Modifier Compound Compositions,
Not Available Aug- Jul- Jan-
441 Formulations, and Methods
10 19 20
3- 1- 23-
US20200024
NOVEL DEPSIPEPTIDE AND USES THEREOF Not Available Dec- Aug Jan-
310
12 -19 20
8- 7- 16-
US20200020 Method for Establishing Machine Learning Model for Predicting
Not Available Dec- Dec Jan-
420 Toxicity of siRNA to Certain Type of Cells and Application Thereof
16 -17 20
7- 28- 16-
US20200017 CELL-FREE NUCLEIC ACIDS FOR THE ANALYSIS OF THE HUMAN
Not Available Nov- Aug Jan-
926 MICROBIOME AND COMPONENTS THEREOF
13 -19 20
2- 3- 26-
US20190390 NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH
Not Available Dec- Jul- Dec
176 ENHANCED HUMAN SKELETAL MUSCLE TROPISM
15 19 -19
4- 8- 12-
US20190376 MODIFIED OLIGONUCLEOTIDES COMPRISING THIOL FUNCTIONS
Not Available Apr- Feb Dec
151 AND USE THEREOF FOR DETECTING NUCLEIC ACIDS
12 -19 -19
5- 18- 28-
US20190359 THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7
Not Available Feb- Jul- Nov
629 INHIBITORS
15 19 -19
12- 12- 28-
US20190358 STOMACH ACID-STABLE AND MUCIN-BINDING PROTEIN-POLYMER
Not Available Jan- Jan Nov
335 CONJUGATES
17 -18 -19
19- 19- 28-
US20190358
ANTIGEN-ADJUVANT COUPLING REAGENTS AND METHODS OF USE Not Available Dec- Dec Nov
312
17 -18 -19
11- 9- 24-
US20190321 IMMUNOMODULATORY COMPOSITIONS, PROCESSES FOR MAKING
NantBio, Inc. Nov- Nov Oct-
481 THE SAME, AND METHODS FOR INHIBITING CYTOKINE STORMS
16 -17 19
2- 30- 24-
US20190321 ENGINEERED B CELLS AND RELATED COMPOSITIONS AND
Juno Therapeutics, Inc. Dec- Nov Oct-
403 METHODS
16 -17 19
9- 9- 26-
US20190292
MODULATION OF IFI16 AND STING ACTIVITY Not Available Aug- Aug Sep
236
16 -17 -19
3- 19- 26-
US20190292
Cyclic Di-Nucleotide Induction of Type I Interferon Not Available May- Feb Sep
216
13 -19 -19
11- 26- 26-
US20190292 HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER
Dana-Farber Cancer Institute, Inc. Apr- Jan Sep
178 VIRUSES
12 -18 -19
2- 31- 26-
US20190290
Composition for Promoting Production of Immunostimulatory Factor Kyoto University Aug- Jul- Sep
674
16 17 -19
24- 24- 19-
US20190285
METABALOMICS AND VIRAL DIAGNOSTICS SUITE Excision Biotherapeutics, Inc. May- May Sep
632
16 -17 -19
21- 30- 19-
US20190284
REVERSE GENETICS USING NON-ENDOGENOUS POL I PROMOTERS Not Available May- Jan Sep
575
09 -19 -19
15- 24- 19-
US20190284 DETECTION OF T CELL EXHAUSTION OR LACK OF T CELL
Not Available May- May Sep
531 COSTIMULATION AND USES THEREOF
15 -19 -19
29- 22- 19-
US20190284
ASSEMBLED GLYCOPROTEINS Not Available Sep- Sep Sep
230
16 -17 -19
14- 30- 19-
US20190282 IMMUNOPROTECTIVE PRIMARY MESENCHYMAL STEM CELLS AND
AUTOIMMUNE TECHNOLOGIES, LLC Mar- May Sep
694 METHODS
13 -19 -19
1- 29- 19-
US20190282
Method Of Treating Inflammation Not Available Apr- May Sep
608
10 -19 -19
2- 5- 12-
US20190276
COMPOSITION AND METHODS OF TREATING B CELL DISORDERS Not Available Sep- Sep Sep
523
16 -17 -19
8- 8- 12-
US20190275
SYSTEM FOR THE PRODUCTION OF CELLS AND/OR CELL PRODUCTS Not Available Nov- Nov Sep
519
16 -17 -19
5- 5- 12-
US20190275 STRUCTURE OF GII.4 NOROVIRUS PROTEASE - DESIGN OF BROAD-
Not Available Oct- Oct Sep
101 SPECTRUM PROTEASE INHIBITORS
16 -17 -19
8- 11- 5-
US20190269
HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS Not Available Mar- Oct Sep
694
11 -18 -19
15- 20- 5-
US20190269
Specific Akt3 Inhibitor and Uses Thereof Not Available Jan- May Sep
672
16 -19 -19
24- 29-
US20190264 25-
PHASING Wave Life Sciences Ltd. Jul- Aug
267 Jul-16
17 -19
18- 10- 29-
US20190264
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available Nov- May Aug
177
13 -19 -19
26- 25- 29-
US20190263 FC VARIANTS WITH ENHANCED BINDING TO FCRN AND
Not Available Jan- Jan Aug
934 PROLONGED HALF-LIFE
18 -19 -19
18- 7- 29-
US20190262
Cationic Oil-In-Water Emulsions GLAXOSMITHKLINE BIOLOGICALS, SA Sep- Mar Aug
448
11 -19 -19
20- 20- 29-
US20190262 METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL
Not Available Oct- Oct Aug
371 INFECTIONS
16 -17 -19
24- 3- 22-
US20190256 MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS The U.S.A., as represented by the Secretary, Department
Feb- May Aug
579 IMMUNOGENS, ANTIBODIES, AND THEIR USE of Health and Human Services
15 -19 -19
16- 1- 22-
US20190255 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE
Not Available Sep- Feb Aug
085 VIRUS INFECTIONS
15 -19 -19
2- 22-
US20190254 6-Jul-
OIL-IN-WATER EMULSIONS THAT CONTAIN NUCLEIC ACIDS GLAXOSMITHKLINE BIOLOGICALS S.A. May Aug
968 11
-19 -19
20- 19- 15-
US20190250 MULTI-CONFIGURABLE SENSING ARRAY AND METHODS OF USING
Board of Regents, The University of Texas System Oct- Oct Aug
153 SAME
16 -17 -19
16- 20- 15-
US20190248
HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) Not Available Dec- Feb Aug
883
02 -19 -19
30- 30- 15-
US20190248 POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF
Not Available Jun- Apr Aug
866 AUTOIMMUNE DISORDERS AND INFECTION
11 -18 -19
15- 15- 8-
US20190241 ANTI-PNEUMOCOCCAL HYPERIMMUNE GLOBULIN FOR THE
Not Available Mar- Apr Aug
646 TREATMENT AND PREVENTION OF PNEUMOCOCCAL INFECTION
17 -19 -19
30- 22- 8-
US20190241
INHIBITION OF TCR SIGNALING WITH PEPTIDE VARIANTS Not Available Sep- Oct Aug
618
09 -18 -19
22- 28- 8-
US20190240
HPIV3 RNA VACCINES ModernaTX, Inc. Oct- Mar Aug
317
15 -19 -19
28- 25- 1-
US20190233 PROTEIN PROXIMITY ASSAY IN FORMALIN FIXED PARAFFIN
Not Available Aug- Feb Aug
447 EMBEDDED TISSUE USING CAGED HAPTENS
15 -19 -19
23- 20- 1-
US20190232
METHODS AND COMPOSITIONS FOR DETECTING ANALYTES Not Available Sep- Sep Aug
282
16 -17 -19
17- 13- 1-
US20190231
MASK NBC MESHTEC INC. Oct- Oct Aug
004
16 -17 -19
GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING 28- 30- 25-
US20190225
LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA Not Available Oct- Nov Jul-
986
VIRUS SPIKE PROTEIN 05 -18 19
10- 4- 25-
US20190225 METHOD OF INCREASING THE REPLICATION OF A CIRCULAR DNA
Not Available Aug- Aug Jul-
971 MOLECULE
15 -16 19
29- 28- 25-
US20190224
COMPOSITIONS FOR THE TREATMENT OF DISEASE Not Available Apr- Apr Jul-
339
16 -17 19
13- 25-
US20190223 14-
ANTIMICROBIAL GEOPOLYMER COMPOSITIONS Not Available Jul- Jul-
445 Jul-16
17 19
16- 29- 18-
US20190220 DETERMINING EXPLANATIONS FOR PREDICTED LINKS IN
Not Available Jan- Mar Jul-
524 KNOWLEDGE GRAPHS
18 -18 19
16- 17- 18-
US20190219
Assay for Detecting TH1 and TH2 Cell Populations Not Available May- Dec Jul-
563
14 -18 19
2- 28- 18-
US20190218
METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR The Trustees of the University of Pennsylvania Oct- Mar Jul-
574
07 -19 19
16- 15- 18-
US20190218 ANTI-DENGUE VIRUS ANTIBODIES, POLYPEPTIDES CONTAINING
Not Available Sep- Sep Jul-
277 VARIANT FC REGIONS, AND METHODS OF USE
16 -17 19
17- 17- 18-
US20190218 3-(Pyridin-3-yl)-Acrylamide and N-(Pyridin-3-yl)-Acrylamide
Not Available Aug- Aug Jul-
207 Derivatives and Their Use as PAK or NAMPT Modulators
15 -16 19
21- 1- 18-
US20190216 METHOD FOR INCREASING EXPRESSION OF RNA-ENCODED
CureVac AG Aug- Apr Jul-
951 PROTEINS
13 -19 19
22- 28- 18-
US20190216
HMPV RNA VACCINES ModernaTX, Inc. Oct- Mar Jul-
917
15 -19 19
2- 15- 18-
US20190216
TRANSGENIC VERO-CD4/CCR5 CELL LINE Not Available Oct- Feb Jul-
915
15 -19 19
20- 20- 18-
US20190216 Regimens and Compositions for AAV-Mediated Passive
Not Available Apr- Mar Jul-
841 Immunization of Airborne Pathogens
11 -19 19
13- 27- 11-
US20190211
COMPOSITIONS COMPRISING CURONS AND USES THEREOF Not Available Jun- Mar Jul-
361
17 -19 19
7- 15- 4-
US20190202
CORONAVIRUS PROTEINS AND ANTIGENS Phibro Animal Health Corporation Feb- Mar Jul-
868
14 -19 19
4- 8- 4-
US20190202
ENANTIOMERS OF THE 1',6'-ISOMER OF NEPLANOCIN A Not Available Aug- Mar Jul-
854
14 -19 19
29- 11- 4-
US20190201 DECONTAMINATION DEVICE AND METHOD USING ULTRASONIC
Not Available Dec- Sep Jul-
565 CAVITATION
17 -18 19
29- 29- 4-
US20190201 DECONTAMINATION DEVICE AND METHOD USING ULTRASONIC
Not Available Dec- Dec Jul-
564 CAVITATION
17 -17 19
28- 28- 4-
US20190201
Aptamer Compositions and Methods of Use Thereof Not Available Dec- Dec Jul-
552
17 -18 19
7- 5- 4-
US20190201 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR
Atea Pharmaceuticals, Inc. Sep- Mar Jul-
433 RNA VIRUS TREATMENT
16 -19 19
30- 12- 4-
US20190201 DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER
Not Available Jan- Mar Jul-
352 NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS ACTIVITY
15 -19 19
3- 3- 4-
US20190201 HYDROPHILIC FILTRATION DURING MANUFACTURE OF VACCINE
Not Available Dec- Jan Jul-
337 ADJUVANTS
09 -19 19
24- 24- 27-
US20190194
Systemic inflammatory and pathogen biomarkers and uses therefor Not Available Aug- Aug Jun-
728
16 -17 19
5- 4- 27-
US20190194
METHOD AND KIT FOR DETECTING PATHOGENIC MICROORGANISM JAPAN SCIENCE AND TECHNOLOGY AGENCY Sep- Sep Jun-
717
16 -17 19
1- 1- 27-
US20190194
METHODS FOR PRODUCING VIRUS FOR VACCINE PRODUCTION Takeda Pharmaceutical Company Limited Sep- Sep Jun-
628
16 -17 19
3- 3- 27-
US20190194 IDENTIFICATION OF VSIG3/VISTA AS A NOVEL IMMUNE
BIO-TECHNE CORPORATION Aug- Aug Jun-
322 CHECKPOINT AND USE THEREOF FOR IMMUNOTHERAPY
16 -17 19
26- 1- 27-
US20190194 FUSED [1,2]IMIDAZO[4,5-C] RING COMPOUNDS SUBSTITUTED
Not Available Aug- Aug Jun-
226 WITH GUANIDINO GROUPS
16 -17 19
30- 27-
US20190194 1-Jul-
COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION Arrakis Therapeutics, Inc. Jun Jun-
150 16
-17 19
11- 11- 27-
US20190192
REGULATED BIOCIRCUIT SYSTEMS Not Available Apr- Apr Jun-
691
16 -17 19
4- 1- 27-
US20190192
Methods of Populating a Gastrointestinal Tract Not Available Feb- Aug Jun-
581
13 -18 19
6- 7- 20-
US20190187 ASSAY FOR QUANTITATION OF PROTEINS AND PEPTIDES USING
UVic Industry Partnerships Inc. Jun- Apr Jun-
151 STABLE ISOTOPE STANDARDS
16 -17 19
28- 19- 20-
US20190187 COLORS FOR CHROMOGENIC IHC AND ISH STAINING WITH MULTI-
Not Available Jun- Dec Jun-
130 DYE QUINONE METHIDE AND TYRAMIDE CONJUGATES
16 -18 19
5- 20- 20-
US20190185 LUMINOPHORE-LABELED MOLECULES COUPLED WITH PARTICLES
CapitalBio Corporation Dec- Nov Jun-
922 FOR MICROARRAY-BASED ASSAYS
13 -18 19
4- 30- 6-
US20190166 METHOD FOR PRODUCING A PROTEIN PHOSPHOLIPID COMPLEX
Not Available Dec- Nov Jun-
866 FROM A CRUSTACEAN CATCH
17 -18 19
1- 1- 30-
US20190160 Novel Polygonum Cuspidatum Extracts and Their Use as
Not Available Oct- Feb May
129 Photodynamic Inactivating Agents
15 -19 -19
31- 30- 30-
US20190160
NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Not Available Dec- Dec May
063
15 -16 -19
17- 7- 23-
US20190154
DETECTION DEVICE AND DETECTION METHOD Kabushiki Kaisha Toshiba Nov- Mar May
687
17 -18 -19
6- 6- 23-
US20190154
BIOAEROSOL DETECTION SYSTEMS AND METHODS OF USE Not Available Apr- Apr May
550
16 -17 -19
29- 28- 23-
US20190153
COMPOSITIONS FOR THE TREATMENT OF DISEASE Not Available Apr- Apr May
471
16 -17 -19
21- 5- 23-
US20190153
Heterodimeric Immunoglobulins Not Available Nov- Feb May
086
12 -19 -19
29- 21- 23-
US20190151 DEVICES AND METHODS FOR THE DETECTION OF MOLECULES
Click Diagnostics, Inc. Jun- Dec May
844 USING A FLOW CELL
16 -18 -19
8- 8- 23-
US20190151 RNA-BASED LOGIC CIRCUITS WITH RNA BINDING PROTEINS,
Kyoto University Sep- Sep May
474 APTAMERS AND SMALL MOLECULES
14 -15 -19
6- 9- 16-
US20190144
ENHANCED METHODS OF RIBONUCLEIC ACID HYBRIDIZATION Not Available Dec- Jan May
930
13 -19 -19
15- 15- 16-
US20190144
DEVICES FOR CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS Not Available Mar- Mar May
929
17 -18 -19
18- 19- 16-
US20190144
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES RUBIUS THERAPEUTICS, INC. Nov- Nov May
827
13 -18 -19
13- 12- 16-
US20190144 ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR
Not Available May- May May
556 SUPERFAMILY ANTIBODIES
16 -17 -19
13- 13- 2-
US20190125 Antimicrobial and Antiviral Agent, Antimicrobial and Antiviral
Murata Manufacturing Co., Ltd. Jun- Dec May
806 Member, and Method for Producing Antimicrobial and Antiviral Agent
16 -18 -19
2- 27- 2-
US20190125
PREVENTION AND TREATMENT OF VIRAL INFECTIONS Not Available Jun- Nov May
724
16 -18 -19
5- 25-
US20190119 CAPTURE PRIMERS AND CAPTURE SEQUENCE LINKED SOLID 31-
Not Available Nov Apr-
744 SUPPORTS FOR MOLECULAR DIAGNOSTIC TESTS Jul-09
-18 19
15- 26- 25-
US20190119 COMPOSITIONS AND METHODS FOR DETECTING RARE SEQUENCE
Not Available Aug- Oct Apr-
743 VARIANTS
16 -18 19
8- 7- 25-
US20190119 METHODS FOR IMPROVED HOMOLOGOUS RECOMBINATION AND
Not Available Sep- Sep Apr-
701 COMPOSITIONS THEREOF
17 -18 19
23- 24- 25-
US20190119
COMPOSITIONS AND METHODS FOR INHIBITING KINASES Not Available Apr- Oct Apr-
266
15 -18 19
18- 23- 25-
US20190119
CARBOXYLIC ACID COMPOUNDS Sumitomo Dainippon Pharma Co., Ltd. May- Oct Apr-
220
12 -18 19
15- 1- 25-
US20190117
MODULAR NANODEVICES FOR SMART ADAPTABLE VACCINES Not Available Feb- Oct Apr-
793
07 -18 19
6- 31- 25-
US20190117
USE OF ASC AND ASC-CM TO TREAT ARDS, SARS, AND MERS Indiana University Research and Technology Corporation May- Oct Apr-
702
14 -18 19
4- 12- 18-
US20190112 TAL-EFFECTOR ASSEMBLY PLATFORM, CUSTOMIZED SERVICES,
Not Available Apr- Apr Apr-
596 KITS AND ASSAYS
12 -18 19
28- 24- 18-
US20190112 USING SORTASES TO INSTALL CLICK CHEMISTRY HANDLES FOR
Whitehead Institute for Biomedical Research Jun- Sep Apr-
394 PROTEIN LIGATION
11 -18 19
METHOD FOR PREPARING VIRAL PARTICLES WITH CYCLIC 16- 16- 11-
US20190105
DINUCLEOTIDE AND USE OF SAID PARTICLES FOR TREATING Not Available Mar- Mar Apr-
381
CANCER 16 -16 19
3- 11-
US20190105 28-
Anti-Viral Azide Containing Compounds Not Available Dec Apr-
334 Jul-10
-18 19
22- 21- 4-
US20190100 Chu Strasbourg, Les Hôpitaux Universitaires de
Humanized Anti-Claudin-1 Antibodies and Uses Thereof Mar- Mar Apr-
586 Strasbourg
16 -17 19
4- 10- 4-
US20190099
Targeting Lipids Arbutus Biopharma Corporation Dec- Oct Apr-
493
07 -17 19
14- 27- 4-
US20190099
RECOMBINANT HCMV AND RHCMV VECTORS AND USES THEREOF Not Available May- Apr Apr-
479
10 -18 19
11- 6- 28-
US20190094 METHODS AND COMPOSITIONS FOR DETECTING SINGLE T CELL
Not Available Apr- Apr Mar
224 RECEPTOR AFFINITY AND SEQUENCE
16 -17 -19
6- 28-
US20190091 6-Jul-
CATIONIC OIL-IN-WATER EMULSIONS GLAXOSMITHKLINE BIOLOGICALS, SA Dec Mar
329 11
-18 -19
11- 23- 28-
US20190091 METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-
TRUSTEES OF BOSTON UNIVERSITY Mar- Apr Mar
221 INDUCED CONDITIONS
10 -18 -19
8- 15- 21-
US20190085 MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA
Not Available Sep- Nov Mar
057 AND VIRAL INFECTION
16 -18 -19
15- 17- 21-
US20190085
Alpha-Ketoamide Inhibitors Of Cysteine Proteases Not Available Sep- Sep Mar
024
17 -18 -19
7- 7- 21-
US20190085 NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND
Not Available Mar- Mar Mar
013 USES RELATED THERETO
16 -17 -19
17- 23- 21-
US20190084 CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL
Parion Sciences, Inc. Dec- Aug Mar
943 SODIUM CHANNEL BLOCKING ACTIVITY
12 -18 -19
22- 22- 21-
US20190083
METHOD FOR PRODUCING RNA MOLECULE COMPOSITIONS Not Available Dec- Dec Mar
602
15 -16 -19
30- 22- 21-
US20190083
IMMUNOSTIMULATORY COMBINATIONS Not Available Dec- Oct Mar
592
02 -18 -19
11- 24- 21-
US20190083 MICROBICIDAL COMPOSITIONS AND METHODS FOR TREATMENT OF
Not Available Jun- Jul- Mar
569 VIRAL INFECTIONS
15 18 -19
10- 21-
US20190083 COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR 11-
Not Available Jul- Mar
525 AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS Jul-17
18 -19
30- 2- 21-
US20190054 ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS
Not Available Sep- Oct Feb
188 CONTAINING SAME, AND USES THEREFOR
03 -18 -19
4- 22- 21-
US20190054
ANTIVIRAL AGENT AND ANTIVIRAL FOOD EDUCATIONAL CORPORATION MUKOGAWA GAKUIN Mar- Nov Feb
127
16 -16 -19
5- 21-
US20190054 INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF 31-
Not Available Nov Feb
122 THERAPY Jul-15
-18 -19
10- 21- 14-
US20190049 CONTINUOUS PROCESS FOR PERFORMING MULTIPLE NUCLEIC
Not Available Mar- Jun Feb
378 ACID AMPLIFICATION ASSAYS
05 -18 -19
23- 16- 14-
US20190048 CHEMICAL MODIFICATIONS OF MONOMERS AND
Not Available Sep- Aug Feb
344 OLIGONUCLEOTIDES WITH CYCLOADDITION
08 -18 -19
30- 25- 14-
US20190048 PSEUDOTYPED ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC
Not Available Jun- Oct Feb
082 POLYPEPTIDES
16 -18 -19
30- 2- 24-
US20190022 ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS
Not Available Sep- Oct Jan-
249 CONTAINING SAME, AND USES THEREFOR
03 -18 19
23- 4- 24-
US20190022 ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES
Not Available Oct- Sep Jan-
216 THEREOF
15 -18 19
27- 26- 24-
US20190022
Attenuated Infectious Bronchitis Virus Not Available Jan- Jan Jan-
214
16 -17 19
29- 29- 24-
US20190022
MERS-CoV Vaccine Not Available Nov- Jun Jan-
213
13 -18 19
26- 16- 24-
US20190022 N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related
Not Available Dec- Dec Jan-
116 Thereto
14 -15 19
11- 10- 17-
US20190017 METHOD OF DIRECT TARGET SEQUENCING USING NUCLEASE
HTG Molecular Diagnostics, Inc. Feb- Feb Jan-
112 PROTECTION
16 -17 19
5- 19- 17-
US20190015 IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE
Not Available Apr- Jul- Jan-
522 THEREOF
12 18 19
23- 27- 17-
US20190015
NUCLEIC ACID VACCINES ModernaTX, Inc. Apr- Sep Jan-
501
14 -18 19
13- 17-
US20190015 13-
Lipid Disulfide Prodrugs and Uses Related Thereto Not Available Jul- Jan-
432 Jul-17
18 19
30- 16- 10-
US20190010
ATTENUATED VIRUSES USEFUL FOR VACCINES Not Available Mar- Jul- Jan-
469
07 18 19
15- 2- 10-
US20190010 COMPOSITION COMPRISED OF ANTIGEN LINKED TO A TNF
Not Available Mar- Aug Jan-
240 SUPERFAMILY LIGAND
13 -18 19
13- 4- 10-
US20190010 ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL
Parion Sciences, Inc. Dec- Apr Jan-
132 SODIUM CHANNEL BLOCKING COMPOUNDS
13 -18 19
31- 11- 10-
US20190008 NEGATIVELY CHARGED NUCLEIC ACID COMPRISING COMPLEXES
CureVac AG Jan- Jun Jan-
954 FOR IMMUNOSTIMULATION
12 -18 19
23- 16- 10-
US20190008
NUCLEIC ACID VACCINES ModernaTX, Inc. Apr- Jul- Jan-
948
14 18 19
9- 17- 10-
US20190008
NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Not Available May- Jul- Jan-
833
12 18 19
4- 3-
US20190004 DETECTING TARGETS USING MASS TAGS AND MASS 2-Jul-
Not Available Aug Jan-
061 SPECTROMETRY 10
-18 19
9- 31- 3-
US20190002 ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND
Kineta, Inc. May- Jan Jan-
477 METHODS OF USE THEREOF
14 -18 19
31- 29- 3-
US20190002 SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS
Not Available Dec- Dec Jan-
448 AND USES THEREOF
15 -16 19
5- 19- 3-
US20190002
Lipids and Lipid Compositions for the Delivery of Active Agents Not Available Sep- Sep Jan-
393
14 -18 19
8- 13- 3-
US20190001 ADDITIVE COMPOSITIONS FOR PIGMENTED DISINFECTION AND
Not Available Dec- Jul- Jan-
010 METHODS THEREOF
14 18 19
23- 27- 3-
US20190000
NUCLEIC ACID VACCINES ModernaTX, Inc. Apr- Jul- Jan-
959
14 18 19
4- 3-
US20190000 POLYMER-BASED ANTIMICROBIAL COMPOSITIONS AND METHODS 28-
eXion labs Inc. Sep Jan-
745 OF USE THEREOF Jul-16
-18 19
22- 21- 27-
US20180372 METHODS OF IDENTIFYING IMMUNE CELLS IN PD-L1 POSITIVE
Not Available Nov- May Dec
747 TUMOR TISSUE
15 -18 -18
27- 21- 27-
US20180372 ANTIBODY-NANOPARTICLE CONJUGATES AND METHODS FOR
Not Available Apr- Jun Dec
733 MAKING AND USING SUCH CONJUGATES
10 -18 -18
1- 26- 27-
US20180371
METHODS FOR RNA QUANTIFICATION Not Available Jun- May Dec
536
15 -16 -18
4- 28- 27-
US20180371
MEANS AND METHODS FOR INFLUENCING THE STABILITY OF CELLS Not Available Dec- Aug Dec
410
09 -18 -18
8- 29- 27-
US20180369 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE
Not Available Mar- Aug Dec
386 AGENTS
13 -18 -18
1- 27-
US20180369 RECOMBINANT VIRUS LIKE PARTICLES USING BOVINE 2-Jul-
Not Available Jul- Dec
364 IMMUNODEFICIENCY VIRUS GAG PROTEIN 15
16 -18
8- 8- 20-
US20180360 METHODS FOR EXPANDING A POPULATION OF ALVEOLAR
Not Available Dec- Dec Dec
877 MACROPHAGES IN A LONG TERM CULTURE
15 -16 -18
2- 23- 20-
US20180360 FILM DOSAGE FORM WITH EXTENDED RELEASE MUCOADHESIVE
Intelgenx Corp. Dec- Aug Dec
736 PARTICLES
13 -18 -18
7- 6- 13-
US20180355
COMPOSITIONS AND METHODS FOR INTERNALIZING ENZYMES Not Available Jun- Jun Dec
017
17 -18 -18
21- 13-
US20180353 26-
METHOD FOR INACTIVATING VIRUSES USING ELECTRON BEAMS Not Available Aug Dec
594 Jul-13
-18 -18
13- 9- 6-
US20180346
ANTI-PD-L1 ANTIBODIES AND USES THEREOF Not Available Jun- Aug Dec
574
16 -18 -18
13- 9- 6-
US20180346
ANTI-PD-L1 ANTIBODIES AND USES THEREOF Not Available Jun- Aug Dec
573
16 -18 -18
27- 28- 6-
US20180346
PEPTIDES AND USES THEREFOR AS ANTIVIRAL AGENTS Not Available Nov- Nov Dec
516
15 -16 -18
5- 1- 6-
US20180346 THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7
Not Available Feb- Mar Dec
480 INHIBITORS
15 -18 -18
16- 8- 6-
US20180344 RECOMBINANT PROMOTERS AND VECTORS FOR PROTEIN
Children's Healthcare of Atlanta, Inc. Apr- Aug Dec
877 EXPRESSION IN LIVER AND USE THEREOF
15 -18 -18
20- 20- 6-
US20180344 METHODS AND COMPOSITIONS FOR COMBINATION
Not Available Apr- Apr Dec
832 IMMUNOTHERAPY
15 -16 -18
17- 26- 6-
US20180344
Broad Spectrum Antiviral and Methods of Use Not Available Apr- Dec Dec
751
06 -17 -18
9- 9- 29-
US20180340
CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS MASSACHUSETTS INSTITUTE OF TECHNOLOGY Dec- Mar Nov
219
16 -18 -18
9- 9- 29-
US20180340
CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS MASSACHUSETTS INSTITUTE OF TECHNOLOGY Dec- Mar Nov
218
16 -18 -18
28- 26- 29-
US20180340 SAMPLE ANALYSIS, PRESENCE DETERMINATION OF A TARGET
Not Available Aug- Aug Nov
215 SEQUENCE
15 -16 -18
24- 23- 29-
US20180340
PRODUCTION OF VIRUSES IN AVIAN EGGS Not Available Nov- Nov Nov
154
15 -16 -18
24- 23- 29-
US20180340
PRODUCTION OF VIRUSES IN CELL CULTURE Not Available Nov- Nov Nov
153
15 -16 -18
30- 24- 29-
US20180339 PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-
Not Available Dec- May Nov
991 SPECIFIC PROTEASE 7 INHIBITORS
14 -18 -18
30- 18- 29-
US20180339 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC
Not Available Dec- Jan Nov
988 PROTEASE 7 INHIBITORS
14 -18 -18
14- 7- 29-
US20180339
PEPTIDOMIMETIC MACROCYCLES Not Available Jan- Jun Nov
014
09 -18 -18
17- 15- 22-
US20180334
CORONAVIRUSES EPITOPE-BASED VACCINES RAMOT AT TEL-AVIV UNIVERSITY LTD. Sep- Sep Nov
480
15 -16 -18
12- 9- 22-
US20180333 Compositions, Comprising Improved Il-12 Genetic Constructs And
Not Available Dec- May Nov
485 Vaccines, Immunotherapeutics And Methods Of Using The Same
11 -18 -18
11- 11- 1-
US20180311
MICRONEEDLE COMPOSITIONS AND METHODS OF USING SAME Not Available Jan- Jul- Nov
338
16 18 -18
1- 26- 1-
US20180311
Method of Treating Inflammation Not Available Apr- Jun Nov
273
10 -18 -18
12- 12- 25-
US20180305 CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS FOR MALARIA
Not Available Apr- Apr Oct-
773 DETECTION
17 -18 18
30- 30- 25-
US20180305
Pathogen biomarkers and uses therefor Not Available Sep- Sep Oct-
760
15 -16 18
13- 25-
US20180305 13-
HIDE1 COMPOSITIONS AND METHODS Not Available Jul- Oct-
451 Jul-15
16 18
19- 9- 25-
US20180305 COMPOSITIONS AND METHODS FOR TREATING DISEASES BY
Not Available Dec- Jul- Oct-
412 INHIBITING EXOSOME RELEASE
16 18 18
22- 25- 25-
US20180305
IMMUNE RESPONSE MODIFIER COMPOSITIONS AND METHDOS Not Available Dec- Jun Oct-
357
06 -18 18
19- 18- 25-
US20180305
NOVEL KINASE INHIBITORS Not Available Oct- May Oct-
356
12 -18 18
10- 30- 25-
US20180303
Compositions and Methods for the Prevention of Microbial Infections Not Available Nov- Nov Oct-
874
11 -17 18
30- 2- 25-
US20180303 DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER
Not Available Jan- Jul- Oct-
768 NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS ACTIVITY
15 18 18
11- 1- 6-
US20180250 PAPAYA MOSAIC VIRUS COMPOSITIONS AND USES THEREOF FOR
Not Available Feb- May Sep
602 STIMULATION OF THE INNATE IMMUNE RESPONSE
14 -18 -18
20- 12- 6-
US20180250
SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES Not Available Aug- Oct Sep
381
10 -17 -18
19- 9- 30-
US20180245 COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND
Not Available Nov- Oct Aug
056 ACTIVITY, AND RELATED METHODS
09 -17 -18
27- 27- 30-
US20180245
VIRAL VACCINES AND METHODS OF FORMING THE SAME Not Available Feb- Feb Aug
053
17 -18 -18
19- 18- 30-
US20180244
NOVEL METHODS OF GENERATING ANTIBODIES Rutgers, The State University of New Jersey Aug- Aug Aug
759
15 -16 -18
24- 24- 30-
US20180244 MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS The United States of America, as Represented by the
Feb- Feb Aug
756 IMMUNOGENS, ANTIBODIES, AND THEIR USE Secretary, Dept. of Health and Human Services
15 -16 -18
31- 26- 30-
US20180244 IMIDAZO[4,5-c] RING COMPOUNDS CONTAINING SUBSTITUTED
Not Available Aug- Aug Aug
669 GUANIDINE GROUPS
15 -16 -18
17- 17- 30-
US20180244 CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE
Not Available Aug- Aug Aug
660 INHIBITORS
15 -16 -18
25- 22- 30-
US20180243 IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE
Not Available Aug- Aug Aug
347 THEREOF
15 -16 -18
29- 23-
US20180237 31-
METHODS OF ANALYZING VIRUS-DERIVED THERAPEUTICS American International Biotechnology, LLC Jul- Aug
835 Jul-15
16 -18
8- 5- 23-
US20180237
IMPROVEMENTS IN OR RELATING TO DNA RECOMBINATION The Regents of the University of California Aug- Aug Aug
788
15 -16 -18
28- 22- 23-
US20180237
ARTIFICIAL NUCLEIC ACID MOLECULES CUREVAC AG Aug- Aug Aug
786
15 -16 -18
11- 11- 23-
US20180237 PAN-EBOLA AND PAN-FILOVIRUS PROTECTIVE EPITOPES,
Integrated BioTherapeutics, Inc. Mar- Mar Aug
502 ANTIBODIES, AND ANTIBODY COCKTAILS
15 -16 -18
31- 26- 23-
US20180237
GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS Not Available Aug- Aug Aug
435
15 -16 -18
16- 23-
US20180236 31-
REVERSE GENETICS SYSTEMS Not Available Oct Aug
058 Jul-09
-17 -18
14- 19- 23-
US20180236
Tetanus Toxoid and CCL3 Improve DC Vaccines Duke University Nov- Apr Aug
054
13 -18 -18
DEVICES, SYSTEM AND METHOD TO CONTROL THE DELIVERY OF 11- 11- 16-
US20180228
ORAL MEDICATIONS TO ENSURE THEY ARE EFFICACIOUS , TAKEN Not Available Aug- Aug Aug
695
AS PRESCRIBED, AND TO AVOID UNWANTED SIDE EFFECTS 15 -16 -18
10- 7- 9-
US20180223 METHOD FOR PROPAGATING ADENOVIRAL VECTORS ENCODING
GenVec, Inc. Nov- Sep Aug
290 INHIBITORY GENE PRODUCTS
05 -17 -18
18- 9- 9-
US20180222 SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND
3M Innovative Properties Company Jun- Apr Aug
906 IMIDAZONAPHTHYRIDINES
04 -18 -18
3- 3- 9-
US20180221 IMMUNOGENIC COMPOSITIONS, ANTIGEN SCREENING METHODS,
Not Available Aug- Aug Aug
464 AND METHODS OF GENERATING IMMUNE RESPONSES
15 -16 -18
15- 19- 2-
US20180216
HIGH DENSITY SELF-CONTAINED BIOLOGICAL ANALYSIS Not Available Nov- Mar Aug
164
06 -18 -18
18- 29- 2-
US20180216
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available Nov- Mar Aug
067
13 -18 -18
27- 2-
US20180215 27-
Antibody Derivatives with Conditionally Enabled Effector Function Not Available Jul- Aug
831 Jul-15
16 -18
29- 29- 2-
US20180215
CRYPTIC POLYPEPTIDES AND USES THEREOF Not Available Jan- Jan Aug
801
15 -16 -18
20- 27- 2-
US20180215
TREATING CANCER WITH VIRAL NUCLEIC ACID Mayo Foundation for Medical Education and Research Feb- Mar Aug
794
07 -18 -18
15- 2-
US20180214 17-
Selective Inhibitors Of i-NOS For Use Against Viral Infection UCL Business PLC Jul- Aug
430 Jul-15
16 -18
23- 11- 26-
US20180209 Method of Determining, Identifying or Isolating Cell-Penetrating
Not Available May- Dec Jul-
960 Peptides
11 -17 18
18- 19- 26-
US20180208
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available Nov- Mar Jul-
897
13 -18 18
13- 13- 26-
US20180208
ANTI-PD-L1 ANTIBODIES AND USES THEREOF Not Available Jun- Jun Jul-
659
16 -17 18
20- 19- 26-
US20180208
METHODS FOR ENHANCING AN IMMUNE RESPONSE Not Available Jan- Jan Jul-
653
17 -18 18
22- 5- 26-
US20180207
ADJUVANTED INFLUENZA VACCINES FOR PEDIATRIC USE Not Available Feb- Mar Jul-
258
08 -18 18
12- 19- 26-
US20180207 PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR
GlaxoSmithKline Intellectual Property (No. 2) Limited May- Mar Jul-
145 TREATING INFECTIOUS DISEASES
14 -18 18
14- 19-
US20180201 COMPOSITIONS AND METHODS FOR DETECTION OF GENETIC 14-
CapitalBio Corporation Jul- Jul-
998 DEAFNESS GENE MUTATION Jul-15
15 18
26- 13- 19-
US20180201
METHODS FOR INCREASING THE INFECTIVITY OF VIRUSES Not Available Jan- Mar Jul-
907
12 -18 18
7- 19-
US20180201 ANTIBODIES HAVING SPECIFICITY TO MYOSIN 18A AND USES 7-Jul-
Not Available Jul- Jul-
687 THEREOF 15
16 18
17- 20- 19-
US20180200
Methods and Compositions for Inhibiting Akt3 Not Available Jan- Feb Jul-
365
17 -18 18
17- 27- 19-
US20180200 LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND
3M Innovative Properties Company Aug- Nov Jul-
364 COMPOSITIONS, FORMULATIONS, AND METHODS
10 -17 18
31- 12- 19-
US20180200 Antiviral Activity from Medicinal Mushrooms and Their Active
Not Available Mar- Mar Jul-
224 Constituents
15 -18 18
1- 3- 19-
US20180200
Modular Particulars for Immunotherapy Not Available Nov- Jan Jul-
196
13 -18 18
7- 12-
US20180196 7-Jul-
INFLUENZA POTENCY ASSAYS Not Available Jul- Jul-
061 15
16 18
13- 12- 12-
US20180195
METHODS FOR PRODUCING VIRUS FOR VACCINE PRODUCTION Takeda Vaccines, Inc. Feb- Feb Jul-
048
15 -16 18
17- 8- 12-
US20180194
Sulfinylphenyl or Sulfonimidoylphenyl Benzazepines Hoffmann La-Roche Inc. Sep- Mar Jul-
735
15 -18 18
15- 12-
US20180193 15-
DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS Not Available Jul- Jul-
477 Jul-15
16 18
6- 5-
US20180187 Variant AAV and Compositions, Methods and Uses for Gene Transfer 22-
The Children's Hospital of Philadelphia Dec Jul-
213 to Cells, Organs and Tissues Jul-13
-17 18
9- 7- 5-
US20180187 METHODS AND COMPOSITIONS FOR COMBINATION
Not Available Jan- Jan Jul-
211 IMMUNOTHERAPY
15 -16 18
7- 27- 5-
US20180187 HAND, FOOT, AND MOUTH VACCINES AND METHODS OF
Takeda Vaccines, Inc. Nov- Oct Jul-
165 MANUFACTURE AND USE THEREOF
14 -17 18
18- 20- 5-
US20180187
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available Nov- Feb Jul-
154
13 -18 18
18- 20- 5-
US20180187
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available Nov- Feb Jul-
153
13 -18 18
16- 15- 5-
US20180187 DISINFECTING AQUEOUS FOAM, PROCESS FOR PREPARING SAME COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX
Jun- Jun Jul-
131 AND USE THEREOF ENERGIES ALTERNATIVES
15 -16 18
26- 24- 5-
US20180186
NOVEL VACCINES IN PREVENTION AND TREATMENT OF MALARIA Not Available Jun- Jun Jul-
897
15 -16 18
28- 28- 5-
US20180186 PROTEIN PROXIMITY ASSAY IN FORMALIN FIXED PAFFAFIN
Not Available Aug- Feb Jul-
821 EMBEDDED TISSUE USING CAGED HAPTENS
15 -18 18
1- 27- 5-
US20180186 COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7
Not Available May- Feb Jul-
802 AGONISTS
14 -18 18
16- 29- 5-
US20180186
Powdered Pouch And Method Of Making Same MONOSOL, LLC Apr- Dec Jul-
534
12 -17 18
24- 14- 5-
US20180185 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING
Not Available Apr- Dec Jul-
469 PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME
12 -17 18
3- 29- 5-
US20180185
Pharmaceutical Compositions and Methods Not Available Aug- Nov Jul-
392
15 -17 18
19- 17- 5-
US20180185 METHODS AND COMPOSITIONS FOR TREATING HERPESVIRUS
Not Available Jun- Jun Jul-
345 INDUCED CONDITIONS
15 -16 18
14- 22- 28-
US20180180 USE OF A FLUORESCENT MATERIAL TO DETECT FAILURE OR
Not Available Jun- Feb Jun-
544 DETERIORATED PERFORMANCE OF A FLUOROMETER
12 -18 18
26- 22- 28-
US20180179
GENERATION OF BINDING MOLECULES Merus N.V. Sep- Nov Jun-
300
11 -17 18
26- 24- 28-
US20180179 PROTEINS COMPRISING A MUTATED LAIR-1 FRAGMENT AND USES
Not Available Jun- Jun Jun-
274 THEREOF
15 -16 18
23- 31- 28-
US20180177
METHODS OF MAKING AND USING LIVE ATTENUATED VIRUSES Not Available Sep- Oct Jun-
863
15 -17 18
26- 24- 28-
US20180177
ANTIGENICALLY MATCHED INFLUENZA VACCINES Not Available Jun- Jun Jun-
862
15 -16 18
11- 7- 28-
US20180177 VACCINE CONTAINING VIRUS INACTIVATED BY GREEN TEA
Not Available Jun- Jun Jun-
860 EXTRACT, AND PREPARATION METHOD THEREFOR
15 -16 18
10- 10- 14-
US20180163 PROCESSES FOR PRODUCTION AND PURIFICATION OF NUCLEIC
Human Services Jun- Jun Jun-
182 ACID-CONTAINING COMPOSITIONS
15 -16 18
18- 13- 14-
US20180162
Chemical Compounds Not Available Mar- Dec Jun-
838
14 -17 18
5- 11- 14-
US20180162 QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-
Not Available Feb- Dec Jun-
835 SPECIFIC PROTEASE 7 INHIBITORS
15 -17 18
10- 10- 14-
US20180161 NOVEL PROTEIN STRUCTURE USED FOR EFFICIENT ANTIBODY
Not Available Dec- Dec Jun-
425 PRODUCTION IN IMMUNIZATION
14 -15 18
2- 2- 26-
US20180111 MODULATORS OF ACTIVIN AND METHODS FOR MODULATING
Not Available Dec- Jun Apr-
991 IMMUNE RESPONSES AND T FOLLICULAR HELPER CELLS
14 -17 18
18- 6- 19-
US20180105
Bivalent siRNA Chimeras and Methods of Use Thereof Not Available Oct- Oct Apr-
815
16 -17 18
17- 15- 19-
US20180105
ANTI-TYRO3 ANTIBODIES AND USES THEREOF Not Available Apr- Apr Apr-
596
15 -16 18
7- 3- 19-
US20180105
HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS Not Available Apr- Jan Apr-
514
16 -18 18
30- 2- 15-
US20180072 COUMARIN DERIVATIVE AS ANTIVIRAL AGENT, PHARMACEUTICAL
Not Available Mar- Feb Mar
752 COMPOSITION THEREOF, ITS PREPARATION AND USE
15 -16 -18
1- 14- 1-
US20180058
SAMPLE FIXATION AND STABILISATION Not Available Mar- Aug Mar
988
13 -17 -18
15- 1- 1-
US20180057 COMPOSITIONS AND METHODS FOR DETECTING RARE SEQUENCE
Not Available Aug- Nov Mar
871 VARIANTS
16 -17 -18
7- 27- 1-
US20180057
METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR Not Available Apr- Oct Mar
841
05 -17 -18
25- 9- 1-
US20180057 Particle-Nucleic Acid Conjugates and Therapeutic Uses Related
Not Available Jun- Oct Mar
817 Thereto
12 -17 -18
30- 29- 1-
US20180057 PSEUDOTYPED ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC
Not Available Jun- Sep Mar
594 POLYPEPTIDES
16 -17 -18
9- 2- 1-
US20180057 ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND
Not Available Feb- Nov Mar
509 THIAZOLONAPHTHYRIDINES
05 -17 -18
23- 7- 1-
US20180057
COMPOSITIONS AND METHODS FOR INHIBITING KINASES Not Available Apr- Nov Mar
488
15 -17 -18
3- 7- 1-
US20180055 The United States of America, as represented by the
DISPLAY PLATFORM FROM BACTERIAL SPORE COAT PROTEINS Mar- Aug Mar
925 Secretary, Department of Health and Human Serv
15 -15 -18
3- 26- 1-
US20180055 CIRCULATION OF COMPONENTS DURING MICROFLUIDIZATION
Not Available Dec- Jun Mar
769 AND/OR HOMOGENIZATION OF EMULSIONS
09 -17 -18
10- 5- 22-
US20180051
TAL EFFECTOR-MEDIATED DNA MODIFICATION Not Available Dec- Oct Feb
267
09 -17 -18
10- 21- 22-
US20180051
TAL EFFECTOR-MEDIATED DNA MODIFICATION Not Available Dec- Aug Feb
266
09 -17 -18
30- 22-
US20180050 6-Jul-
DELIVERY OF RNA TO DIFFERENT CELL TYPES GLAXOSMITHKLINE BIOLOGICALS, SA Aug Feb
059 10
-17 -18
12- 11- 15-
US20180044 ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN
Not Available Dec- Dec Feb
687 EXPRESSION
14 -15 -18
5- 4- 15-
US20180044 PEPTIDYL NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I
Prozymex A/S Mar- Mar Feb
328 INHIBITORS
15 -16 -18
17- 21- 15-
US20180043
INFLUENZA VIRUS VECTORS AND USES THEREFOR Not Available Mar- Aug Feb
007
14 -17 -18
28- 21- 8-
US20180037 SYSTEM AND METHOD FOR DNA SEQUENCING AND BLOOD
Nanomedical Diagnostics, Inc. Apr- Aug Feb
952 CHEMISTRY ANALYSIS
14 -17 -18
3- 1- 8-
US20180037
ENZYME-INDEPENDENT MOLECULAR INDEXING Not Available Aug- Aug Feb
942
16 -17 -18
8- 8- 8-
US20180037
CANCER INITIATING CELL AND USE THEREOF Not Available Aug- Aug Feb
871
16 -16 -18
18- 21- 8-
US20180037 STRUCTURED VIRAL PEPTIDE COMPOSITIONS AND METHODS OF
DANA-FARBER CANCER INSTITUTE, INC. Jun- Sep Feb
636 USE
09 -17 -18
2- 2- 8-
US20180037
ENGINEERED POLYPEPTIDES AND USES THEREOF Not Available Aug- Aug Feb
634
16 -17 -18
27- 25- 8-
US20180036
FLAVIVIRUS REPLICONS Not Available Feb- Feb Feb
398
15 -16 -18
27- 1-
US20180028 24-
Technology for the Preparation of Microparticles Not Available Jun Feb
449 Jul-07
-17 -18
27- 1-
US20180028 POLYMER-BASED ANTIMICROBIAL COMPOSITIONS AND METHODS 28-
eXion labs Inc. Jul- Feb
431 OF USE THEREOF Jul-16
17 -18
29- 22- 25-
US20180023
ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS Not Available Oct- Sep Jan-
048
04 -17 18
13- 12- 25-
US20180022 POLYPEPTIDES FOR ENGINEERING INTEGRASE CHIMERIC CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Feb- Feb Jan-
781 PROTEINS AND THEIR USE IN GENE THERAPY (CNRS)
15 -16 18
16- 25-
US20180021 12-
Conjugates of Cell Binding Molecules with Cytotoxic Agents Hangzhou DAC Biotech Co., Ltd. Apr Jan-
448 Jul-12
-14 18
10- 10- 18-
US20180016 The United States of America, as represented by the
GRIFFITHSIN MUTANTS Feb- Feb Jan-
307 Secretary, Department of Health and Human Serv
15 -16 18
20- 28- 18-
US20180016
Boron-Containing Small Molecules Not Available Jun- Sep Jan-
285
07 -17 18
13- 12- 18-
US20180016
HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS Not Available Feb- Feb Jan-
243
15 -16 18
14- 18-
US20180015 SYNTHETIC NANOPARTICLES FOR DELIVERY OF 15-
Not Available Jul- Jan-
174 IMMUNOMODULATORY COMPOUNDS Jul-16
17 18
2- 26- 11-
US20180010
ORGANISM IDENTIFICATION PANEL Not Available Apr- Jul- Jan-
167
07 17 18
12- 15- 11-
US20180010 DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4
Quark Pharmaceuticals Inc. Sep- Feb Jan-
125 AND METHODS OF USE THEREOF
12 -17 18
31- 22- 11-
US20180009
NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. May- Sep Jan-
787
16 -17 18
28- 28- 11-
US20180008 RNA VIRUS ATTENUATION BY ALTERATION OF MUTATIONAL
Not Available Jan- Jan Jan-
689 ROBUSTNESS AND SEQUENCE SPACE
15 -16 18
18- 16- 4-
US20180002 FLUOROGENIC PROBES AND THEIR USE IN QUANTITATIVE
Not Available Jun- Jun Jan-
743 DETECTION OF TARGET RNA SEQUENCES
16 -17 18
7- 8- 4-
US20180002 The United States of America, as represented by the
NEUTRALIZING GP41 ANTIBODIES AND THEIR USE Nov- Sep Jan-
406 Secretary, Department of Health and Human
11 -17 18
30- 14- 4-
US20180000 D-AMINO ACID DERIVATIVE-MODIFIED PEPTIDOGLYCAN AND
Not Available Nov- Sep Jan-
929 METHODS OF USE THEREOF
12 -17 18
15- 15- 4-
US20180000 METHODS OF INDUCING AN IMMUNE RESPONSE TO HEPATITIS C
Not Available Jan- Jan Jan-
926 VIRUS
15 -16 18
26- 15- 4-
US20180000
Induced Hepatocytes and Uses Thereof Not Available Nov- Sep Jan-
868
14 -17 18
10- 4-
US20180000 METHODS FOR INDUCING AN IMMUNE RESPONSE VIA BUCCAL 26-
Not Available May Jan-
724 AND/OR SUBLINGUAL ADMINISTRATION OF A VACCINE Jul-10
-17 18
21- 6- 28-
US20170368 COMPOSITIONS AND METHODS RELATED TO NEUROLOGICAL
Not Available Aug- Jun Dec
167 DISORDERS
12 -16 -17
4- 7- 21-
US20170362
OLIGOPEPTIDE-FREE CELL CULTURE MEDIA Not Available Jan- Aug Dec
300
06 -17 -17
19- 21- 21-
US20170362
CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF Not Available Dec- Dec Dec
297
14 -15 -17
3- 29- 21-
US20170362
HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS Not Available Aug- Jun Dec
170
07 -17 -17
3- 2- 21-
US20170360 VACCINE PHARMACEUTICAL COMPOSITION FOR CELL-MEDIATED
NITTO DENKO CORPORATION Sep- Sep Dec
908 IMMUNITY CONTAINING BISPHOSPHONATES
14 -15 -17
16- 16- 7-
US20170348 NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS The Board of Trustees of the Leland Stanford Junior
Feb- Feb Dec
433 RESISTANT TO PRE-EXISTING HUMAN NEUTRALIZING ANTIBODIES University
16 -17 -17
30- 7-
US20170348 SYSTEM AND METHOD FOR DELIVERING GENETIC MATERIAL OR 30-
Not Available Jul- Dec
402 PROTEIN TO CELLS Jul-14
15 -17
16- 18- 7-
US20170348
Plant Extract and Its Therapeutic Use Not Available May- Jul- Dec
369
08 17 -17
11- 15- 30-
US20170342 RECOMBINANT SELF-REPLICATING POLYCISTRONIC RNA
GLAXOSMITHKLINE BIOLOGICALS, SA Oct- Aug Nov
442 MOLECULES
11 -17 -17
31- 16- 30-
US20170342
MOLECULAR INDEXING OF INTERNAL SEQUENCES Not Available May- May Nov
405
16 -17 -17
31- 26- 30-
US20170342
NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. May- May Nov
056
16 -17 -17
1- 19- 30-
US20170340
Anti-TIGIT Antigen-Binding Proteins and Methods of Use Thereof Not Available Oct- Jun Nov
735
15 -17 -17
22- 11- 30-
US20170340
COMBINATION PIV3/HMPV RNA VACCINES ModernaTX, Inc. Oct- Aug Nov
725
15 -17 -17
3- 3- 30-
US20170340 METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE
Not Available Sep- Sep Nov
721 RESPONSES
14 -15 -17
31- 26- 30-
US20170340
NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. May- May Nov
611
16 -17 -17
27- 2- 23-
US20170337
SPATIALLY ADDRESSABLE MOLECULAR BARCODING Not Available Feb- Aug Nov
459
15 -17 -17
4- 19- 23-
US20170336
Multiplex Immuno Screening Assay Institut Pasteur May- Jul- Nov
412
12 17 -17
8- 9- 23-
US20170336 The University of Pittsburgh - Of the Commonwealth
B-CELL ANTIGEN PRESENTING CELL ASSAY Apr- Aug Nov
411 System of Higher Education
10 -17 -17
15- 15- 23-
US20170335
Methods and Systems of Multi-Assay Processing and Analysis Not Available Mar- Mar Nov
408
16 -17 -17
2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H-
15- 27- 23-
US20170334 PYRAZOLO[3,4-D]PYRIMIDIN-1 -YL)METHYL)-3-(2-(TRIFLUORO-MET
RESPIVERT LTD. Mar- Jul- Nov
919 HYL)BENZYL)QUINAZOLIN-4(3H)-ONE DERIVATIVES AND THEIR
13 17 -17
USE AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS
8- 23- 23-
US20170333 ADDITIVE COMPOSITIONS FOR PIGMENTED DISINFECTION AND
Not Available Dec- May Nov
586 METHODS THEREOF
14 -15 -17
21- 1- 23-
US20170333 LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND
Not Available May- Aug Nov
553 COMPOSITIONS, FORMULATIONS, AND METHODS
13 -17 -17
10- 9- 23-
US20170333
PROBIOTIC THERAPEUTIC APPLICATIONS Not Available Nov- Nov Nov
494
14 -15 -17
8- 23-
US20170333 28-
Anti-Viral Azide Containing Compounds Not Available Aug Nov
457 Jul-10
-17 -17
12- 11- 23-
US20170333
MOBILE CLINICS Baylor College of Medicine Nov- Nov Nov
267
14 -15 -17
1- 30- 16-
US20170328
SAMPLE FIXATION AND STABILISATION Not Available Mar- May Nov
819
13 -17 -17
8- 31- 16-
US20170327
POLYIONIC PAPILLOMA VIRUS-LIKE PARTICLE (VLP) VACCINES Not Available Sep- Jan Nov
543
10 -17 -17
17- 7- 16-
US20170327 CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL
Parion Sciences, Inc. Dec- Mar Nov
472 SODIUM CHANNEL BLOCKING ACTIVITY
12 -17 -17
3- 3- 16-
US20170327
DIHYDRONAPHTHALENE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. Dec- Dec Nov
439
14 -14 -17
16- 15- 16-
US20170326 RECOMBINANT PROMOTERS AND VECTORS FOR PROTEIN
Children's Healthcare of Atlanta, Inc. Apr- Apr Nov
256 EXPRESSION IN LIVER AND USE THEREOF
15 -16 -17
12- 12- 16-
US20170326
Throat solution for treatment of cold, flu and sore throat Not Available May- May Nov
123
16 -16 -17
25- 27- 9-
US20170322 SYSTEM AND METHOD FOR DETECTING, COLLECTING, ANALYZING,
Georgetown University Feb- Jul- Nov
682 AND COMMUNICATING EVENT-RELATED INFORMATION
08 17 -17
8- 20- 9-
US20170322 University of Pittsburgh - Of the Commonwealth System of
ANTIGEN PRESENTING CELL ASSAY Apr- Jul- Nov
201 Higher Education
10 17 -17
6- 6- 9-
US20170321
Recombinant RNA Viruses and Uses Thereof Icahn School of Medicine at Mount Sinai Jun- Apr Nov
192
10 -17 -17
10- 27- 9-
US20170319 METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE
3M INNOVATIVE PROPERTIES COMPANY Apr- Jul- Nov
712 RESPONSE
03 17 -17
13- 12- 9-
US20170319
TRI-SEGMENTED ARENAVIRUSES AS VACCINE VECTORS Not Available Nov- Nov Nov
673
14 -15 -17
9- 24- 9-
US20170319
NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Not Available May- Jan Nov
551
12 -17 -17
29- 28- 2-
US20170313
DIRECT EXPRESSION OF ANTIBODIES Not Available Oct- Oct Nov
765
14 -15 -17
28- 28- 2-
US20170313 BROAD-SPECTRUM NON-COVALENT CORONAVIRUS PROTEASE
Purdue Research Foundation Apr- Apr Nov
685 INHIBITORS
16 -17 -17
22- 20- 2-
US20170312
MODIFIED VIRUS-LIKE PARTICLES OF CMV SAIBA GMBH Oct- Oct Nov
371
14 -15 -17
17- 1- 26-
US20170306 ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES,
Not Available Dec- May Oct-
354 VECTORS CONTAINING SAME, AND USES THEREFOR
01 -17 17
9- 2- 26-
US20170306 MEANS AND METHODS FOR INFLUENCING THE STABILITY OF
Not Available Dec- Jun Oct-
293 ANTIBODY PRODUCING CELLS
05 -17 17
13- 1- 26-
US20170305 ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL
Parion Sciences, Inc. Dec- Mar Oct-
868 SODIUM CHANNEL BLOCKING COMPOUNDS
13 -17 17
22- 21- 26-
US20170304 PRINTED CIRCUIT BOARD HEATER FOR AN AMPLIFICATION
Click Diagnostics, Inc. Apr- Apr Oct-
829 MODULE
16 -17 17
6- 6- 26-
US20170304
AAV-Based Gene Therapy Not Available Oct- Oct Oct-
466
14 -15 17
10- 7- 26-
US20170304 METHODS AND COMPOSITIONS FOR INHALATION DELIVERY OF
Not Available Oct- Oct Oct-
459 CONJUGATED OLIGONUCLEOTIDE
14 -15 17
26- 25- 26-
US20170304
VACCINATION OF IMMUNOCOMPROMISED SUBJECTS Not Available Sep- Sep Oct-
429
14 -15 17
10- 9- 26-
US20170304
POLYMER ADJUVANT Oxford University Innovation Limited Oct- Oct Oct-
420
14 -15 17
15- 13- 26-
US20170304 TREATMENT OF DISEASE WITH POLY-N-ACETYLGLUCOSAMINE
Marine Polymer Technologies, Inc. Apr- Mar Oct-
354 NANOFIBERS
11 -17 17
6- 13- 19-
US20170299 EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS
Not Available Oct- Dec Oct-
591 INFECTIONS AND DISEASES
08 -16 17
1- 30- 19-
US20170298
ANTI-VIRAL PEPTIDES Not Available Oct- Sep Oct-
100
14 -15 17
16- 16- 19-
US20170296
Conjugates of Cell Binding Molecules with Cytotoxic Agents Hangzhou DAC Biotech Co., Ltd. Apr- Apr Oct-
663
14 -14 17
1- 28- 19-
US20170296
Method of Treating Inflammation Not Available Apr- Jun Oct-
574
10 -17 17
29- 20- 12-
US20170292 TISSUE PREFERENTIAL CODON MODIFIED EXPRESSION
Not Available Apr- Jun Oct-
132 CASSETTES, VECTORS CONTAINING SAME, AND USES THEREOF
13 -17 17
1- 28- 5-
US20170281
Device to Kill Micro-Organisms Inside the Respiratory Tract Not Available Apr- Mar Oct-
966
16 -17 17
3- 2- 5-
US20170281 BISPHOSPHONATE-CONTAINING VACCINE PHARMACEUTICAL
NITTO DENKO CORPORATION Sep- Sep Oct-
759 COMPOSITION FOR HUMORAL IMMUNITY
14 -15 17
17- 28-
US20170275 13-
CHIRAL CONTROL Not Available Mar Sep
621 Jul-12
-17 -17
27- 27- 28-
US20170275
CULTURE MEDIUM Koninklijke Nederlandse Akademie Van Wetenschappen Nov- Nov Sep
592
14 -15 -17
4- 7- 28-
US20170275 GLYCOLIPIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF
THE UNIVERSITY OF NOTTINGHAM Apr- Apr Sep
323 FOR USE IN THERAPY
14 -15 -17
18- 14- 28-
US20170275
BENZAZEPINE SULFONAMIDE COMPOUNDS Hoffmann-La Roche Inc. Dec- Jun Sep
253
14 -17 -17
5- 4- 28-
US20170275
Lipids and Lipid Compositions for the Delivery of Active Agents Novartis AG Sep- Sep Sep
243
14 -15 -17
5- 4- 28-
US20170274
MODIFIED BAT INFLUENZA VIRUSES AND THEIR USES Not Available Sep- Sep Sep
064
14 -15 -17
28- 17- 28-
US20170274
AAV Vectors Targeted to Oligodendrocytes Not Available Sep- Apr Sep
024
12 -17 -17
24- 10-
US20170224 6-Jul-
OIL-IN-WATER EMULSIONS THAT CONTAIN NUCLEIC ACIDS GLAXOSMITHKLINE BIOLOGICALS SA Apr Aug
616 11
-17 -17
31- 10- 3-
US20170219 United States of America as Represented by the Secretary
MALARIA ANTIGEN SCREENING METHOD Aug- Apr Aug
560 of the Navy
05 -17 -17
2- 1- 3-
US20170216 VACCINE PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL
NITTO DENKO CORPORATION Oct- Oct Aug
431 ADMINISTRATION
14 -15 -17
4- 4- 3-
US20170216 COMPOSITION FOR ENHANCING INDUCTION OF HUMORAL
NITTO DENKO CORPORATION Aug- Aug Aug
429 IMMUNITY, AND VACCINE PHARMACEUTICAL COMPOSITION
14 -15 -17
23- 3-
US20170216 23-
Coronavirus Not Available Jul- Aug
427 Jul-14
15 -17
7- 7- 3-
US20170216
METAL NANOCLUSTERS AND USES THEREOF Not Available Aug- Aug Aug
348
14 -15 -17
7- 27- 27-
US20170211 USE OF THE CHROMOSOME 19 MICRORNA CLUSTER (C19MC) FOR University of Pittsburgh - Of the Commonwealth System of
Mar- Jan Jul-
069 TREATING MICROBIAL DISEASE AND PROMOTING AUTHOPHAGY Higher Education
12 -17 17
6- 5- 27-
US20170211 METHOD AND APPARATUS FOR AUTOMATED PROCESSING OF
Not Available Aug- Aug Jul-
058 POOLED SAMPLES
14 -15 17
18- 5- 27-
US20170209
MICROSPOTTING DEVICE Not Available Apr- Jan Jul-
844
12 -17 17
5- 27-
US20170209 DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELL- 15-
Suzhou M-Conj Biotech Co., Ltd. Apr Jul-
595 BINDING MOLECULE Jul-15
-17 17
2- 31- 20-
US20170205
POLYMERS AND CONJUGATES COMPRISING THE SAME Not Available Oct- Mar Jul-
399
14 -17 17
29- 20-
US20170202 DEFECTIVE RIBOSOMAL PRODUCTS IN BLEBS (DRIBBLES) AND 29-
Providence Health & Services - Oregon Dec Jul-
949 METHODS OF USE TO STIMULATE AN IMMUNE RESPONSE Jul-05
-16 17
10- 22-
US20170173 POINT OF CARE POLYMERASE CHAIN REACTION DEVICE FOR 11-
Not Available Jul- Jun-
585 DISEASE DETECTION Jul-14
15 17
3- 22-
US20170173 ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC 15-
SUZHOU M-CONJ BIOTECH CO., LTD. Mar Jun-
176 CONJUGATION OF A CELL-BINDING MOLECULE Jul-15
-17 17
3- 22-
US20170173 ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC 15-
SUZHOU M-CONJ BIOTECH CO., LTD. Mar Jun-
168 CONJUGATION OF A CELL-BINDING MOLECULE Jul-15
-17 17
3- 6- 22-
US20170173 HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES
Not Available Jun- Mar Jun-
164 MADE THEREFROM
11 -17 17
6- 13- 15-
US20170168 EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS
Not Available Oct- Dec Jun-
052 INFECTIONS AND DISEASES
08 -16 17
9- 24- 15-
US20170168 QUANTITATIVE ANALYSIS METHOD BASED ON AIR PRESSURE
XIAMEN UNIVERSITY Jun- Sep Jun-
044 MEASURING
14 -14 17
14- 12- 15-
US20170166
NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. Dec- Dec Jun-
574
15 -16 17
1- 13- 15-
US20170165
Anti-TIGIT Antigen-Binding Proteins and Methods of Use Thereof Not Available Oct- Feb Jun-
366
15 -17 17
11- 23- 15-
US20170165 IMMUNOSTIMULATORY COMBINATIONS OF TLR LIGANDS AND
Not Available Aug- Aug Jun-
359 METHODS OF USE
10 -16 17
24- 15- 15-
US20170165
REPLICATION DEFECTIVE ADENOVIRUS VECTOR IN VACCINATION Not Available Aug- Feb Jun-
341
12 -17 17
9- 9- 15-
US20170165 USE OF GSK-3 INHIBITORS OR ACTIVATORS WHICH MODULATE
Not Available Apr- Apr Jun-
230 PD-1 OR T-BET EXPRESSION TO MODULATE T CELL IMMUNITY
14 -15 17
23- 8-
US20170160 APPARATUS AND SYSTEM FOR PERFORMING THERMAL MELT 31-
Not Available Feb Jun-
218 ANALYSES AND AMPLIFICATIONS Jul-12
-17 17
2- 2- 8-
US20170159 Novel Recombinant Adeno-Associated Virus Capsids with Enhanced
Not Available Dec- Dec Jun-
026 Human Skeletal Muscle Tropism
15 -16 17
25- 27- 8-
US20170158 MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS
Not Available Apr- Apr Jun-
752 NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF
14 -15 17
12- 8-
US20170157 CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC 12-
Not Available Jul- Jun-
262 AGENTS Jul-12
12 17
17- 16- 8-
US20170157
Broad Spectrum Antiviral and Methods of Use Not Available Apr- Feb Jun-
151
06 -17 17
28- 28- 1-
US20170152
CHARGED LINKERS AND THEIR USES FOR CONJUGATION Hangzhou DAC Biotech Co., Ltd. Feb- Feb Jun-
274
14 -14 17
23- 1-
US20170152 23-
GAK MODULATORS AS ANTIVIRALS Katholieke Universiteit Leuven Jul- Jun-
271 Jul-14
15 17
13- 1-
US20170151 DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELL- 15-
SUZHOU M-CONJ BIOTECH CO., LTD. Feb Jun-
346 BINDING MOLECULE Jul-15
-17 17
25- 25- 1-
US20170151 SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF
Not Available Nov- Nov Jun-
291 PRODUCTION AND USE THEREOF
13 -14 17
23- 22- 25-
US20170145 TRACKING AND MANIPULATING CELLULAR RNA VIA NUCLEAR
Not Available Nov- Nov May
394 DELIVERY OF CRISPR/CAS9
15 -16 -17
4- 25- 25-
US20170144
MODULATORS OF THE RELAXIN RECEPTOR 1 Not Available May- Aug May
984
12 -16 -17
3- 25-
US20170143 ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC 15-
SUZHOU M-CONJ BIOTECH CO., LTD Feb May
845 CONJUGATION OF A CELL-BINDING MOLECULE Jul-15
-17 -17
13- 12- 25-
US20170143
IMMUNOGENIC COMBINATIONS GLAXOSMITHKLINE SA Jun- Jun May
820
14 -15 -17
11- 4- 25-
US20170143 INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY
Advanced Inhalation Therapies (AIT) Ltd. Sep- Jan May
758 DISEASES
13 -17 -17
24- 2- 25-
US20170143 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS
Not Available Jun- Feb May
749 THEREOF
14 -17 -17
25- 7- 18-
US20170137 GITR ANTIBODIES AND METHODS OF INDUCING OR ENHANCING
Not Available Mar- Nov May
527 AN IMMUNE RESPONSE
05 -16 -17
22- 18-
US20170137 29-
Nuclear Transport Modulators And Uses Thereof Not Available Jul- May
430 Jul-11
16 -17
28- 8- 18-
US20170136
NEUTRALIZING MOLECULES TO VIRAL ANTIGENS Not Available Mar- Jun May
118
08 -16 -17
11- 30- 18-
US20170136 THERAPEUTIC USES OF SELECTED PYRROLOPYRIMIDINE
The University of North Carolina at Chapel Hill Apr- Jan May
043 COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY
14 -17 -17
27- 12- 11-
US20170131 ANTIBODY-NANOPARTICLE CONJUGATES AND METHODS FOR
Not Available Apr- Sep May
271 MAKING AND USING SUCH CONJUGATES
10 -16 -17
29- 11-
US20170130 INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF 31-
Not Available Jul- May
200 THERAPY Jul-15
16 -17
20- 11-
US20170129 REGULATING THE INTERACTION BETWEEN TAM LIGANDS AND 25-
Kolltan Pharmaceuticals, Inc. Sep May
947 LIPID MEMBRANES WITH EXPOSED PHOSPHATIDYL SERINE Jul-12
-16 -17
21- 2- 30-
US20170088 Recombinant Influenza Virus-Like Particles (VLPs) Produced in
Medicago Inc. Jan- Sep Mar
848 Transgenic Plants Expressing Hemagglutinin
08 -16 -17
9- 12- 30-
US20170088 ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND
Not Available Feb- Dec Mar
559 THIAZOLONAPHTHYRIDINES
05 -16 -17
3- 12- 30-
US20170086
ANTIVIRAL AGENT Not Available Sep- Dec Mar
463
08 -16 -17
16- 15- 23-
US20170082
Assay for Detecting TH1 and TH2 Cell Populations Not Available May- May Mar
608
14 -15 -17
31- 19- 23-
US20170082
MALARIA ANTIGEN SCREENING METHOD Not Available Aug- Apr Mar
607
05 -13 -17
13- 23-
US20170081 PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM 14-
Not Available Jul- Mar
655 OXIDES Jul-15
16 -17
31- 2- 23-
US20170081 The U.S.A., as represented by the Secretary, Department
ENGINEERED ANTIBODY CONSTANT DOMAIN MOLECULES Jan- Dec Mar
393 of Health and Human Services
08 -16 -17
13- 13- 23-
US20170081 COMPOSITIONS COMPRISING AAV EXPRESSING DUAL ANTIBODY
Not Available May- May Mar
392 CONSTRUCTS AND USES THEREOF
14 -15 -17
24- 3- 23-
US20170080 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING
Not Available Apr- Oct Mar
078 PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME
12 -16 -17
5- 23-
US20170079 24-
Technology for the Preparation of Microparticles Not Available Dec Mar
920 Jul-07
-16 -17
23- 23- 23-
US20170079 COMPOSITIONS AND METHODS FOR MODIFIED DENDRIMER
Not Available Sep- Sep Mar
916 NANOPARTICLE DELIVERY
15 -16 -17
1- 25- 16-
US20170073 Compositions and Methods for Detecting and Quantifying Nucleic
Longhorn Vaccines and Diagnostics, LLC Oct- Nov Mar
738 Acid Sequences in Blood Samples
07 -16 -17
11- 8- 16-
US20170073
METHODS AND COMPOSITIONS FOR LIBRARY NORMALIZATION Not Available Sep- Sep Mar
730
15 -16 -17
8- 2- 16-
US20170073 METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING
Not Available Nov- Nov Mar
727 ADSORPTION MEDIA
13 -16 -17
6- 5- 16-
US20170073 Method for Identifying and Validating Dominant T Helper Cell
Not Available Jan- Dec Mar
390 Epitopes Using an HLA-DM-Assisted Class II Binding Assay
06 -14 -17
12- 29- 16-
US20170073
NOVEL SUBSTITUTED SPIROCYCLES Not Available Sep- Nov Mar
352
14 -16 -17
12- 22- 16-
US20170072
METHODS FOR PREPARING SQUALENE Not Available May- Nov Mar
053
10 -16 -17
2- 22- 16-
US20170071 METHOD OF USING OXIDATIVE REDUCTIVE POTENTIAL WATER
OCULUS INNOVATIVE SCIENCES, INC. May- Nov Mar
980 SOLUTION IN DENTAL APPLICATIONS
05 -16 -17
16- 16- 16-
US20170071 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE
Not Available Sep- Sep Mar
964 VIRUS INFECTIONS
15 -16 -17
3- 28- 16-
US20170071
NOVEL NANOPARTICLE COMPOSITIONS Not Available Apr- Nov Mar
867
13 -16 -17
30- 7- 9-
US20170067
ATTENUATED VIRUSES USEFUL FOR VACCINES Not Available Mar- Sep Mar
030
07 -16 -17
2- 9-
US20170067 31-
MODIFIED CELLS AND METHODS OF THERAPY Not Available Sep Mar
021 Jul-15
-16 -17
16- 18- 9-
US20170066
BORON-CONTAINING SMALL MOLECULES Not Available Feb- Nov Mar
788
05 -16 -17
16- 18- 9-
US20170066
BORON-CONTAINING SMALL MOLECULES Not Available Feb- Nov Mar
787
05 -16 -17
7- 5- 9-
US20170066
SMALL MOLECULE FATTY ACID SYNTHASE INHIBITORS Not Available Mar- Mar Mar
731
14 -15 -17
14- 9-
US20170065 METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS 2-Jul-
Not Available Sep Mar
706 VECTOR FOR USE WITH MULTIPLE VACCINATIONS 07
-16 -17
14- 9-
US20170065 Sequential administration of a replication defective adenovirus 2-Jul-
Not Available Sep Mar
693 vector in vaccination protocols 07
-16 -17
8- 22- 9-
US20170065 EV576 FOR USE IN THE TREATMENT OF VIRAL INFECTIONS OF THE
Volution Immuno Pharmaceuticals SA Jan- Jul- Mar
677 RESPIRATORY TRACT
10 16 -17
29- 9-
US20170065 31-
MODIFIED CELLS AND METHODS OF THERAPY Not Available Aug Mar
636 Jul-15
-16 -17
18- 18- 2-
US20170058
BACTERIAL IDENTIFICATION IN CLINICAL INFECTIONS Not Available Feb- Feb Mar
430
14 -15 -17
1- 3- 2-
US20170058
SYSTEMS AND METHODS FOR ANALYZING VIRAL NUCLEIC ACIDS Not Available Sep- Feb Mar
365
15 -16 -17
9- 8- 2-
US20170057 ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND
Kineta, Inc. May- May Mar
978 METHODS OF USE THEREOF
14 -15 -17
1- 29- 2-
US20170057 COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7
NOVARTIS AG May- Apr Mar
968 AGONISTS
14 -15 -17
5- 29- 9-
US20170037 NUCLEIC ACID DETECTION OR QUANTIFICATION METHOD USING
Not Available Feb- Jan Feb
457 MASK OLIGONUCLEOTIDE, AND DEVICE FOR SAME
14 -15 -17
2- 3- 9-
US20170037 CHIMERIC VIRUSES PRESENTING NON-NATIVE SURFACE PROTEINS
Icahn School of Medicine at Mount Sinai Dec- Mar Feb
379 AND USES THEREOF
05 -16 -17
15- 12- 9-
US20170037 METHOD FOR PREPARING INDUCED PLURIPOTENT STEM CELL, GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH,
Nov- Nov Feb
376 COMPOSITION USED IN METHOD, AND USES THEREOF CHINESE ACADEMY OF SCIENCES
13 -14 -17
8- 26- 9-
US20170037 RECOMBINANT EXPRESSION OF MULTIPROTEIN COMPLEXES USING
Not Available Nov- Oct Feb
090 POLYGENES
05 -16 -17
11- 11- 9-
US20170035
Multi-Functional Mucosal Vaccine Platform Not Available Feb- Feb Feb
878
14 -15 -17
7- 5- 9-
US20170035 Compositions and Methods for Inhibiting Pro-Inflammatory Cytokine
Not Available Aug- Aug Feb
845 Gene Expression
15 -16 -17
26- 31- 2-
US20170029
POLYTAG PROBES Not Available Feb- Mar Feb
877
10 -16 -17
30- 28- 2-
US20170029
ARTIFICIAL NUCLEIC ACID MOLECULES CureVac AG Dec- Jun Feb
847
13 -16 -17
14- 1- 2-
US20170029 HUMAN MONOCLONAL ANTIBODY WITH SPECIFICITY FOR DENGUE
Not Available Dec- Jun Feb
489 VIRUS SEROTYPE 1 E PROTEIN AND USES THEREOF
10 -16 -17
30- 3- 2-
US20170028 ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS
Not Available Sep- Aug Feb
082 CONTAINING SAME, AND USES THEREFOR
03 -16 -17
4- 11- 2-
US20170028
VACCINE COMPOSITION NITTO DENKO CORPORATION Apr- Oct Feb
054
12 -16 -17
7- 7- 2-
US20170027 United States Government as represented by the
Methods of Treating Coronavirus Infection Apr- Apr Feb
975 Secretary, Department of Health and Human Services
14 -15 -17
6- 20- 12-
US20170010 EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS
Not Available Oct- Sep Jan-
264 INFECTIONS AND DISEASES
08 -16 17
21- 28- 12-
US20170009
Short Interfering RNA (siRNA) Analogues Not Available Mar- Mar Jan-
237
03 -16 17
29- 19- 12-
US20170007 METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF
Not Available Nov- Sep Jan-
577 BRAIN INFLAMMATION AND SEPSIS
02 -16 17
1- 5-
US20170002 1-Jul-
PEPTIDOMIMETIC MACROCYCLES Not Available Jul- Jan-
042 15
16 17
23- 9- 5-
US20170000 CONSTRAINED IMMUNOGENIC COMPOSITIONS AND USES
Not Available Jun- Aug Jan-
878 THEREFOR
10 -16 17
14- 13- 5-
US20170000
Dimethyl Fumarate and Vaccination Regimens Not Available Mar- Mar Jan-
873
14 -15 17
28- 25- 29-
US20160376 COMPOSITIONS AND METHODS FOR INDUCING AN ENHANCED
Bavarian Nordic A/S Nov- Nov Dec
596 IMMUNE RESPONSE USING POXVIRUS VECTORS
13 -14 -16
26- 21- 29-
US20160376
A NOVEL SARS IMMUNOGENIC COMPOSITION BAYLOR COLLEGE OF MEDICINE Nov- Nov Dec
321
13 -14 -16
4- 22- 29-
US20160375
TARGETING LIPIDS Tekmira Pharmaceuticals Corporation Dec- Oct Dec
137
07 -13 -16
15- 5- 29-
US20160375 HOMOGENOUS SUSPENSION OF IMMUNOPOTENTIATING
Not Available Dec- Jul- Dec
132 COMPOUNDS AND USES THEREOF
09 16 -16
25- 22-
US20160369 TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) LIBRARIES 1-Jul-
The Board of Regents of the University of Texas System Jun Dec
268 AND METHODS OF SYNTHESIS AND USE 13
-14 -16
9- 23- 22-
US20160368 METHOD OF PREVENTIVELY TREATING A SUBJECT AT THE RISK OF
Not Available May- Aug Dec
956 DEVELOPING INFECTIONS OF A RESPIRATORY VIRUS
13 -16 -16
3- 22-
US20160368 SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS 3-Jul-
Not Available Jul- Dec
904 AND USES THEREOF 13
14 -16
12- 12- 22-
US20160367
Systemic In Vivo Delivery of Oligonucleotides OncoImmunin, Inc. Jun- Jun Dec
587
13 -14 -16
17- 10- 22-
US20160367 ORAL SENSOR ALERTING AND COMMUNICATION SYSTEM AND
Not Available Jun- Sep Dec
188 DEVELOPERS' TOOL KIT
15 -15 -16
25- 25- 15-
US20160363
AMPEROMETRIC GAS SENSOR Not Available Jun- Aug Dec
557
12 -16 -16
26- 26- 15-
US20160362
PHOTO-SELECTIVE METHOD FOR BIOLOGICAL SAMPLE ANALYSIS Not Available Feb- Aug Dec
730
14 -16 -16
7- 10- 15-
US20160362 Identification and Attenuation of the Immunosuppressive Domains
Not Available Oct- Jun Dec
454 in Fusion Proteins of Enveloped RNA Viruses
11 -16 -16
11- 13- 15-
US20160361 MICROBICIDAL COMPOSITIONS AND METHODS FOR TREATMENT OF
Not Available Jun- Jun Dec
382 VIRAL INFECTIONS
15 -16 -16
31- 9- 8-
US20160354 METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN
Not Available Aug- Jun Dec
451 AMYLOIDOSES AND PROTEIN AGGREGATION DISORDERS
07 -16 -16
8- 2- 8-
US20160354 METHODS AND COMPOSITIONS RELATED TO INHIBITION OF VIRAL
Not Available Feb- Jun Dec
428 ENTRY
07 -16 -16
9- 6- 8-
US20160354
Nuclear Transport Modulators and Uses Thereof Not Available May- Jan Dec
347
12 -16 -16
29- 31- 1-
US20160348 EXTRACTION AND PRESERVATION OF NUCLEIC ACID MOLECULES THE UNITED STATES OF AMERICA, as represented by the
May- May Dec
153 FROM PATHOGENS Secretary, Department of Health and Human Serv
15 -16 -16
18- 11- 1-
US20160348
TC-83-DERIVED ALPHAVIRUS VECTORS, PARTICLES AND METHODS Not Available May- Aug Dec
132
04 -16 -16
27- 26- 1-
US20160348 CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with
Not Available Sep- May Dec
115 Enhanced Immunostimulatory Activity
06 -16 -16
2- 11- 1-
US20160348
NUCLEIC ACID CHEMICAL MODIFICATIONS Not Available Mar- Aug Dec
110
09 -16 -16
15- 29- 1-
US20160347 POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR
Not Available Apr- Feb Dec
816 TREATMENT OF IMMUNE RELATED DISORDERS AND CANCER
11 -16 -16
27- 1-
US20160347 6-Jul-
NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF Not Available May Dec
784 09
-16 -16
1- 21- 1-
US20160346 TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL
Not Available Jun- Dec Dec
309 METABOLIC PATHWAYS
07 -15 -16
6- 20- 24-
US20160340 STABILIZING COMPOSITIONS AND METHODS FOR EXTRACTION OF
Not Available Oct- May Nov
713 RIBONUCLEIC ACID
06 -16 -16
6- 5- 24-
US20160340 SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE
Not Available Feb- Aug Nov
319 AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
13 -16 -16
7- 4- 24-
US20160339
CORONAVIRUS PROTEINS AND ANTIGENS MJ Biologics, Inc. Feb- Aug Nov
097
14 -16 -16
20- 19- 24-
US20160338 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND
3-V Biosciences, Inc. Dec- Dec Nov
998 COMBINATIONS THEREOF
13 -14 -16
3- 28- 17-
US20160333 OLIGONUCLEOTIDE MODULATORS OF THE TOLL-LIKE RECEPTOR
Not Available Mar- Jul- Nov
356 PATHWAY
11 16 -16
8- 18- 17-
US20160333
Antigenic GM-CSF Peptides and Antibodies to GM-CSF Not Available Feb- Jul- Nov
089
06 16 -16
7- 2- 17-
US20160333 The United States of America, as represented by the
NEUTRALIZING GP41 ANTIBODIES AND THEIR USE Nov- Aug Nov
076 Secretary, Department of Health and Human Serv
11 -16 -16
23- 5- 17-
US20160331
NUCLEIC ACID VACCINES Moderna Therapeutics, Inc. Apr- Apr Nov
828
14 -16 -16
1- 21- 17-
US20160331
TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE Not Available Aug- Dec Nov
758
08 -15 -16
6- 5- 10-
US20160327
CAPACITIVE LIQUID CRYSTAL BIOSENSORS Not Available May- May Nov
506
15 -16 -16
8- 1- 13-
US20160299 NAD ANALOGS AND METHODS OF USING SAID NAD ANALOGS IN Biolog Life Science Institute Forschungslabor und
Apr- Apr Oct-
141 DETERMINING RIBOSYLATION OF PROTEINS WITH PARP MUTANTS Biochemica-Vertrieb GmbH
15 -16 16
5- 2- 13-
US20160298 LUMINOPHORE-LABELED MOLECULES COUPLED WITH PARTICLES
CapitalBio Corporation Dec- Dec Oct-
179 FOR MICROARRAY-BASED ASSAYS
13 -14 16
18- 7- 6-
US20160287 COMPOSITIONS AND METHODS FOR TREATING IMMUNE AND VIRAL
Massachusetts Institute of Technology Nov- Nov Oct-
622 DISORDERS AND MODULATING PROTEIN-RNA INTERACTION
13 -14 16
GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING 28- 10- 29-
US20160281
LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA Not Available Oct- Jun Sep
109
VIRUS SPIKE PROTEIN 05 -16 -16
3- 13- 29-
US20160280
ALKOXY SUBSTITUTED IMIDAZOQUINOLINES Not Available Oct- Jun Sep
707
03 -16 -16
24- 24- 29-
US20160279
ADJUVANT COMPOSITIONS AND RELATED METHODS Not Available Mar- Mar Sep
237
15 -16 -16
6- 6- 29-
US20160279
IMMUNOSUPPRESSIVE AGENTS AND THEIR USE IN THERAPY Not Available Nov- Nov Sep
193
13 -14 -16
24- 24- 29-
US20160279 PULSE INHALATION OF NITRIC OXIDE FOR TREATING
Not Available Mar- Mar Sep
165 RESPIRATORY DISEASES
15 -16 -16
1- 3- 29-
US20160279
Method of Treating Inflammation Not Available Apr- Jun Sep
163
10 -16 -16
27- 23- 29-
US20160278
Immunocompromised Ungulates Not Available Oct- Mar Sep
349
08 -15 -16
6- 4- 8-
US20160257
Benzazepine Dicarboxamide Compounds Hoffmann-La Roche Inc. Mar- Mar Sep
653
15 -16 -16
5- 4- 11-
US20160229 THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7
Not Available Feb- Feb Aug
864 INHIBITORS
15 -16 -16
5- 4- 11-
US20160229 QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-
Not Available Feb- Feb Aug
833 SPECIFIC PROTEASE 7 INHIBITORS
15 -16 -16
3- 2- 11-
US20160228
NASAL MUCOSAL VACCINE COMPOSITION NITTO DENKO CORPORATION Oct- Oct Aug
540
13 -14 -16
23- 23- 11-
US20160228 Use of EGFR Pathway Inhibitors to Increase Immune Responses to
Emory University Sep- Sep Aug
533 Antigens
13 -14 -16
16- 13- 11-
US20160228 METHOD OF OBTAINING THERMOSTABLE DRIED VACCINE
Merck Sharp & Dohme Corp. Oct- Oct Aug
532 FORMULATIONS
13 -14 -16
16- 20- 11-
US20160228
BORON-CONTAINING SMALL MOLECULES Not Available Feb- Apr Aug
463
05 -16 -16
23- 22- 4-
US20160222
Universal Protein Tag for Double Stranded Nucleic Acid Delivery Not Available Oct- Oct Aug
072
13 -14 -16
30- 29- 4-
US20160222
NOVEL MONOTHIOL MUCOLYTIC AGENTS PARION SCIENCES, INC. Jan- Jan Aug
023
15 -16 -16
22- 7- 4-
US20160222
4-AMINO-IMIDAZOQUINOLINE COMPOUNDS Hoffmann-La Roche Inc. Apr- Apr Aug
010
14 -16 -16
29- 27- 4-
US20160221
Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof Not Available Nov- Nov Aug
994
12 -13 -16
13- 12- 4-
US20160220
ANTIGEN AND METHOD FOR PRODUCTION THEREOF Not Available Sep- Sep Aug
664
13 -14 -16
11- 10- 4-
US20160220 NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND
Not Available Sep- Sep Aug
595 USES RELATED THERETO
13 -14 -16
22- 5- 21-
US20160206 COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1
CureVac AG Feb- Apr Jul-
719 PATHWAY
13 -16 16
16- 5- 21-
US20160206
BORON-CONTAINING SMALL MOLECULES Not Available Feb- Apr Jul-
638
05 -16 16
31- 28- 21-
US20160206
Inhibition of Biofilm Organisms NOVABIOTICS LIMITED Mar- Mar Jul-
575
09 -16 16
8- 21- 14-
US20160202 University of Pittsburgh - Of the Commonwealth System of
B-CELL ANTIGEN PRESENTING CELL ASSAY Apr- Mar Jul-
258 Higher Education
10 -16 16
9- 17- 14-
US20160201
DIAGNOSIS AND TREATMENT OF INCIPIENT DIABETES Not Available Jan- Nov Jul-
110
15 -15 16
3- 22- 14-
US20160199 ARRANGING INTERACTION AND BACK PRESSURE CHAMBERS FOR
Not Available Dec- Mar Jul-
486 MICROFLUIDIZATION
09 -16 16
21- 21- 14-
US20160199 METHOD OF REDUCING ANTIGENIC DRIFT OR REASSORTMENT OF
Hemispherx Biopharma, Inc. Aug- Aug Jul-
449 VIRUSES IN A HOST ANIMAL USING ALPHA INTERFERON
13 -14 16
7- 17- 7-
US20160193 PEPTIDES SHARED AMONG LETHAL CANCERS AND THERAPEUTIC
Not Available Aug- Mar Jul-
315 COMPOSITIONS COMPRISING SAID PEPTIDES
09 -16 16
13- 5- 7-
US20160192
HYDROGEN-CONTAINING ANTIMICROBIAL AGENT Not Available Aug- Aug Jul-
658
13 -14 16
30- 29- 30-
US20160185 PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-
Not Available Dec- Dec Jun-
786 SPECIFIC PROTEASE 7 INHIBITORS
14 -15 16
30- 29- 30-
US20160185 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC
Not Available Dec- Dec Jun-
785 PROTEASE 7 INHIBITORS
14 -15 16
17- 17- 30-
US20160184
INTRANASAL VACCINATION DOSAGE REGIMEN Not Available Dec- Dec Jun-
424
12 -13 16
16- 11- 30-
US20160184
BORON-CONTAINING SMALL MOLECULES Not Available Feb- Mar Jun-
334
05 -16 16
8- 23-
US20160177 METHOD FOR PRODUCTION OF REPROGRAMMED CELL USING 16-
Not Available Mar Jun-
337 CHROMOSOMALLY UNINTEGRATED VIRUS VECTOR Jul-08
-16 16
9- 11- 23-
US20160177
Expression Tools for Multiprotein Applications Not Available Mar- Dec Jun-
336
04 -15 16
17- 15- 23-
US20160175 LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND
Not Available Aug- Dec Jun-
433 COMPOSITIONS, FORMULATIONS, AND METHODS
10 -15 16
12- 11- 23-
US20160175
Compositions and Uses of Lectins Emory University Feb- Dec Jun-
394
10 -15 16
10- 10- 23-
US20160175
Use of Immune Suppressive Domains as Medicaments Not Available Apr- Apr Jun-
387
13 -14 16
24- 9- 16-
US20160168
Cyclic Antimicrobial Peptides NOVABIOTICS LIMITED Feb- Nov Jun-
203
06 -15 16
15- 27- 16-
US20160168
NOVEL COMPOUNDS CHIESI FARMACEUTICI S.p.A. Dec- Nov Jun-
101
14 -15 16
21- 19- 16-
US20160166 METHOD FOR INCREASING EXPRESSION OF RNA-ENCODED
CureVac AG Aug- Feb Jun-
710 PROTEINS
13 -16 16
10- 10- 16-
US20160166
Use of Immune Suppressive Peptides as Adjuvants Not Available Apr- Apr Jun-
676
13 -14 16
26- 8- 9-
US20160160 MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION
Not Available Feb- Feb Jun-
258 OF B CELLS
03 -16 16
9- 2- 9-
US20160160
IMMUNOTHERAPY USING STEM CELLS Not Available Dec- Dec Jun-
178
14 -15 16
18- 7- 9-
US20160158
PREPARATION OF INFLUENZA VIRUS VACCINE ANTIGENS Novartis AG Mar- Dec Jun-
341
08 -15 16
12- 14- 9-
US20160158 TREATMENT OF MULTIPLE EVOLVING BACTERIAL RESISTANCE
CHILDREN'S HEALTHCARE OF ATLANTA, INC. Nov- Aug Jun-
308 DISEASES WITH LIPOSOMALLY FORMULATED GLUTATHIONE
13 -14 16
4- 4- 9-
US20160158
Methods of Populating a Gastrointestinal Tract Not Available Feb- Feb Jun-
294
13 -14 16
5- 7- 9-
US20160158 PROTEIN VESICLES AND METHODS OF MAKING AND USING
Not Available Dec- Dec Jun-
154 THEREOF
14 -15 16
19- 11- 2-
US20160153
Rapid Epidemiologic Typing of Bacteria Not Available May- Nov Jun-
034
08 -15 16
7- 9- 2-
US20160152 HELIX-GRAFTED PROTEINS AS INHIBITORS OF DISEASE-RELEVANT
COLORADO STATE UNIVERSITY RESEARCH FOUNDATION Nov- Nov Jun-
676 PROTEIN-PROTEIN INTERACTIONS
14 -15 16
23- 9- 2-
US20160152 COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL
Not Available Jan- Feb Jun-
667 INFECTIONS
08 -16 16
21- 20- 2-
US20160152
Nuclear Transport Modulators and Uses Thereof Karyopharm Therapeutics Inc. Jun- Jun Jun-
596
13 -14 16
16- 17- 2-
US20160151
BORON-CONTAINING SMALL MOLECULES Not Available Feb- Feb Jun-
399
05 -16 16
17- 19- 26-
US20160146
RECEPTORS FOR B7-H4 Not Available May- May May
806
13 -14 -16
26- 26- 26-
US20160146
Method of monitoring cellular trafficking of peptides Not Available Jun- Jun May
786
13 -14 -16
9- 23- 26-
US20160145
NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Not Available May- Jun May
246
12 -15 -16
4- 26-
US20160144 Compositions and Imaging Methods Comprising Detectably Labeled 15-
Not Available Feb May
061 Phosphatidylethanolamine-Binding Peptides Jul-02
-16 -16
28- 19-
US20160139 DETECTING TARGETS USING MASS TAGS AND MASS 2-Jul-
Not Available Dec May
143 SPECTROMETRY 10
-15 -16
12- 7- 19-
US20160137
GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIES Not Available Sep- Aug May
702
07 -15 -16
16- 5-
US20160122 ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND 16-
Not Available Jul- May
312 METHODS OF USE THEREOF Jul-13
14 -16
METHOD FOR PREPARING VIRAL PARTICLES WITH CYCLIC 16- 16- 17-
US20160074
DINUCLEOTIDE AND USE OF SAID PARTICLES FOR INDUCING Not Available Sep- Sep Mar
507
IMMUNE RESPONSE 14 -15 -16
23- 17-
US20160074 DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE 6-Jul-
Not Available Nov Mar
506 POLYMER PARTICLES 10
-15 -16
7- 30- 17-
US20160074 Clottable Concentrate Of Platelet Growth Factors And Preparation
Zheng Yang Biomedical Technology Co., LTD. Jan- Nov Mar
481 Method Thereof
08 -15 -16
7- 10-
US20160068 Compositions and Methods for "Resistance-Proof" SiRNA 8-Jul-
Sirnaomics, Inc. Jul- Mar
843 Therapeutics for Influenza 12
13 -16
3- 16- 10-
US20160068
OLIGOPEPTIDE-FREE CELL CULTURE MEDIA Not Available Jan- Nov Mar
587
07 -15 -16
14- 14- 10-
US20160068
PEPTIDOMIMETIC MACROCYCLES Not Available Jan- Sep Mar
573
09 -15 -16
3- 2- 10-
US20160067
GENERATING PEPTOID VACCINES The Board of Regents of the University of Texas System May- May Mar
333
13 -14 -16
9- 26- 3-
US20160060 MEANS AND METHODS FOR INFLUENCING THE STABILITY OF
Not Available Dec- Aug Mar
598 ANTIBODY PRODUCING CELLS
05 -15 -16
6- 9- 3-
US20160060 SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE
Not Available Feb- Nov Mar
231 AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
13 -15 -16
6- 9- 3-
US20160060 SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE
Not Available Feb- Nov Mar
230 AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
13 -15 -16
2- 31- 3-
US20160060
N-MYRISTOYL TRANSFERASE INHIBITORS UNIVERSITY OF DUNDEE Sep- Aug Mar
224
08 -15 -16
26- 26- 3-
US20160058 PLANT EXTRACTS AND RELATED COMPOSITIONS, METHODS AND
Not Available Aug- Aug Mar
814 SYSTEMS
14 -14 -16
14- 24- 3-
US20160058 WEAR RESISTANT ANTIMICROBIAL COMPOSITIONS AND METHODS
Not Available Dec- Sep Mar
012 OF USE
10 -15 -16
28- 28- 3-
US20160058 ANTIMICROBIAL COMPOSITIONS AND METHODS WITH NOVEL
Not Available Aug- Aug Mar
008 POLYMERIC BINDING SYSTEM
14 -15 -16
28- 15- 25-
US20160054
CHEMICALLY DIFFERENTIATED SENSOR ARRAY Nanomedical Diagnostics, Inc. Apr- Oct Feb
312
14 -15 -16
27- 27- 25-
US20160053 PROBE KIT FOR DETECTING A SINGLE STRAND TARGET
Fondzione Istituto Italiano Di Tecnolgia Dec- Dec Feb
308 NUCLEOTIDE SEQUENCE
12 -13 -16
18- 9- 25-
US20160053
BACILLUS BASED DELIVERY SYSTEM AND METHODS OF USE Not Available Apr- Sep Feb
222
11 -15 -16
2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H-
PYRAZOLO[3,4-D]PYRIMIDIN-1 -YL)METHYL)-3-(2- 15- 14- 11-
US20160039
(TRIFLUOROMETHYL)BENZYL) QUINAZOLIN-4(3H)-ONE Not Available Mar- Mar Feb
826
DERIVATIVES AND THEIR USE AS PHOSPHOINOSITIDE 3-KINASE 13 -14 -16
INHIBITORS
27- 11-
US20160039 SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE 31-
Not Available Jul- Feb
812 AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY Jul-14
15 -16
15- 14- 4-
US20160032 VECTORS COMPRISING STUFFER/FILLER POLYNUCLEOTIDE
THE CHILDREN'S HOSPITAL OF PHILADELPHIA Mar- Mar Feb
319 SEQUENCES AND METHODS OF USE
13 -14 -16
1- 31- 4-
US20160031 SUBSTITUTED OXETANES AND THEIR USE AS INHIBITORS OF
Not Available Aug- Jul- Feb
861 CATHEPSIN C
14 15 -16
27- 4-
US20160031 SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE 31-
Not Available Jul- Feb
831 AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY Jul-14
15 -16
27- 4-
US20160031 SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE 31-
Not Available Jul- Feb
830 AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY Jul-14
15 -16
27- 4-
US20160031 SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE 31-
Not Available Jul- Feb
829 AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY Jul-14
15 -16
27- 4-
US20160031 SUBSTITUTED DIHYDROPYRIMIDINONES AND THEIR USE AS 31-
Not Available Jul- Feb
825 INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY Jul-14
15 -16
14- 14- 4-
US20160030 METHODS AND COMPOSITIONS FOR MODULATING REGULATORY T
Not Available Mar- Mar Feb
443 CELL FUNCTION
13 -14 -16
28- 1- 28-
US20160025
METHOD FOR ELECTRONIC BIOLOGICAL SAMPLE ANALYSIS Nanomedical Diagnostics, Inc. Apr- Oct Jan-
675
14 -15 16
21- 28-
US20160025 AIRBORNE AGENT COLLECTORS, METHODS, SYSTEMS AND 22-
Not Available Jul- Jan-
603 DEVICES FOR MONITORING AIRBORNE AGENTS Jul-14
15 16
21- 7- 28-
US20160024
REVERSE GENETICS USING NON-ENDOGENOUS POL I PROMOTERS NOVARTIS AG May- May Jan-
525
09 -15 16
15- 14- 28-
US20160024
Inhibitory Polypeptides Specific to WNT Inhibitors Not Available Mar- Mar Jan-
158
13 -14 16
15- 14- 28-
US20160022 RODENT HEPADNAVIRUS CORES WITH REDUCED CARRIER-
Not Available Mar- Mar Jan-
801 SPECIFIC ANTIGENICITY
13 -14 16
16- 21-
US20160016 17-
INHIBITORY PEPTIDES OF VIRAL INFECTION Not Available Jul- Jan-
999 Jul-14
15 16
21- 21-
US20160016 21-
STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT Not Available Jul- Jan-
986 Jul-14
15 16
8- 2- 14-
US20160008 METHODS OF GENERATING ROBUST PASSIVE AND ACTIVE IMMUNE
Not Available Jan- Aug Jan-
461 RESPONSES
13 -14 16
14- 14- 14-
US20160008
NANOPARTICLE-BASED COMPOSITIONS Not Available Mar- Mar Jan-
451
13 -14 16
10- 14-
US20160008 IMMUNOMODULATION BY CONTROLLING EXPRESSION LEVELS OF 14-
Not Available Jul- Jan-
397 MICRORNAS IN DENDRITIC CELLS Jul-14
15 16
15- 17- 14-
US20160008
DRUG COMBINATION VERONA PHARMA PLC Mar- Mar Jan-
363
13 -14 16
16- 11- 7-
US20160003
Apparatus for two-step surface-enhanced raman spectroscopy REAL-TIME ANALYZERS, INC Dec- Sep Jan-
747
11 -15 16
20- 10- 7-
US20160002
METHODS TO PRODUCE BUNYAVIRUS REPLICON PARTICLES Not Available Sep- Jul- Jan-
608
10 15 16
25- 24- 7-
US20160000
Nanoparticle Delivery of TLR Agonists and Antigens Not Available Feb- Feb Jan-
905
13 -14 16
15- 17- 7-
US20160000
DRUG COMBINATION VERONA PHARMA PLC Mar- Mar Jan-
790
13 -14 16
6- 14- 7-
US20160000 Antiviral Activity from Medicinal Mushrooms and their Active
Not Available Jan- Sep Jan-
754 Constituents
04 -15 16
27- 27- 31-
US20150377
IN SITU AFFINITY MATURATION OF ANTIBODIES Not Available Feb- Feb Dec
887
13 -14 -15
28- 14- 31-
US20150376 MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS
ARROWHEAD RESEARCH CORPORATION Feb- May Dec
621 OF USE
08 -15 -15
1- 30- 24-
US20150366 INTRADERMAL DELIVERY OF IMMUNOLOGICAL COMPOSITIONS
Not Available Feb- Jan Dec
796 COMPRISING TOLL-LIKE RECEPTOR AGONISTS
13 -14 -15
29- 26-
US20150337 METHOD FOR PRODUCTION OF REPROGRAMMED CELL USING 16-
Not Available Jul- Nov
334 CHROMOSOMALLY UNINTEGRATED VIRUS VECTOR Jul-08
15 -15
6- 4- 26-
US20150337 ANTIVIRAL RIFT VALLEY FEVER VIRUS PEPTIDES AND METHODS OF The United States of America, as represented by the
Dec- Jun Nov
015 USE Secretary of the Army, on behalf of the United
12 -15 -15
8- 27- 26-
US20150335 Immunogenic Composition and Methods of Using the Compositions
Not Available Apr- Apr Nov
733 for Inducing Humoral and Cellular Immune Responses
11 -15 -15
27- 18- 26-
US20150335 METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST
Academia Sinica Mar- Feb Nov
728 VIRUS
09 -14 -15
5- 4- 26-
US20150335
Methods for Modulating Sirtuin Enzymes Not Available May- May Nov
657
14 -15 -15
25- 8- 19-
US20150329
NOVEL siRNAS AND METHODS OF USE THEREOF Not Available Oct- Jan Nov
866
06 -15 -15
9- 4- 19-
US20150329
METHODS OF PROPAGATING MONKEY ADENOVIRAL VECTORS GenVec, Inc. Nov- Aug Nov
834
09 -15 -15
24- 5- 19-
US20150328
METHODS FOR TREATING VIRAL DISORDERS Not Available Sep- Aug Nov
282
09 -15 -15
15- 16- 12-
US20150322
High density self-contained biological analysis Not Available Nov- Jul- Nov
491
06 15 -15
15- 12-
US20150322 ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC 15-
Robert Yongxin Zhao Jul- Nov
155 CONJUGATION OF A CELL-BINDING MOLECULE Jul-15
15 -15
28- 28- 12-
US20150322 HUMAN ANTIBODY SPECIFIC TO HUMAN METAPNEUMOVIRUS, OR
Not Available Jan- Jan Nov
137 ANTIGEN-BINDING FRAGMENT THEREOF
13 -14 -15
12- 11- 12-
US20150322
THERAPEUTIC CATECHOLS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY May- May Nov
022
14 -15 -15
12- 11- 12-
US20150322 INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR
ACTELION PHARMACEUTICALS LTD Dec- Dec Nov
008 ANTAGONIST
12 -13 -15
6- 6- 12-
US20150320
USE OF ASC AND ASC-CM TO TREAT ARDS, SARS, AND MERS Not Available May- May Nov
801
14 -15 -15
30- 20- 5-
US20150315 ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS
Not Available Sep- Jul- Nov
612 CONTAINING SAME, AND USES THEREFOR
03 15 -15
6- 1- 22-
US20150301
CIRCULATING BIOMARKERS FOR DISEASE Not Available Apr- Jul- Oct-
055
10 15 15
18- 6- 22-
US20150299
TC-83-DERIVED ALPHAVIRUS VECTORS, PARTICLES AND METHODS Not Available May- Jul- Oct-
728
04 15 15
17- 8- 22-
US20150299 3,5-DIAMINO-6-CHLORO-N-(4-PHENYLBUTYL)CARBAMIMIDOYL)
PARION SCIENCES, INC. Dec- Jan Oct-
142 PYRAZINE-2-CARBOXAMIDE COMPOUNDS
12 -15 15
11- 3- 15-
US20150290 THERAPEUTIC USES OF SELECTED PYRAZOLOPYRIMIDINE
Not Available Apr- Apr Oct-
212 COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY
14 -15 15
11- 3- 15-
US20150290 THERAPEUTIC USES OF SELECTED PYRROLOPYRIMIDINE
Not Available Apr- Apr Oct-
197 COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY
14 -15 15
11- 3- 15-
US20150290 THERAPEUTIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH
Not Available Apr- Apr Oct-
194 ANTI-MER TYROSINE KINASE ACTIVITY
14 -15 15
7- 7- 8-
US20150283 ATTENUATED LISTERIA MONOCYTOGENES MUTANT AS A VACCINE
The Board of Trustees of the University of Illinois Apr- Apr Oct-
221 VECTOR FOR THE DELIVERY OF EXOGENEOUS ANTIGENS
14 -15 15
23- 23- 1-
US20150275 Human Betacoronavirus Lineage C and Identification of N-Terminal
Not Available Sep- Sep Oct-
183 Dipeptidyl Peptidase As Its Virus Receptor
12 -13 15
10- 1-
US20150274 Hydrazide Containing Nuclear Transport Modulators And Uses 29-
Not Available Jun Oct-
698 Thereof Jul-11
-15 15
7- 7- 1-
US20150272 INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY
Advanced Inhalation Therapies (AIT) Ltd. Mar- Mar Oct-
988 DISEASES
12 -13 15
14- 14- 24-
US20150267 PRESERVATION OF BIOLOGICAL MATERIALS IN NON-AQUEOUS
GenTegra, LLC Mar- Mar Sep
245 FLUID MEDIA
13 -14 -15
16- 6- 24-
US20150267 ANTISENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING
Not Available Sep- Nov Sep
202 ss/RNA VIRAL INFECTION
04 -14 -15
12- 12- 24-
US20150267 DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4
Quark Pharmaceutical, Inc. Sep- Sep Sep
194 AND METHODS OF USE THEREOF
12 -13 -15
17- 4- 24-
US20150266 VIRUS-LIKE PARTICLES, METHODS OF PREPARATION, AND
Not Available May- May Sep
929 IMMUNOGENIC COMPOSITIONS
02 -15 -15
9- 8- 24-
US20150266 ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND
Not Available Feb- Jun Sep
901 THIAZOLONAPHTHYRIDINES
05 -15 -15
19- 18- 24-
US20150266
PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS Not Available Oct- Oct Sep
882
12 -13 -15
23- 23- 24-
US20150265
Compounds and Methods for Modulating an Immune Response Not Available Mar- Dec Sep
721
09 -14 -15
5- 11- 24-
US20150265 HIGH-YIELD TRANSGENIC MAMMALIAN EXPRESSION SYSTEM FOR
Academia Sinica Sep- Feb Sep
697 GENERATING VIRUS-LIKE PARTICLES
06 -15 -15
24- 23- 24-
US20150265 Compositions And Methods For Treating And Preventing Porcine
Not Available Apr- Feb Sep
696 Reproductive And Respiratory Syndrome
12 -15 -15
25- 23- 17-
US20150259
GITR BINDING MOLECULES AND USES THEREFOR Not Available Mar- Mar Sep
427
05 -15 -15
4- 4- 20-
US20150232 MODIFIED OLIGONUCLEOTIDES COMPRISING THIOL FUNCTIONS
Not Available Apr- Apr Aug
957 AND USE THEREOF FOR DETECTING NUCLEIC ACIDS
12 -13 -15
7- 7- 20-
US20150232 CRISPR-RELATED METHODS AND COMPOSITIONS WITH
EDITAS MEDICINE, INC. Nov- Nov Aug
881 GOVERNING gRNAS
13 -14 -15
28- 20- 20-
US20150232
Construct Not Available Mar- Oct Aug
878
06 -14 -15
11- 11- 20-
US20150232 THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY Sep- Sep Aug
454 AND HYDROXYPYRIDAZINONES
12 -13 -15
18- 18- 20-
US20150231
OUTER MEMBRANE VESICLES Not Available Sep- Sep Aug
232
12 -13 -15
2- 24- 13-
US20150225
COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS Novartis AG Sep- Apr Aug
432
09 -15 -15
18- 13- 6-
US20150218 SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND
Not Available Jun- Apr Aug
162 IMIDAZONAPHTHYRIDINES
04 -15 -15
21- 19- 6-
US20150218
C-REL INHIBITORS AND USES THEREOF Not Available Sep- Sep Aug
109
12 -13 -15
8- 8- 6-
US20150216
METHOD FOR THE INDUCTION OF AN IMMUNE RESPONSE Not Available Aug- Aug Aug
973
12 -13 -15
12- 30-
US20150211 13-
CHIRAL CONTROL Not Available Jul- Jul-
006 Jul-12
13 15
2- 22- 30-
US20150210
NUCLEIC ACID CHEMICAL MODIFICATIONS Not Available Mar- Jan Jul-
733
09 -15 15
4- 9-
US20150191 3-Jul-
Anti-fouling Paints and Coatings REACTIVE SURFACES, LTD Dec Jul-
607 03
-13 15
27- 27- 2-
US20150184
BIOAGENT DETECTION OLIGONUCLEOTIDES Not Available Dec- Dec Jul-
231
11 -12 15
17- 13- 2-
US20150183
IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF Not Available Dec- Feb Jul-
837
07 -15 15
18- 23- 2-
US20150182
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available Nov- Dec Jul-
588
13 -14 15
20- 5- 25-
US20150175
CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS Not Available Mar- Mar Jun-
656
09 -15 15
29- 3- 25-
US20150174 METHODS AND REAGENTS FOR EFFICIENT AND TARGETED GENE
Not Available Apr- Mar Jun-
257 TRANSFER TO MONOCYTES AND MACROPHAGES
09 -15 15
GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING 28- 17- 25-
US20150174
LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA Not Available Oct- Nov Jun-
198
VIRUS SPIKE PROTEIN 05 -14 15
7- 7- 25-
US20150174 INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY
Not Available Mar- Mar Jun-
158 DISEASES
12 -13 15
1- 16- 25-
US20150173
PHYSICAL ANTIMICROBIAL METHOD NMS TECHNOLOGIES CO., LTD. Aug- Jul- Jun-
366
12 13 15
16- 24- 18-
US20150168
OLIGONUCLEOTIDE BASED ANALYTE DETECTION METHOD Not Available Feb- Feb Jun-
405
10 -15 15
25- 27- 18-
US20150166 PARTICLE-NUCLEIC ACID CONJUGATES AND THERAPEUTIC USES
Not Available Jun- Feb Jun-
989 RELATED THERETO
12 -13 15
20- 1- 18-
US20150166
REVERSE GENETICS METHODS FOR VIRUS RESCUE Not Available Oct- Oct Jun-
966
09 -14 15
16- 16- 18-
US20150166
NOVEL COMPOUNDS CHIESI FARMACEUTICI S.p.A. Dec- Dec Jun-
548
13 -14 15
11- 15- 18-
US20150166 HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER
Not Available Apr- Mar Jun-
532 VIRUSES
12 -13 15
13- 19- 18-
US20150166 ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPTHELIAL
PARION SCIENCES, INC. Dec- Dec Jun-
488 SODIUM CHANNEL BLOCKING COMPOUNDS
13 -14 15
13- 13- 18-
US20150166 ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL
Parion Sciences, Inc. Dec- Dec Jun-
487 SODIUM CHANNEL BLOCKING COMPOUNDS
13 -13 15
24- 5- 18-
US20150165
Saccharide Conjugate Vaccines Not Available Dec- Aug Jun-
019
04 -14 15
24- 20- 18-
US20150165 TLR5 LIGANDS, THERAPEUTIC METHODS, AND COMPOSITIONS
Emory University Sep- Sep Jun-
009 RELATED THERETO
10 -11 15
6- 6- 11-
US20150159 The United States of America, as represented by the
METHODS AND REAGENTS FOR AMPLIFYING NUCLEIC ACIDS Aug- Aug Jun-
205 Secretary, Department of Health and Human
12 -12 15
7- 18- 11-
US20150159
METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR The Trustees of the University of Pennsylvania Apr- Feb Jun-
173
05 -15 15
24- 18- 11-
US20150157
METHODS FOR TREATING VIRAL DISORDERS Not Available Sep- Feb Jun-
636
09 -15 15
9- 21- 4-
US20150152 Peptides Having Activity of Inhibiting Infections of Respiratory
Not Available May- Feb Jun-
149 Viruses and Use of the Same
13 -14 15
5- 5- 4-
US20150150
VACCINATION WITH INTERLEUKIN-4 ANTAGONISTS THE AUSTRALIAN NATIONAL UNIVERSITY Jun- Jun Jun-
963
12 -13 15
18- 31- 4-
US20150150
ANDROGRAPHOLIDE ANALOGS AND THEIR USE FOR MEDICATION Not Available Jun- May Jun-
893
12 -13 15
4- 4- 4-
US20150150 Methods For Inhibiting Viruses By Targeting Cathepsin-L Cleavage
Not Available Apr- Apr Jun-
878 Sites In The Viruses' Glycoproteins
12 -13 15
1- 9- 28-
US20150148 MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS
NOVARTIS AG Oct- May May
402 OF USE
04 -14 -15
8- 14-
US20150132 Compositions and Imaging Methods Comprising Detectably Labeled 15-
Not Available Jan May
220 Phosphatidylethanolamine-Binding Peptides Jul-02
-15 -15
24- 4- 7-
US20150126 OLIGONUCLEOTIDE COMPOUND AND METHOD FOR TREATING
Not Available Dec- Jun May
722 NIDOVIRUS INFECTIONS
03 -14 -15
15- 5- 7-
US20150125
RELEASE OF AGENTS FROM CELLS Not Available Oct- Jan May
540
09 -15 -15
6- 4- 7-
US20150125 DISINFECTING COMPOSITION AND WIPES WITH REDUCED
Not Available Nov- Nov May
502 CONTACT TIME
13 -14 -15
27- 29- 7-
US20150125 FUSION PROTEINS OF CILIATE GRANULE LATTICE PROTEINS,
Tetragenetics, Inc. May- May May
483 GRANULAR PROTEIN PARTICLES THEREOF, AND USES THEREFOR
11 -12 -15
7- 7- 7-
US20150125
IMMUNOLOGICALLY USEFUL ARGININE SALTS Not Available Mar- Mar May
475
12 -13 -15
15- 10- 7-
US20150125
MODULAR NANODEVICES FOR SMART ADAPTABLE VACCINES Not Available Feb- Nov May
384
07 -14 -15
4- 22- 30-
US20150119
Carbohydrate Conjugates as Delivery Agents for Oligonucleotides Not Available Dec- Jul- Apr-
445
07 14 15
4- 11- 30-
US20150119
Carbohydrate Conjugates as Delivery Agents for Oligonucleotides Not Available Dec- Jul- Apr-
444
07 14 15
29- 2- 16-
US20150104
ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS Baxter Healthcare SA Oct- May Apr-
867
04 -14 15
9- 28- 16-
US20150104
Methods and Compositions for Preventing a Condition Not Available Aug- Aug Apr-
500
10 -14 15
18- 17- 9-
US20150099
CARBOXYLIC ACID COMPOUNDS Not Available May- May Apr-
770
12 -13 15
6- 15- 9-
US20150099 PYRROLO[3,2-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE
Not Available Dec- Sep Apr-
769 IN THERAPY
04 -14 15
4- 3- 9-
US20150099
Multiplex Immuno Screening Assay Not Available May- May Apr-
656
12 -13 15
5- 15- 9-
US20150099
SELECTIVE DETECTION OF HUMAN RHINOVIRUS Not Available Dec- Dec Apr-
263
08 -14 15
9- 10- 9-
US20150099
RESPIRATORY INFECTION ASSAY Not Available Dec- Dec Apr-
261
11 -12 15
Human Respiratory Syncytial Virus Consensus Antigens, Nucleic Acid 10- 10- 19-
US20150079
Constructs And Vaccines Made Therefrom, And Methods Of Using Not Available Apr- Apr Mar
121
Same 12 -13 -15
7- 6- 12-
US20150045 USE OF THE CHROMOSOME 19 MICRORNA CLUSTER (C19MC) FOR
Not Available Mar- Mar Feb
412 TREATING MICROBIAL DISEASE AND PROMOTING AUTHOPHAGY
12 -13 -15
7- 7- 12-
US20150044 INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY
Not Available Mar- Mar Feb
305 DISEASES
12 -13 -15
10- 6- 12-
US20150044 METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE
Not Available Apr- Oct Feb
279 RESPONSE
03 -14 -15
26- 25- 5-
US20150037
METHODS FOR INCREASING THE INFECTIVITY OF VIRUSES Not Available Jan- Jan Feb
288
12 -13 -15
2- 1- 5-
US20150037 VARIANTS OF PROTHYMOSIN ALPHA AND METHODS OF USING
Icahn School of Medicine at Mount Sinai Mar- Mar Feb
281 SAME
12 -13 -15
7- 7- 5-
US20150034 INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY
Advanced Inhalation Therapies (AIT) Ltd. Mar- Mar Feb
084 DISEASES
12 -13 -15
6- 6- 29-
US20150031
SAMPLE PREPARATION METHODS Not Available Sep- Sep Jan-
038
11 -12 15
24- 4- 29-
US20150031 Mixed Cell Diagnostic Systems For Detection Of Respiratory, Herpes
Diagnostic Hybrids Inc. Apr- Aug Jan-
016 and Enteric Viruses
98 -14 15
25- 29-
US20150031 25-
DETECTING ANALYTES WITH A PH METER The Board of Trustees of the University of Illinois Jul- Jan-
014 Jul-13
14 15
17- 8- 29-
US20150030 Trans-complementing, replication deficient lentiviral vectors and
VIRxSYS.CON390 Aug- Oct Jan-
627 methods for making and using them
06 -14 15
9- 9- 29-
US20150030
IMMUNOMODULATORY CONJUGATES Ascend Biopharamaceuticals Ltd Nov- Nov Jan-
626
11 -12 15
20- 9- 29-
US20150030 INFLUENZA HEMAGGLUTININ-SPECIFIC MONOCLONAL ANTIBODIES
Not Available Oct- Oct Jan-
607 FOR PREVENTING AND TREATING INFLUENZA VIRUS INFECTION
10 -14 15
22- 22-
US20150023 VARIANT AAV AND COMPOSITIONS, METHODS AND USES FOR 22-
Not Available Jul- Jan-
924 GENE TRANSFER TO CELLS, ORGANS AND TISSUES Jul-13
14 15
3- 3- 22-
US20150023
HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS BIOTRON LIMITED Aug- Apr Jan-
921
07 -14 15
8- 8- 22-
US20150023
DIAGNOSTIC CHEWING GUM FOR PATHOGENS Julius-Maximilians-Universitaet Wuerzburg Mar- Mar Jan-
879
12 -13 15
25- 30- 22-
US20150021
AMPEROMETRIC GAS SENSOR Not Available Jun- Sep Jan-
204
12 -14 15
25- 30- 22-
US20150021
AMPEROMETRIC GAS SENSOR Not Available Jun- Sep Jan-
203
12 -14 15
26- 15-
US20150018 29-
Nuclear Transport Modulators and Uses Thereof KARYOPHARM THERAPEUTICS INC. Jul- Jan-
332 Jul-11
12 15
6- 18- 15-
US20150017
MICROPARTICLES FOR USE IN IMMUNOGENIC COMPOSITIONS NOVARTIS AG Aug- Jul- Jan-
251
08 14 15
4- 11- 8-
US20150011
Carbohydrate Conjugates as Delivery Agents for Oligonucleotides Not Available Dec- Jul- Jan-
615
07 14 15
1- 28- 8-
US20150011
COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC Sep- Aug Jan-
508
11 -12 15
5- 19- 8-
US20150010 COMPOSITIONS, METHODS AND USES FOR INDUCING VIRAL
Not Available Dec- Sep Jan-
983 GROWTH
08 -14 15
18- 7- 1-
US20150005 METHOD OF TREATING AN ISCHEMIA-REPERFUSION INJURY-
Not Available Sep- Sep Jan-
227 RELATED DISORDER BY ADMINISTERING GPCR LIGANDS
06 -14 15
29- 11-
US20140364 Hydrazide Containing Nuclear Transport Modulators And Uses 29-
KARYOPHARM THERAPEUTICS INC. Jul- Dec
408 Thereof Jul-11
12 -14
5- 7- 11-
US20140364
Method for Preventing and Treating Hyperpermeability Apeptico Forschung UND Entwicklung GMBH Mar- Mar Dec
358
09 -14 -14
4- 4- 11-
US20140363 MYCOBACTERIAL VACCINE VECTORS AND METHODS OF USING THE
Beth Israel Deaconess Medical Center, Inc. Apr- Apr Dec
465 SAME
11 -12 -14
28- 2- 11-
US20140363 METHOD OF PROVIDING MONOCLONAL AUTO-ANTIBODIES WITH
Not Available Dec- Jan Dec
422 DESIRED SPECIFICITY
11 -13 -14
24- 31- 4-
US20140357
Deubiquitinase Inhibitors and Methods for Use of the Same Not Available Sep- Jul- Dec
673
10 14 -14
8- 20- 4-
US20140356 MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF The Government of the United States of America as
Oct- Aug Dec
390 SYNONYMOUS CODONS represented by the Secretary of the Department of
04 -14 -14
30- 12- 27-
US20140349 METHYLSULFONYLMETHANE (MSM) TO MODULATE MICROBIAL
Biogentic Innovations, LLC Oct- Aug Nov
375 ACTIVITY
09 -14 -14
13- 27-
US20140348 IMMUNOSTIMULATORY COMPOSITIONS COMPRISING LIPOSOME- 17-
Not Available Aug Nov
906 ENCAPSULATED OLIGONUCLEOTIDES AND EPITOPES Jul-09
-14 -14
9- 7- 27-
US20140348 MODIFIED ADENOVIRAL VECTORS AND METHODS OF TREATMENT
Beth Israel Deaconess Medical Center, Inc. Sep- Sep Nov
791 USING SAME
11 -12 -14
7- 7- 27-
US20140348
NEUTRALIZING GP41 ANTIBODIES AND THEIR USE Not Available Nov- Nov Nov
785
11 -12 -14
22- 20- 27-
US20140348 CONJUGATES OF GM-CSF AND IL-9, COMPOSITIONS AND METHODS
CHILDREN'S HEALTHCARE OF ATLANTA, INC May- May Nov
781 RELATED THERETO
13 -14 -14
1- 5- 20-
US20140342
METHOD FOR USING PERMUTED NUCLEIC ACID PROBES Ventana Medical Systems, Inc. Sep- Aug Nov
941
06 -14 -14
7- 4- 20-
US20140342 The United States of America, as represented by the
NEUTRALIZING GP41 ANTIBODIES AND THEIR USE Nov- Aug Nov
407 Secretary, Department of Health and Human Serv
11 -14 -14
22- 21- 13-
US20140336
VIRUS VECTORS FOR HIGHLY EFFICIENT TRANSGENE DELIVERY Not Available Nov- Nov Nov
245
11 -12 -14
10- 14- 13-
US20140335
TAL EFFECTOR-MEDIATED DNA MODIFICATION Iowa State University Research Foundation, Inc. Dec- Apr Nov
618
09 -14 -14
10- 24- 13-
US20140335
TAL EFFECTOR-MEDIATED DNA MODIFICATION Iowa State University Research Foundation, Inc. Dec- Feb Nov
592
09 -14 -14
7- 5- 13-
US20140335 Identification and Attenuation of the Immunosuppressive Domains
Not Available Oct- Oct Nov
117 in Fusion Proteins of Enveloped RNA Viruses
11 -12 -14
4- 28- 13-
US20140335 VACCINES AND IMMUNOTHERAPEUTICS USING IL-28 AND
The Trustees of the University of Pennsylvania Apr- Apr Nov
111 COMPOSITIONS AND METHODS OF USING THE SAME
08 -14 -14
13- 14- 13-
US20140335 Methods of Detecting Cells with a Disrupted Cell Membrane, Cells
Not Available May- Apr Nov
104 Infected with A Pathogen, Dying Cells or Dead Cells
08 -14 -14
3- 2- 6-
US20140329
CYCLIC DI-NUCLEOTIDE INDUCTION OF TYPE I INTERFERON Not Available May- May Nov
889
13 -14 -14
3- 1- 6-
US20140329 OLIGONUCLEOTIDE MODULATORS OF THE TOLL-LIKE RECEPTOR
Not Available Mar- Mar Nov
878 PATHWAY
11 -12 -14
24- 24- 6-
US20140329 MYXOVIRUS THERAPEUTICS, COMPOUNDS, AND USES RELATED
CHILDREN'S HEATLHCARE OF ATLANTA, INC. Oct- Oct Nov
817 THERETO
11 -12 -14
13- 21- 6-
US20140328 ANTIMICROBIAL SOLUTIONS CONTAINING DICHLORIDE MONOXIDE
Not Available Mar- Jul- Nov
946 AND METHODS OF MAKING AND USING THE SAME
07 14 -14
19- 19- 6-
US20140328
SAMPLE QUANTIFICATION BY DISC CENTRIFUGATION Not Available Oct- Oct Nov
874
11 -12 -14
9- 7- 23-
US20140314 IPNV-ISAV BIVALENT VACCINE USING A VIRUS-LIKE PARTICLE-
Advanced BioNutrition Corporation Sep- Sep Oct-
858 BASED PLATFORM AND METHODS OF USING THE SAME
11 -12 14
2- 30- 23-
US20140314 CONTROLLED-RELEASE PEPTIDE COMPOSITIONS AND USES
Not Available Dec- Nov Oct-
839 THEREOF
11 -12 14
19- 19- 23-
US20140314
MALARIA ANTIGEN SCREENING METHOD Not Available Apr- Apr Oct-
809
13 -13 14
4- 28- 4-
US20140248 INFLUENZA VACCINES INCLUDING COMBINATIONS OF
NOVARTIS VACCINES AND DIAGNOSTICS SRL Nov- Feb Sep
312 PARTICULATE ADJUVANTS AND IMMUNOPOTENTIATORS
05 -14 -14
25- 1- 14-
US20140227
PD-1 Antagonists and Methods for Treating Infectious Disease AMPLIMMUNE, INC. Aug- Nov Aug
262
08 -13 -14
16- 7- 7-
US20140221
BORON-CONTAINING SMALL MOLECULES Anacor Pharmaceuticals, Inc. Feb- Mar Aug
631
06 -14 -14
12- 7- 7-
US20140221
HYDROBENZAMIDE DERIVATIVES AS INHIBITORS OF HSP90 Astex Therapeutic Ltd. Oct- Jan Aug
394
06 -14 -14
6- 28- 7-
US20140221 SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE
BOEHRINGER INGELHEIM INTERNATIONAL GMBH Feb- Jan Aug
335 AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
13 -14 -14
11- 28- 7-
US20140220
MAMMALIAN GENES INVOLVED IN INFECTION VANDERBILT UNIVERSITY Nov- Oct Aug
690
09 -10 -14
19- 7-
US20140220 EMBODIMENTS OF A PROBE AND METHOD FOR TARGETING 19-
University Of Idaho Jul- Aug
573 NUCLEIC ACIDS Jul-11
12 -14
21- 21- 7-
US20140220
Antimicrobial Compositions and Methods of Use Thereof Not Available Sep- Sep Aug
086
11 -12 -14
6- 7-
US20140220 6-Jul-
CATIONIC OIL-IN-WATER EMULSIONS Not Available Jul- Aug
083 11
12 -14
5- 29- 7-
US20140220
VACCINE COMPOSITION Not Available Feb- Jan Aug
063
13 -14 -14
6- 31-
US20140212 6-Jul-
OIL-IN-WATER EMULSIONS THAT CONTAIN NUCLEIC ACIDS Not Available Jul- Jul-
498 11
12 14
7- 16- 31-
US20140212
BINDING MEMBERS-513 MEDIMMUNE LIMITED Nov- Apr Jul-
429
08 -14 14
1- 31- 24-
US20140206
COMPOUNDS AND COMPOSITIONS AS PDGFR KINASE INHIBITORS IRM LLC Sep- Aug Jul-
682
11 -12 14
6- 19- 24-
US20140206 Systems and Methods for Identifying Replikin Scaffolds and Uses of
Not Available Jun- Jun Jul-
556 Said Replikin Scaffolds
03 -13 14
18- 28- 24-
US20140205
TC-83-DERIVED ALPHAVIRUS VECTORS, PARTICLES AND METHODS AlphaVax, Inc. May- Mar Jul-
629
04 -14 14
SYSTEMS AND METHODS FOR DISTINGUISHING OPTICAL SIGNALS 24- 21- 24-
US20140203
OF DIFFERENT MODULATION FREQUENCIES IN AN OPTICAL SIGNAL Gen-Probe Incorporated Feb- Mar Jul-
192
DETECTOR 11 -14 14
SYSTEMS AND METHODS FOR DISTINGUISHING OPTICAL SIGNALS 24- 21- 24-
US20140203
OF DIFFERENT MODULATION FREQUENCIES IN AN OPTICAL SIGNAL GEN-PROBE INCORPORATED Feb- Mar Jul-
189
DETECTOR 11 -14 14
6- 6- 17-
US20140200 Methods and compositions for identification of source of microbial
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Mar- Mar Jul-
149 contamination in a sample
12 -13 14
23- 17-
US20140199 COMPOSITIONS HAVING MEANS FOR TARGETING AT LEAST ONE 22-
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS Jul- Jul-
379 ANTIGEN TO DENDRITIC CELLS Jul-11
12 14
28- 6- 3-
US20140186 METHODS FOR STABILIZING INFLUENZA ANTIGEN ENVELOPED
TAKEDA VACCINES, INC. Dec- Mar Jul-
396 VIRUS-BASED VIRUS-LIKE PARTICLE SOLUTIONS
09 -14 14
10- 3-
US20140186 DEFECTIVE RIBOSOMAL PRODUCTS IN BLEBS (DRIBBLES) AND 29-
Providence Health & Services - Oregon Feb Jul-
292 METHODS OF USE TO STIMULATE AN IMMUNE RESPONSE Jul-05
-14 14
4- 22- 26-
US20140179
TARGETING LIPIDS Tekmira Pharmaceuticals Corporation Dec- Oct Jun-
761
08 -13 14
14- 11- 26-
US20140179
NOVEL COMPOUNDS Chiesi Farmaceutici S.p.A. Sep- Feb Jun-
714
11 -14 14
10- 3- 26-
US20140178 SYSTEMS AND METHODS FOR DETECTING MULTIPLE OPTICAL
Gen-Probe Incorporated Mar- Mar Jun-
977 SIGNALS
05 -14 14
6- 24- 26-
US20140178
Vaccines Including Antigen From Four Strains of Influenza Virus NOVARTIS AG Dec- Sep Jun-
429
06 -13 14
8- 27- 26-
US20140178 QUALITY CONTROL METHODS FOR OIL-IN-WATER EMULSIONS
Novartis AG Nov- Aug Jun-
428 CONTAINING SQUALENE
06 -13 14
21- 15- 26-
US20140178
PRIMARY MESENCHYMAL STEM CELLS AS A VACCINE PLATFORM The Administrators of the Tulane Educational Fund Dec- Nov Jun-
422
12 -13 14
17- 13- 19-
US20140171 CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL
Parion Sciences, Inc. Dec- Dec Jun-
447 SODIUM CHANNEL BLOCKING ACTIVITY
12 -13 14
18- 17- 19-
US20140171
NOVEL COMPOUNDS CHIESI FARMACEUTICI S.p.A. Dec- Dec Jun-
414
12 -13 14
20- 31- 19-
US20140170
VECTOR FOR GENE THERAPY TAKARA BIO INC. Apr- Jan Jun-
709
07 -14 14
16- 12-
US20140161 Compositions and Imaging Methods Comprising Detectably Labeled 15-
Board of Regents, The University of Texas System Dec Jun-
724 Phosphatidylethanolamine-Binding Peptides Jul-02
-13 14
5- 28- 5-
US20140155
NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Not Available Mar- Jun Jun-
370
10 -13 14
13- 1- 5-
US20140154 PAPAYA MOSAIC VIRUS COMPOSITIONS AND USES THEREOF FOR
FOLIA BIOTECH INC. May- May Jun-
288 STIMULATION OF THE INNATE IMMUNE RESPONSE
11 -12 14
26- 26- 5-
US20140154 CONJUGATES UTILIZING PLATFORM TECHNOLOGY FOR
Not Available Jan- Jan Jun-
282 STIMULATING IMMUNE RESPONSE
11 -12 14
21- 21- 5-
US20140154
HETERODIMERIC IMMUNOGLOBULINS AMGEN INC. Nov- Nov Jun-
254
12 -13 14
18- 18- 29-
US20140148
CIRCULATING BIOMARKERS FOR DISEASE Not Available Aug- Aug May
350
10 -11 -14
25- 1-
US20140120 METHODS FOR INDUCING AN IMMUNE RESPONSE VIA BUCCAL 26-
Board of Regents, The University of Texas System Jan May
139 AND/OR SUBLINGUAL ADMINISTRATION OF A VACCINE Jul-10
-13 -14
3- 28- 1-
US20140116 ELECTROCHEMISTRY AND ELECTROGENERATED
Board of Regents of the University of Texas System Jun- Oct May
887 CHEMILUMINESCENCE WITH A SINGLE FARADAIC ELECTRODE
05 -13 -14
13- 13- 3-
US20140094 METHODS AND REAGENTS FOR EFFICIENT AND TARGETED
Not Available Jan- Jan Apr-
404 DELIVERY OF THERAPEUTIC MOLECULES TO CXCR4 CELLS
11 -12 14
22- 22- 3-
US20140093 Immunogenic Compositions In Particulate Form And Methods For
MUCOSIS B.V. Mar- Mar Apr-
532 Producing The Same
11 -12 14
4- 26- 27-
US20140087 QUANTITATIVE NUCLEASE PROTECTION ASSAY (QNPA) AND
HTG Molecular Diagnostics, Inc. May- Apr Mar
954 SEQUENCING (QNPS) IMPROVEMENTS
11 -12 -14
8- 26- 27-
US20140086
Antigenic GM-CSF Peptides and Antibodies to GM-CSF MORPHOTEK, INC. Feb- Nov Mar
928
06 -13 -14
11- 12- 20-
US20140082 MOLECULES AND METHODS FOR INHIBITION AND DETECTION OF
Not Available Mar- Mar Mar
769 PROTEINS
11 -12 -14
31- 28- 20-
US20140080
IMIDAZOLYL AMIDE COMPOUNDS AND USES RELATED THERETO CHILDREN'S HEATLHCARE OF ATLANTA, INC. Mar- Mar Mar
828
11 -12 -14
6- 25- 20-
US20140080
OPTICAL CYTOMETRY The Regents of the University of California May- Nov Mar
171
09 -13 -14
21- 20- 20-
US20140080
PRIMATE T-LYMPHOTROPIC VIRUSES Johns Hopkins University Feb- Sep Mar
121
05 -13 -14
5- 23- 20-
US20140079
TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE Infinity Pharmaceuticals, Inc. May- Aug Mar
667
10 -13 -14
12- 13-
US20140073 MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS 26-
Not Available Mar Mar
683 OF USE Jul-02
-13 -14
22- 21- 13-
US20140073
BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. Feb- Feb Mar
651
11 -12 -14
15- 28- 13-
US20140072
COMPOSITION, DEVICE AND ASSOCIATED METHOD General Electric Company Dec- Feb Mar
956
05 -07 -14
1- 13- 13-
US20140072 RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING
MedImmune Limited Jun- Sep Mar
575 THEM
07 -13 -14
26- 11- 6-
US20140066 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
City of Hope Jan- Oct Mar
592 OR OTHER DISEASES
07 -13 -14
23- 20- 27-
US20140057 SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF
BOEHRINGER INGELHEIM INTERNATIONAL GMBH Aug- Aug Feb
926 NEUTROPHIL ELASTASE ACTIVITY
12 -13 -14
23- 20- 27-
US20140057 SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF
BOEHRINGER INGELHEIM INTERNATIONAL GMBH Aug- Aug Feb
920 NEUTROPHIL ELASTASE ACTIVITY
12 -13 -14
23- 20- 27-
US20140057 SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF
BOEHRINGER INGELHEIM INTERNATIONAL GMBH Aug- Aug Feb
916 NEUTROPHIL ELASTASE ACTIVITY
12 -13 -14
8- 11- 27-
US20140057 University of Pittsburgh - Of the Commonwealth System of
ANTIGEN PRESENTING CELL ASSAY Apr- Oct Feb
315 Higher Education
10 -13 -14
23- 23- 27-
US20140056 IMMUNOMODULATION BY CONTROLLING INTERFERON-GAMMA The Board of Trustees of the Leland Stanford Junior
Aug- Aug Feb
929 LEVELS WITH THE LONG NON-CODING RNA NeST University
12 -13 -14
22- 15- 20-
US20140051 Cells and Methodology to Generate Non-Segmented Negative-
Centre National De La Recherche Scientifique Dec- Oct Feb
148 Strand RNA Viruses
06 -13 -14
28- 28- 20-
US20140050 NUCLEIC ACID BINDING COMPOUNDS, METHODS OF MAKING, AND
UNIVERSITY OF ROCHESTER Dec- Dec Feb
778 USE THEREOF
10 -11 -14
24- 13- 6-
US20140038
HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS AstraZeneca AB Dec- Sep Feb
978
04 -13 -14
26- 8- 6-
US20140038 Compositions and Methods for Detecting and Identifying Nucleic
LONGHORN VACCINES AND DIAGNOSTICS, LLC Apr- Oct Feb
174 Acid Sequences in Biological Samples
11 -13 -14
31- 6-
US20140038 APPARATUS, SYSTEMS, AND METHODS FOR PERFORMING THERMAL 31-
Not Available Jul- Feb
170 MELT ANALYSES AND AMPLIFICATIONS Jul-12
13 -14
20- 19- 6-
US20140037
Composition and Method for Enhancing an Immune Response MICO BIO, INC. Apr- Apr Feb
700
11 -12 -14
20- 20- 30-
US20140031 Regimens and Compositions for AAV-Mediated Passive
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Apr- Apr Jan-
418 Immunization of Airborne Pathogens
11 -12 14
26- 1- 30-
US20140031
POLY AROMATIC SODIUM CHANNEL BLOCKERS PARION SCIENCES, Inc. Feb- Oct Jan-
371
08 -13 14
1- 19- 30-
US20140031
COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC Sep- Sep Jan-
333
11 -13 14
2- 19- 30-
US20140031 COMPOUNDS AND METHODS FOR PREVENTING OR TREATING A CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Nov- Jun Jan-
276 VIRAL INFECTION (C.N.R.S.)
07 -13 14
7- 2- 30-
US20140030
Rapid Bioluminescence Detection System The Secretary of State for Health Jan- Aug Jan-
740
09 -13 14
11- 12- 30-
US20140030 MUTANT PROTEASE BIOSENSORS WITH ENHANCED DETECTION
PROMEGA CORPORATION May- Nov Jan-
725 CHARACTERISTICS
10 -12 14
12- 8- 30-
US20140030 Compositions and Methods for Detecting and Identifying Nucleic
LONGHORN VACCINES AND DIAGNOSTICS, LLC Sep- Oct Jan-
703 Acid Sequences in Biological Samples
06 -13 14
28- 30-
US20140030 ANTIVIRAL COMPOSITIONS COMPRISING ETHANOL EXTRACT OF 24-
Not Available Mar Jan-
364 TETRACERA SCANDENS AND USE THEREOF Jul-12
-13 14
7- 17- 30-
US20140030 Use of Sirt1 Activators or Inhibitors to Modulate an Immune
THE J. DAVID GLADSTONE INSTITUTES Feb- Dec Jan-
295 Response
08 -12 14
20- 24- 23-
US20140024
Crystalline Tripeptide Epoxy Ketone Protease Inhibitors Onyx Therapeutics, Inc. Mar- Sep Jan-
804
09 -13 14
5- 15- 23-
US20140024
ORGANIC COMPOUNDS Not Available Jun- Jul- Jan-
583
06 13 14
31- 1- 23-
US20140023 The United States of America, as represented by the
ENGINEERED ANTIBODY CONSTANT DOMAIN MOLECULES Jan- Oct Jan-
645 Secretary, Dept. of Health & Human Services
08 -13 14
30- 23-
US20140023 Fraunhofer-Gesellschaft zur Forderung der Angewandten 25-
SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS Sep Jan-
592 Forschung e.V. Jul-07
-13 14
12- 7- 16-
US20140017 Cna-B DOMAIN ANTIGENS IN VACCINES AGAINST GRAM POSITIVE
Not Available Jan- Jun Jan-
727 BACTERIA
09 -13 14
24- 23- 16-
US20140017
ADJUVANT NANOEMULSIONS WITH PHOSPHOLIPIDS NOVARTIS AG Mar- Mar Jan-
285
11 -12 14
27- 27- 16-
US20140017
ADJUVANT NANOEMULSIONS WITH CRYSTALLISATION INHIBITORS Novartis AG Jan- Jan Jan-
279
11 -12 14
6- 12- 9-
US20140011
Antibodies Against Influenza Virus and Methods of Use Thereof BURNHAM INSTITUTE FOR MEDICAL RESEARCH Dec- Aug Jan-
982
07 -13 14
8- 7- 9-
US20140011
Methods of Treating Inflammation Massachusetts Institute of Technology Oct- Oct Jan-
812
10 -11 14
18- 9- 9-
US20140011 SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND
3M INNOVATIVE PROPERTIES COMPANY Jun- Sep Jan-
777 IMIDAZONAPHTHYRIDINES
04 -13 14
24- 24- 2-
US20140004 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING
Not Available Apr- Apr Jan-
193 PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME
12 -13 14
17- 19- 2-
US20140004 METHOD FOR PRODUCING VIRUS-LIKE PARTICLE BY USING INSTITUT PASTEUR OF SHANGHAI, CHINESE ACADEMY OF
Mar- Mar Jan-
146 DROSOPHILA CELL AND APPLICATIONS THEREOF SCIENCES
11 -12 14
17- 13- 2-
US20140004 ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES,
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Dec- Sep Jan-
143 VECTORS CONTAINING SAME, AND USES THEREFOR
01 -13 14
20- 20- 2-
US20140004
ANTI-IL-18 ANTIBODIES AND THEIR USES Medimmune Limited Dec- Dec Jan-
128
10 -11 14
26- 25- 2-
US20140004 MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION
Institute For Research in Biomedicine Feb- Apr Jan-
123 OF B CELLS
03 -13 14
20- 26- 26-
US20130345
TREATING CANCER WITH VIRAL NUCLEIC ACID Not Available Feb- Jul- Dec
414
07 13 -13
29- 26-
US20130345 siRNA Compositions and Methods for Treatment of HPV and Other 29-
Not Available Jan Dec
284 Infections Jul-10
-13 -13
12- 7- 26-
US20130345
METHODS OF TREATING CANCER AND OTHER DISORDERS Waake Forest University Health Sciences Nov- Nov Dec
270
10 -11 -13
14- 7- 26-
US20130344 USE OF A FLUORESCENT MATERIAL TO DETECT FAILURE OR
GEN-PROBE INCORPORATED Jun- Jun Dec
613 DETERIORATED PERFORMANCE OF A FLUOROMETER
12 -13 -13
22- 22- 26-
US20130344
VIRUS LIKE PARTICLE PRODUCTION IN PLANTS MEDICAGO INC. Dec- Dec Dec
100
10 -11 -13
25- 26- 26-
US20130341
AMPEROMETRIC GAS SENSOR STERIS CORPORATION Jun- Feb Dec
206
12 -13 -13
5- 15- 7-
US20130295 IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE
MASSACHUSETTS INSTITUTE OF TECHNOLOGY Apr- Mar Nov
129 THEREOF
12 -13 -13
24- 22- 31-
US20130291
HUMANIZED TRANSGENIC MOUSE MODEL BRUMEANU TEPDPR D Sep- Aug Oct-
134
10 -12 13
15- 27- 31-
US20130289 (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-
AstraZeneca AB Dec- Jun Oct-
043 CARBOXAMIDE DERIVATIVES
08 -13 13
2- 11- 31-
US20130288 ARRAYED DETECTOR SYSTEM FOR MEASUREMENT OF INFLUENZA
UNIV ROCHESTER May- Jul- Oct-
922 IMMUNE RESPONSE
08 13 13
Rapid High Resolution, High Throughput RNA Structure, RNA- 21- 21- 31-
US20130288 The Board of Trustees of the Leland Stanford Junior
Macromolecular Interaction, and RNA-Small Molecule Interaction Oct- Oct Oct-
917 University
Mapping 10 -11 13
4- 3- 10-
US20130266
VACCINE COMPOSITION NITTO DENKO CORPORATION Apr- Apr Oct-
612
12 -13 13
11- 10- 3-
US20130261 Nucleic Acids For Multiplex Organism Detection and Methods Of Use
DIAMOND LISA Jun- Jun Oct-
196 And Making The Same
10 -11 13
6- 2- 3-
US20130261 ALPHABODIES SPECIFICALLY BINDING TO CLASS-I VIRAL FUSION
COMPLIX SA Jan- Dec Oct-
049 PROTEINS AND METHODS FOR PRODUCING THE SAME
11 -11 13
7- 4- 3-
US20130259
REOVIRUS VACCINES AND METHODS OF USE THEREFOR BOEHME KARL W Apr- Apr Oct-
887
10 -11 13
14- 14- 3-
US20130259 Human Monoclonal Antibody with Specificity for Dengue Virus
DSO NATIONAL LABORATORIES Dec- Dec Oct-
871 Serotype 1 E Protein and Uses Thereof
10 -11 13
6- 3-
US20130259 CLIP INHIBITORS AND METHODS OF MODULATING IMMUNE 25-
Viral Genetics, Inc. Jun Oct-
829 FUNCTION Jul-08
-13 13
3- 22- 26-
US20130253
COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS CORTEZ ALEX Mar- Apr Sep
002
08 -13 -13
1- 20- 26-
US20130251
Methods and Compositions for Poxvirus A35R Protein East Carolina University Dec- Dec Sep
746
08 -12 -13
9- 8- 26-
US20130251
USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIALS The Salk Institute for Biological Studies Nov- Mar Sep
734
07 -13 -13
Peracid/Peroxide Composition, Process for Accurately Making the 11- 21- 26-
US20130251
Same, and Method for Use as an Evaporating Film Anti-Microbial BioMed Protect ,LLC Jan- Sep Sep
590
Solution and as a Photosensitizer 05 -09 -13
3- 3- 12-
US20130236 NANOPARTICLES PRODUCED FROM RECOMBINANT POLYMERS AND
UNIVERSITY OF UTAH RESEARCH FOUNDATION May- May Sep
396 METHODS OF MAKING AND USING THE SAME
10 -11 -13
10- 9- 5-
US20130231
ANTIMICROBIAL SOLUTIONS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Sep- Sep Sep
302
10 -11 -13
29- 16- 5-
US20130230
ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS Baxter Healthcare S.A. Oct- Apr Sep
919
04 -13 -13
27- 27- 5-
US20130230 CAPTURE OF TARGET DNA AND RNA BY PROBES COMPRISING
QUANTIBACT A/S Oct- Oct Sep
856 INTERCALATOR MOLECULES
10 -11 -13
6- 6- 15-
US20130209
RECOMBINANT RNA VIRUSES AND USES THEREOF TENOEVER BENJAMIN R Jun- Jun Aug
406
10 -11 -13
28- 15-
US20130209 28-
Anti-Viral Azide Containing Compounds LIFE TECHNOLOGIES CORPORATION Jul- Aug
364 Jul-10
11 -13
1- 31- 8-
US20130203
2' AND 5' MODIFIED MONOMERS AND OLIGONUCLEOTIDES ALNYLAM PHARMACEUTICALS, INC. Apr- Mar Aug
836
10 -11 -13
12- 9- 8-
US20130203
METHODS FOR PREVENTING OR TREATING VIRAL INFECTION KIELIAN MARGARET Feb- Feb Aug
655
10 -11 -13
26- 26- 8-
US20130203 PRODUCTION OF ALPHAVIRUS REPLICON PARTICLES IN
BALSITIS SCOTT Apr- Apr Aug
151 PACKAGING CELLS
10 -11 -13
31- 31- 8-
US20130202 PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN ENCODING
Lichtstrasse Aug- Aug Aug
684 RNA
10 -11 -13
12- 14- 8-
US20130202
GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIES GRANDI GUIDO Sep- Mar Aug
609
07 -13 -13
27- 1-
US20130195 USE OF A PNEUMOCOCCAL P4 PEPTIDE FOR ENHANCING The Government of the United States of America as 31-
Mar Aug
893 OPSONOPHAGOCYTOSIS IN RESPONSE TO A PATHOGEN represented by the Secretary of the department of Jul-08
-13 -13
1- 1- 1-
US20130195
METHOD OF TREATING INFLAMMATION CYTOSORBENTS CORPORATION Apr- Apr Aug
792
10 -11 -13
31- 8- 25-
US20130190
PURINE ANALOGS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA May- Mar Jul-
494
06 -13 13
18- 18- 25-
US20130190 INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID
THE TRUSTEES OF PRINCETON UNIVERSITY Feb- Feb Jul-
381 METABOLISM AS BROAD SPECTRUM ANTI-VIRALS
10 -11 13
13- 25-
US20130190 13-
Direct Clone Analysis and Selection Technology Dublin City University Jul- Jul-
206 Jul-10
11 13
23- 18- 25-
US20130189
POLYMER STABILIZATION OF CHROMOGEN SOLUTIONS VENTANA MEDICAL SYSTEMS, INC. Jan- Jan Jul-
680
12 -13 13
31- 31- 25-
US20130189 LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN CODING
NOVARTIS AG Aug- Aug Jul-
351 RNA
10 -11 13
3- 3- 25-
US20130189 ARRANGING INTERACTION AND BACK PRESSURE CHAMBERS FOR
Novartis AG Dec- Dec Jul-
311 MICROFLUIDIZATION
09 -10 13
12- 11- 25-
US20130189
Multimeric Proteins Comprising Immunoglobulin Constant Domains RESEARCH CORPORATION TECHNOLOGIES, INC. Feb- Feb Jul-
247
10 -11 13
5- 4- 18-
US20130184 OLIGONUCLEOTIDE AMPLIFICATION PRIMERS FOR TARGETING
GENERA BIOSYSTEMS LIMITED Apr- Jun Jul-
170 ONCOGENIC HPV
07 -12 13
1- 11- 18-
US20130183
METHOD FOR PRODUCING NUCLEIC ACID PROBES Ventana Medical Systems, Inc. Sep- Mar Jul-
670
06 -13 13
7- 18-
US20130183 DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE 6-Jul-
NOVARTIS AG Jun Jul-
355 POLYMER PARTICLES 10
-11 13
4- 18-
US20130183 INFLUENZA VIRUS-LIKE PARTICLES (VLPS) COMPRISING 13-
MEDICAGO INC. Jan Jul-
341 HEMAGGLUTININ PRODUCED WITHIN A PLANT Jul-07
-13 13
25- 1- 18-
US20130183
GITR BINDING MOLECULES AND USES THEREFOR GITR, INC. Mar- Mar Jul-
321
05 -13 13
4- 4- 11-
US20130178 CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR
ALNYLAM PHARMACEUTICALS, INC Dec- Dec Jul-
512 OLIGONUCLEOTIDES
07 -12 13
11- 9- 11-
US20130178
Treatment of Microbial Infections BIOCOPEA LIMITED Nov- Nov Jul-
466
09 -10 13
5- 4- 11-
US20130178
Treatment of Respiratory Disorders BANNISTER ROBIN MARK Feb- Feb Jul-
448
10 -11 13
19- 14- 4-
US20130172 SUBSTITUTED N- [1-CYANO-2- (PHENYL) ETHYL] -2-AZABICYCLO
BOEHRINGER INGELHEIM INTERNATIONAL GMBH Sep- Sep Jul-
327 [2.2.1] HEPTANE-3-CARBOXAMIDE INHIBITORS OF CATHEPSIN C
11 -12 13
6- 4-
US20130171 LIPOSOMES WITH LIPIDS HAVING AN ADVANTAGEOUS PKA-VALUE 6-Jul-
NOVARTIS AG Jul- Jul-
241 FOR RNA DELIVERY 10
11 13
23- 23- 4-
US20130171 CONSTRAINED IMMUNOGENIC COMPOSITIONS AND USES
COULIBALY FASSELI JOSEPH Jun- Jun Jul-
129 THEREFOR
10 -11 13
22- 20- 27-
US20130165
TLR AGONISTS The Regents of The University of California Aug- Nov Jun-
455
05 -12 13
23- 23- 27-
US20130165 METHODS AND COMPOSITIONS FOR TREATING ACE2-RELATED
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION Apr- Apr Jun-
417 DISORDERS
10 -11 13
2- 1- 20-
US20130157
Blockade Of Inflammatory Proteases With Cyclic Peptides THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Jun- Jun Jun-
964
11 -12 13
21- 21- 20-
US20130157
Systems and Methods for Detecting Antibiotic Resistance TESSARAE, LLC Aug- Feb Jun-
876
10 -13 13
19- 19- 20-
US20130157
RAPID PATHOGEN DIAGNOSTIC DEVICE AND METHOD PRESIDENT AND FELLOWS OF HARVARD COLLEGE Jan- Jan Jun-
283
10 -11 13
16- 16- 20-
US20130157 Method and apparatus for two-step surface-enhanced raman
Real-Time Analyzers, Inc. Dec- Dec Jun-
254 spectroscopy
11 -11 13
7- 8- 20-
US20130156
CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR The Regents of The University of California Feb- Jan Jun-
807
07 -13 13
6- 13-
US20130149 6-Jul-
IMMUNISATION OF LARGE MAMMALS WITH LOW DOSES OF RNA GEALL ANDREW Jul- Jun-
375 10
11 13
6- 6- 13-
US20130149 ORGANIC PEROXIDE COMPOUNDS FOR MICROORGANISM
GREGERSEN JENS PETER May- May Jun-
194 INACTIVATION
10 -11 13
27- 25- 6-
US20130145
ANTIBODY PRODUCING NON-HUMAN MAMMALS MERUS B.V. Jun- Jan Jun-
484
08 -13 13
25- 26- 6-
US20130143 Virally-Inactivated Growth Factors-Containing Platelet Lysate
BURNOUF THIERRY May- Nov Jun-
810 Depleted of PDGF and VEGF and Preparation Method Thereof
10 -12 13
3- 21- 6-
US20130143 COMPOSITIONS FOR USE IN IDENTIFICATION OF ADVENTITIOUS
IBIS BIOSCIENCES, INC. Mar- May Jun-
203 VIRUSES
05 -12 13
3- 3- 6-
US20130142 CIRCULATION OF COMPONENTS DURING HOMOGENIZATION OF
Novartis AG Dec- Dec Jun-
833 EMULSIONS
09 -10 13
21- 23- 6-
US20130142 RECOMBINANT INFLUENZA VIRUS-LIKE PARTICLES (VLPS)
MEDICAGO, INC. Jan- Jan Jun-
826 PRODUCED IN TRANSGENIC PLANTS EXPRESSING HEMAGGLUTININ
08 -13 13
4- 14- 6-
US20130142
Mutations in OAS1 Genes KINETA TWO, LLC May- Nov Jun-
773
05 -12 13
28- 31- 30-
US20130137
Antiviral Compounds and Uses Thereof MOUNT SINAI SCHOOL OF MEDICINE May- May May
678
10 -11 -13
15- 28- 30-
US20130137
HIGH DENSITY SELF-CONTAINED BIOLOGICAL ANALYSIS BioFire Diagnostics, Inc. f/k/a Idaho Technology, Inc. May- Jan May
172
09 -13 -13
17- 15- 30-
US20130137 INCREASED PROTEIN EXPRESSION THROUGH INCREASED
UNIVERSITEIT GENT Jun- Jun May
140 MEMBRANE FORMATION
10 -11 -13
14- 14- 30-
US20130136
Recombinant HCMV and RHCMV vectors and uses thereof Oregon Health & Science University May- Nov May
768
10 -12 -13
29- 28- 23-
US20130130
SAMPLE-TO-ANSWER MICROFLUIDIC CARTRIDGE BATTRELL C FREDERICK Jan- Jan May
262
10 -11 -13
3- 3- 23-
US20130129 HYDROPHILIC FILTRATION DURING MANUFACTURE OF VACCINE
Novartis AG Dec- Dec May
786 ADJUVANTS
09 -10 -13
9- 11- 23-
US20130129 DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH
NOVARTIS AG Sep- Jan May
782 INFLUENZA VACCINES
04 -13 -13
15- 15- 23-
US20130129
METHODS AND COMPOSITIONS FOR INTRANASAL DELIVERY HARUTA SHUNJI Apr- Apr May
781
10 -11 -13
30- 17- 23-
US20130129 MATERIALS AND METHODS FOR PREVENTION AND TREATMENT OF
UNIVERSITY OF SOUTH FLORIDA Apr- Sep May
702 RNA VIRAL DISEASES
02 -12 -13
10- 10- 16-
US20130122
TAL EFFECTOR-MEDIATED DNA MODIFICATION IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. Dec- Jan May
581
09 -13 -13
1- 16-
US20130122 DETECTING TARGETS USING MASS TAGS AND MASS 2-Jul-
BIENIARZ CHRISTOPHER Jul- May
516 SPECTROMETRY 10
11 -13
9- 10- 16-
US20130122 DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH
Novartis AG Sep- Jan May
487 INFLUENZA VACCINES
04 -13 -13
20- 20- 16-
US20130122
MODIFIED POLYPEPTIDES AND PROTEINS AND USES THEREOF WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH Apr- Apr May
043
10 -11 -13
14- 13- 16-
US20130122 HETEROLOGOUS PRIME-BOOST IMMUNIZATION USING MEASLES
Crucell Holland B.V. Nov- Nov May
038 VIRUS-BASED VACCINES
11 -12 -13
27- 16-
US20130122 HMGB1-DERIVED PEPTIDES ENHANCE IMMUNE RESPONSE TO 27-
MESSMER DAVORKA Jul- May
031 ANTIGENS Jul-10
11 -13
16- 12- 9-
US20130115 SUBSTRATES FOR CHROMOGENIC DETECTION AND METHODS OF
Ventana Medical Systems, Inc. Aug- Aug May
593 USE IN DETECTION ASSAYS AND KITS
10 -11 -13
13- 1- 9-
US20130115 Immunogenic Substances Comprising a Polyinosinic Acid -
Yisheng Biopharma (Singapore) PTE. LTD. Jan- Oct May
244 Polycytidilic Acid Based Adjuvant
06 -12 -13
30- 22- 9-
US20130115
IMMUNOSTIMULATORY COMBINATIONS TRUSTEES OF DARTMOUTH COLLEGE Dec- Oct May
228
02 -12 -13
14- 9-
US20130115 14-
DOMAIN INSERTION IMMUNOGLOBULIN ZHOU HONGXING Jul- May
215 Jul-10
11 -13
6- 18-
US20130095 PROCESS FOR REMOVING ADVENTITIOUS AGENTS DURING THE 8-Jul-
GlaxoSmithKline Biologicals S.A. Jul- Apr-
135 PRODUCTION OF A VIRUS IN CELL CULTURE 10
11 13
7- 19- 4-
US20130084 PEPTIDES SHARED AMONG LETHAL CANCERS AND THERAPEUTIC
BOGOCH ELENORE S Aug- Jul- Apr-
303 COMPOSITIONS COMPRISING SAID PEPTIDES
09 12 13
22- 17-
US20110067 Transgenic mice having a human major histocompatibility complex 30-
INSTITUT PASTEUR Dec Mar
121 (MHC) phenotype, experimental uses and applications Jul-03
-09 -11
27- 27- 3-
US20110052
Adjuvant Comprising Aluminum, Oligonucleotide and Polycation O'HAGAN DEREK Aug- Aug Mar
716
09 -10 -11
30- 15- 3-
US20110052 MATERIALS AND METHODS FOR PREVENTION AND TREATMENT OF
UNIVERSITY OF SOUTH FLORIDA Apr- Dec Mar
558 RNA VIRAL DISEASES
02 -09 -11
12- 12- 24-
US20110046
HYDROBENZAMIDE DERIVATIVES AS INHIBITORS OF HSP90 FREDERICKSON MARTYN Oct- Oct Feb
155
06 -07 -11
21- 29- 24-
US20110046 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-
BISCHOFF ALEXANDER Jun- Oct Feb
134 CoA DESATURASE
07 -10 -11
20- 20- 24-
US20110046
Multiplex Assay for Respiratory Viruses AUTOGENOMICS, INC. Nov- Nov Feb
001
07 -08 -11
14- 12- 24-
US20110045 COMPOSITIONS FOR USE IN IDENTIFICATION OF ADVENTITIOUS
IBIS BIOSCIENCES, INC. Jun- Jun Feb
456 CONTAMINANT VIRUSES
07 -08 -11
6- 6- 16-
US20100319 MULTI-TARGETED RNAI THERAPEUTICS FOR SCARLESS WOUND
SIR NAOMICS, INC. Nov- Nov Dec
074 HEALING OF SKIN
07 -08 -10
1- 28- 16-
US20100317
Casein Derived Peptides And Uses Thereof SIDELMAN ZVI Mar- Jul- Dec
601
00 10 -10
29- 29- 16-
US20100317
PORCINE DC-SIGN, ICAM-3 AND LSECtin AND USES THEREOF VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. Oct- Oct Dec
054
07 -08 -10
21- 1- 16-
US20100317
PRIMATE T-LYMPHOTROPIC VIRUSES and Johns Hopkins University Feb- Jul- Dec
034
05 10 -10
14- 11- 16-
US20100316 CONDENSATION PRODUCTS BASED ON BICYCLIC OR POLYCYCLIC
BASF SE Nov- Nov Dec
695 AROMATICS OR HETEROAROMATICS
07 -08 -10
31- 30- 16-
US20100316
ENGINEERED ANTIBODY CONSTANT DOMAIN MOLECULES DIMITROV DIMITER S Jan- Jan Dec
641
08 -09 -10
21- 12- 9-
US20100310 RECOMBINANT INFLUENZA VIRUS-LIKE PARTICLES (VLPS)
MEDICAGO INC. Jan- Jan Dec
604 PRODUCED IN TRANSGENIC PLANTS EXPRESSING HEMAGGLUTININ
08 -09 -10
20- 19- 9-
US20100310 SYSTEM FOR DELIVERY INTO XCR1 POSITIVE CELL AND USES Bundesrepublik Deutschland letztvertreten durch das
Nov- Nov Dec
562 THEREOF Robert Koch-Institut vertreten durch seinen
07 -08 -10
15- 2-
US20100305 29-
PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. Jun Dec
138 Jul-03
-10 -10
27- 26- 2-
US20100304 PEPTIDE COMPOUNDS FOR DETECTING OR INHIBITING SARS ELECTRONICS AND TELECOMMUNICATIONS RESEARCH
May- May Dec
363 CORONAVIRUS AND APPLICATION THEREOF INSTITUTE
09 -10 -10
28- 2-
US20100304 METHOD AND DEVICE FOR MONITORING A THERAPEUTIC 26-
DAS DEVELOPMENT PARTNERS Jul- Dec
361 TREATMENT REGIME Jul-07
08 -10
16- 11- 2-
US20100303
HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) GENMAB A/S Dec- Nov Dec
823
02 -09 -10
7- 7- 25-
US20100298 METHODS FOR THE DIRECTED EXPANSION OF EPITOPES FOR USE
BONNIN DUSTAN May- May Nov
547 AS ANTIBODY LIGANDS
07 -08 -10
21- 20- 25-
US20100298
SALTS 756 AstraZeneca AB May- May Nov
364
09 -10 -10
2- 31- 25-
US20100298
COMPOUNDS FOR PREVENTING OR TREATING A VIRAL INFECTION ESTAQUIER JEROME Nov- Oct Nov
209
07 -08 -10
21- 21- 25-
US20100297
Methods of Modulating Vesicular Trafficking THE GENERAL HOSPITAL CORPORATION May- May Nov
651
09 -10 -10
24- 24- 25-
US20100297 IMMUNOSTIMULATORY COMBINATIONS OF TLR LIGANDS AND
Office of Technology Transfer Sep- Sep Nov
165 METHODS OF USE
07 -08 -10
31- 1- 25-
US20100297 METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN
GRIMM JAN Aug- Sep Nov
108 AMYLOIDOSES AND PROTEIN AGGREGATION DISORDERS
07 -08 -10
29- 29- 4-
US20100278 METHODS AND COMPOSITIONS FOR PREDICTING EMERGENCE AND
NIMAN HENRY L Jan- Jan Nov
861 EXPANSION OF DRUG RESISTANT STRAINS OF INFLUENZA VIRUS
09 -10 -10
9- 9- 28-
US20100273
Ribozyme to cleave coronavirus gene FUKUDA NOBORU Aug- Aug Oct-
997
05 -06 10
15- 12- 28-
US20100273 COMPOSITIONS AND METHODS FOR INHIBITING NADPH OXIDASE
FEINSTEIN ELENA Jun- Jun Oct-
854 EXPRESSION
07 -08 10
20- 23- 28-
US20100273 Phospholipids for the Treatment of Infection by Togaviruses, Herpes
FLEMING RONALD A Feb- Nov Oct-
740 Viruses and Coronaviruses
04 -09 10
21- 21- 28-
US20100273 DETECTION OF ANTIVIRAL RESISTANCE IN INFLUENZA A USING
DAWSON ERICA Aug- Aug Oct-
670 DNA MICROARRAY
06 -07 10
18- 7-
US20100256 20-
RECOMBINANT VIBRIO CHOLERAE EXOTOXINS SEED BRIAN Jul- Oct-
070 Jul-07
08 10
3- 6- 7-
US20100254
Protein Formulations MEDIMMUNE, LLC Feb- May Oct-
985
06 -10 10
14- 13- 7-
US20100254
Albumin Fusion Proteins STUMP DAVID CARTER Sep- Sep Oct-
944
06 -07 10
3- 4- 7-
US20100254
HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS BIOTRON LIMITED Aug- Aug Oct-
942
07 -08 10
20- 30- 30-
US20100249
Novel Compounds 569 CONNOLLY STEPHEN Dec- Mar Sep
200
06 -10 -10
14- 18- 30-
US20100249 METHOD AND MEDICAMENT FOR INHIBITING THE INFECTION OF INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF
Nov- Dec Sep
021 INFLUENZA VIRUS SCIENCES
07 -07 -10
17- 17- 30-
US20100248
Compositions for use in identification of influenza viruses ESHOO MARK W Oct- Oct Sep
219
05 -06 -10
21- 21- 30-
US20100247
CHIMERIC NEWCASTLE DISEASE VIRUS VLPs MAHMOOD KUTUB Feb- Feb Sep
574
07 -08 -10
27- 26- 30-
US20100247 METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST
ACADEMIA SINICA Mar- Mar Sep
571 VIRUS
09 -10 -10
25- 25- 30-
US20100247 MUTANT BOTULINUM NEUROTOXIN SEROTYPE A POLYPEPTIDE AND
THOMAS JEFFERSON UNIVERSITY Sep- Sep Sep
560 USES THEREOF
07 -08 -10
9- 7- 30-
US20100247
USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIALS BHATTACHARYYA SUCHITA Nov- Nov Sep
554
07 -08 -10
15- 16- 2-
US20100221 USE OF ANTIBODY SECRETING CELL ELISPOT TO ASSESS
University of Rochester Jun- Jun Sep
755 ANTIBODY RESPONSES FOLLOWING ANTIGEN EXPOSURE
07 -08 -10
1- 1- 2-
US20100221
NUCLEIC ACID CONSTRUCTS Powderject Vaccines, Inc. Feb- Feb Sep
349
05 -06 -10
20- 20- 2-
US20100221 ANTIVIRAL AGENTS, ANTIVIRAL FIBERS AND ANTIVIRAL FIBER
DAIWABO HOLDINGS CO., LTD. Feb- Feb Sep
307 STRUCTURES
08 -09 -10
7- 5- 2-
US20100221
BINDING MEMBERS-513 MEDIMMUNE LIMITED Nov- Nov Sep
257
08 -09 -10
1- 1- 2-
US20100221 ANTI-VIRAL GRIFFITHSIN COMPOUNDS, COMPOSITIONS AND
MCMAHON JAMES B Dec- Dec Sep
242 METHODS OF USE
05 -06 -10
20- 16- 26-
US20100216
NOVEL SALT 628 ASTRAZENECA R&D Feb- Feb Aug
843
09 -10 -10
24- 11- 26-
US20100216
PHENANTHROINDOLIZIDINE ANALOGUES National Health Research Institutes Feb- Feb Aug
773
09 -10 -10
8- 7- 26-
US20100216 National University Corporation, Hamamatsu University
CYTOTOXIC T CELL ACTIVATOR COMPRISING EP4 AGONIST May- May Aug
689 School of Medicine
07 -08 -10
20- 16- 26-
US20100215 PROTECTIVE ANTIGENS FOR GROUP B STREPTOCOCCUS
NOVARTIS AG Feb- Feb Aug
683 HYPERVIRULENT STRAINS
09 -10 -10
9- 27- 19-
US20100210
Novel Benzothiazolone Derivatives BONNERT ROGER Aug- Apr Aug
688
05 -10 -10
30- 31- 19-
US20100209
ATTENUATED VIRUSES USEFUL FOR VACCINES CELLO JERONIMO Mar- Mar Aug
454
07 -08 -10
16- 18- 19-
US20100209 Compositions and Methods Related to Adenovirus Based Delivery of
INTROGEN THERAPEUTICS, INC. Jun- Jun Aug
451 Antigens
06 -07 -10
26- 25- 19-
US20100209
Targeted Delivery of siRNA Immune Disease Institute, Inc. Jan- Jan Aug
440
07 -08 -10
12- 11- 12-
US20100204 METHOD FOR REDUCING GASTROINTESTINAL ADVERSE EFFECTS
BYRNES JOHN J Feb- Feb Aug
286 OF CYTOTOXIC AGENTS
09 -10 -10
23- 21- 12-
US20100204 COMPOSITIONS FOR USE IN IDENTIFICATION OF MIXED
Ibis Biosciences, INC Mar- Mar Aug
266 POPULATIONS OF BIOAGENTS
07 -08 -10
11- 10- 12-
US20100204 Chemical Compounds 637: Pyridopyrimidinediones as PDE4
BONNERT ROGER VICTOR Jan- Jan Aug
203 Inhibitors
07 -08 -10
12- 12- 12-
US20100203 Protein Expression System Involving Mutated Severe Respiratory
Academia Sinica Feb- Feb Aug
582 Syndrome-Associated Coronavirus 3C-Like Protease
09 -09 -10
17- 5-
US20100197 17-
ANTI-MICROBIAL COMPOSITION BYOTROL PLC Jul- Aug
748 Jul-07
08 -10
7- 7- 5-
US20100197
INDOLE COMPOUNDS BARDEN TIMOTHY Aug- Aug Aug
708
06 -07 -10
7- 6- 5-
US20100196 Use of Deuterium Oxide to Treat Virus-Based Diseases of the
BAYERL THOMAS Jan- Jan Aug
285 Respiratory Tract
09 -10 -10
20- 19- 5-
US20100196
AIR CLEANING APPARATUS FUJIFILM CORPORATION Sep- Sep Aug
222
07 -08 -10
16- 21- 29-
US20100190
BORON-CONTAINING SMALL MOLECULES Anacor Pharmaceuticals, Inc. Feb- Jul- Jul-
748
05 09 10
27- 27- 29-
US20100189
Compositions of TLR ligands and antivirals COLEY PHARMACEUTICAL GMBH Sep- Sep Jul-
772
06 -07 10
21- 21- 29-
US20100186 LIVESTOCK STERILIZING METHOD, LIVESTOCK STERILIZING
HAGIWARA NOBUKO Feb- Feb Jul-
680 APPARATUS, AND LIVESTOCK OR LIVESTOCK MEAT
05 -06 10
8- 8- 22-
US20100184
Methods and Compositions Related to Inhibition of Viral Entry University of Utah Research Foundation Feb- Feb Jul-
663
07 -08 10
10- 9- 22-
US20100184 Proteome Epitope Tags and Methods of Use Thereof in Protein
Millipore Corporation May- Oct Jul-
613 Modification Analysis
02 -09 10
19- 22-
US20100184 11-
AVIAN INFLUENZA CHIMERIC VLPS PUSHKO PETER Jan Jul-
192 Jul-03
-10 10
17- 9- 22-
US20100184
Influencing viral lipid constituents MedImmune, LLC Oct- Oct Jul-
190
06 -07 10
24- 10- 22-
US20100184 Novel Human Virus Causing Severe Acute Respiratory Syndrome
CHAN KWOK HUNG Mar- Feb Jul-
019 (SARS) and Uses Thereof
03 -10 10
4- 22-
US20100183 METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS 2-Jul-
ETUBICS CORPORATION Jan Jul-
673 VECTOR FOR USE WITH MULTIPLE VACCINATIONS 07
-10 10
27- 27- 22-
US20100183
LOW-ADDITIVE INFLUENZA VACCINES Novartis Vaccines & Diagnostics GmbH & Co., KG Jun- Jun Jul-
671
07 -08 10
1- 31- 22-
US20100183
MULTIFUNCTIONAL NUCLEIC ACID NANO-STRUCTURES Cornell University, a New York Corporation Jan- Dec Jul-
634
09 -09 10
25- 22-
US20100183 25-
SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS BARTH STEFAN Jul- Jul-
516 Jul-07
08 10
12- 12- 15-
US20100179
PHARMACEUTICAL COMBINATIONS GALLAGHER NEIL JAMES Oct- Oct Jul-
145
06 -07 10
13- 13- 15-
US20100178 METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE
Northeastern University Feb- Feb Jul-
299 RESPONSES
07 -08 10
13- 21- 8-
US20100173
ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV JUTEAU JEAN-MARC Sep- Dec Jul-
980
02 -09 10
6- 6- 8-
US20100173 Substituted 3,4,6,7-Tetrahydro-5H-1,2a,4a,8-
GRIESGRABER GEORGE W Sep- Sep Jul-
906 Tetraazacyclopenta[cd]Phenalenes and Methods
06 -07 10
17- 4- 8-
US20100173
Composition and Method for Analysis of Target Analytes Millipore Corporation Sep- Jul- Jul-
325
03 09 10
20- 19- 8-
US20100173 Systems for Detection and Production of Respiratory, Herpes and
Diagnostic Hybrids, Inc Sep- Sep Jul-
280 Enteric Viruses
05 -06 10
13- 21- 8-
US20100172
ANTIVIRAL OLIGONUCLEOTIDES TARGETING VIRAL FAMILIES JUTEAU JEAN-MARC Sep- Dec Jul-
965
02 -09 10
16- 8-
US20100172 22-
Binding molecules against SARS-coronavirus and uses thereof Crucell Holland B.V. Nov Jul-
917 Jul-03
-09 10
24- 8- 1-
US20100166
Technology for Preparation of Macromolecular Microspheres FANG FANG Jan- Dec Jul-
874
06 -09 10
23- 1-
US20100166 CLIP INHIBITORS AND METHODS OF MODULATING IMMUNE 25-
AGADJANYAN MICHAEL Jul- Jul-
782 FUNCTION Jul-08
09 10
27- 27- 1-
US20100166 CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with
Pfizer Inc Sep- Sep Jul-
780 Enhanced Immunostimulatory Activity
06 -07 10
5- 12- 1-
US20100166 High-yield Transgenic Mammalian Expression System for Generating
Academia Sinica Sep- Feb Jul-
769 Virus-like Particles
06 -10 10
11- 11- 1-
US20100166 siRNA COMPOSITIONS AND METHODS FOR POTENTLY INHIBITING
LIN YONGPING Dec- Dec Jul-
661 VIRAL INFECTION
08 -09 10
19- 19- 24-
US20100160 POLYOLEFIN ANTIMICROBIAL COMPOSITIONS AND MELT-
BISHOP KEVIN L Dec- Dec Jun-
486 PROCESSING METHODS
08 -08 10
23- 22- 24-
US20100160 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-
BISCHOFF ALEXANDER Dec- Dec Jun-
323 CoA DESATURASE
08 -09 10
24- 18- 24-
US20100160 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory
BIRKINSHAW TIMOTHY NICHOLAS Aug- Dec Jun-
285 Disease
04 -09 10
16- 24-
US20100160 17-
Quercetin-Containing Compositions Quercegen Pharma LLC Dec Jun-
245 Jul-06
-09 10
4- 6- 24-
US20100158 ADMINISTRATION ROUTES FOR PRIMING/BOOSTING WITH
NOVARTIS VACCINES AND DIAGNOSTICS SRL Nov- Nov Jun-
943 INFLUENZA VACCINES
05 -06 10
21- 24- 24-
US20100158
MUTANT FORMS OF STREPTOLYSIN O NOVARTIS AG Dec- Feb Jun-
935
07 -10 10
25- 20- 24-
US20100158
IMMUNE RESPONSE MODIFIER COMPOSITIONS AND METHODS GRIESGRABER GEORGE W Dec- Dec Jun-
928
06 -07 10
2- 1- 17-
US20100152
HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS Pfizer Inc. Sep- Sep Jun-
230
05 -06 10
15- 10- 17-
US20100152 (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-
ASTRAZENECA AB Dec- Dec Jun-
197 CARBOXAMIDE DERIVATIVES
08 -09 10
3- 5- 17-
US20100152 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA
XENON PHARMACEUTICALS INC. Jun- Jun Jun-
187 DESATURASE INHIBITORS
05 -06 10
16- 12- 17-
US20100152
PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED Nov- Oct Jun-
184
06 -07 10
1- 25- 17-
US20100151
Antigenic Protein Conjugates and Process for Preparing Same ABBOTT LABORATORIES Sep- Feb Jun-
490
06 -10 10
22- 21- 17-
US20100150 COMPOSITIONS AND METHODS FOR CHITOSAN ENHANCED The United States of America, as represented by the
Sep- Sep Jun-
960 IMMUNE RESPONSE Secretary,Department of Health and Human Servi
06 -07 10
26- 17-
US20100150 26-
IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA NOVARTIS AG Jul- Jun-
943 Jul-06
07 10
12- 8- 10-
US20100144 NOVEL N-(FLUORO-PYRAZINYL)-PHENYLSULFONAMIDES AS
AstraZeneca AB Dec- Dec Jun-
759 MODULATORS OF CHEMOKINE RECEPTOR CCR4
05 -09 10
10- 10- 6-
US20100112 METHODS AND COMPUTER SYSTEMS FOR IDENTIFYING TARGET-
NANOSTRING TECHNOLOGIES, INC. Apr- Apr May
710 SPECIFIC SEQUENCES FOR USE IN NANOREPORTERS
07 -08 -10
4- 4- 6-
US20100112 The Government of the United States of America, as
METHOD FOR DIRECT CAPTURE OF RIBONUCLEIC ACID Nov- Nov May
643 represented by the Secretary of the Navy
08 -08 -10
13- 13- 6-
US20100112 ANTIMICROBIAL SOLUTIONS CONTAINING DICHLORINE MONOXIDE
Oculus Innovative Sciences, Inc. Mar- Mar May
092 AND METHODS OF MAKING AND USING THE SAME
07 -08 -10
20- 20- 6-
US20100111
TREATING CANCER WITH VIRAL NUCLEIC ACID HADAC ELIZABETH M Feb- Feb May
873
07 -08 -10
23- 22-
US20100099 22-
METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. Dec Apr-
672 Jul-04
-09 10
1- 1- 22-
US20100099
ISOQUINOLINONE DERIVATIVES AstraZeneca AB Oct- Oct Apr-
665
08 -09 10
6- 5- 22-
US20100099 STABILIZING COMPOSITIONS AND METHODS FOR EXTRACTION OF
DNA GENOTEK INC. Oct- Oct Apr-
149 RIBONUCLEIC ACID
06 -07 10
26- 24- 22-
US20100099 Non-dividing cell-based assay for high throughput antiviral
SAINZ JR BRUNO Sep- Sep Apr-
079 compound screening
08 -09 10
20- 19- 15-
US20100093
NOVEL ADENINE COMPOUND AstraZeneca Aktiebolag Mar- Mar Apr-
998
07 -08 10
6- 6- 15-
US20100093 POTENTIATION OF CELLULAR IMMUNITY USING HISTONE Sapporo Medical Univeristy and Japan Science and
Dec- Dec Apr-
862 DEACETYLASE (HDAC) INHIBITORS. Technology Agency
06 -07 10
14- 14- 15-
US20100093
SILVER POLYAMIDE COMPOSITE BISHOP KEVIN L Oct- Oct Apr-
851
08 -08 10
7- 6- 15-
US20100093
SALT ARGENTA DISCOVERY LTD. Feb- Feb Apr-
816
07 -08 10
8- 6- 15-
US20100093
Salts 668 ASTRAZENECA AB Feb- Feb Apr-
813
07 -08 10
9- 3- 15-
US20100093
ALBUMIN FUSION PROTEINS Human Genome Sciences. Inc. Feb- Aug Apr-
627
04 -09 10
9- 9- 15-
US20100093 Academisch Medisch Centrum bij de Universiteit van
Means and Methods for Influencing the Stability of Cells Dec- Dec Apr-
038 Amsterdam
05 -05 10
12- 12- 15-
US20100092
PHARMACEUTICAL COMBINATIONS GALLAGHER NEIL JAMES Oct- Oct Apr-
474
06 -07 10
22- 21- 15-
US20100092
ANTIBODIES, ANALOGS AND USES THEREOF ICB International, Inc. Sep- Sep Apr-
470
08 -09 10
12- 15-
US20100092 18-
IMMUNE RESPONSE MODIFIER FORMULATIONS Graceway Pharmaceuticals, LLC Jul- Apr-
401 Jul-06
07 10
19- 19- 8-
US20100087 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE
Not Available Mar- Mar Apr-
443 RECEPTOR (TLR7) MODULATORS
07 -08 10
3- 3- 8-
US20100087
ODCASE INHIBITORS AS ANTI-VIRALS AND ANTIBIOTICS Not Available Oct- Oct Apr-
388
05 -06 10
5- 5- 8-
US20100086
IP-10 BASED IMMUNOLOGICAL MONITORING Hvidovre Hospital Sep- Sep Apr-
950
06 -07 10
21- 4- 8-
US20100086
COMPOUNDS AstraZeneca AB Feb- Dec Apr-
942
07 -09 10
5- 5- 8-
US20100086 METHODS TO DECREASE THE RISK OF METABOLIC SYNDROME
CLASSEN JOHN BARTHELOW Oct- Oct Apr-
571 POST IMMUNIZATION
06 -07 10
23- 23- 25-
US20100075
Method for rapid identification and quantification of microorganisms The Regents of the University of California Sep- Sep Mar
298
08 -08 -10
12- 18-
US20100070 COMPUTER-IMPLEMENTED BIOLOGICAL SEQUENCE IDENTIFIER The Government of the United States of America, as 2-Jul-
Nov Mar
195 SYSTEM AND METHOD represented by the Secretary of the Navy 04
-09 -10
13- 13- 4-
US20100055
Methods and Compositions for Targeting c-Rel CHENG SHUHUA Apr- Apr Mar
116
06 -07 -10
2- 25-
US20100048 30-
PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. Sep Feb
584 Jul-03
-09 -10
2- 2- 18-
US20100042 System and Method to Predict the Global Spread of Infectious
KHAN KAMRAN Apr- Apr Feb
394 Agents Via Commercial Air Travel
07 -08 -10
27- 26- 18-
US20100041
Chemical Compounds 293 ANDREWS GLEN May- May Feb
638
08 -09 -10
27- 27- 18-
US20100041
Modulating mxa expression CHUNG EUN J Sep- Sep Feb
617
04 -05 -10
14- 14- 18-
US20100041
ASSAY FOR A HEALTH STATE HUMAN GENETIC SIGNATURES PTY LTD. Sep- Sep Feb
013
05 -06 -10
13- 12- 18-
US20100040
USE OF NITRIC OXIDE MILLER CHRIS Aug- Aug Feb
703
08 -09 -10
5- 22- 18-
US20100040
POLYCISTRONIC HIV VECTOR CONSTRUCTS Novartis Vaccines and Diagnostics, Inc. May- Oct Feb
676
04 -09 -10
16- 16- 18-
US20100040
Anti-viral Formulations Nanomaterials And Nanoparticles INTRINSIQ MATERIALS LIMITED Feb- Feb Feb
655
06 -07 -10
28- 27- 18-
US20100040
NEUTRALIZING ANTIBODIES TO INFLUENZA VIRUSES Sea Lane Biotechnologies Mar- Mar Feb
635
08 -09 -10
13- 11-
US20100035 DISRUPTION OF PROGRAMMED DEATH 1 (PD-1) LIGAND TO 17-
Nationwide Children's Hospital, Inc. Jul- Feb
973 ADJUVANT ADENO-ASSOCIATED VIRUS VECTOR VACCINES Jul-06
07 -10
8- 6- 4-
US20100029
Combinations of Beta-2-Adrenoceptor Agonistic Benzothiazolone ASTRAZENECA AB Feb- Feb Feb
732
07 -08 -10
20- 19- 4-
US20100029
ORGANIC COMPOUNDS DALES NATALIE Dec- Dec Feb
722
06 -07 -10
22- 19- 4-
US20100029
ORGANIC COMPOUNDS Novartis AG Sep- Sep Feb
718
06 -07 -10
1- 31- 4-
US20100029
TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE DIETSCH GREGORY Aug- Jul- Feb
585
08 09 -10
17- 15- 4-
US20100029
ALPHA-LACTALBUMIN COMPOSITION GULDMANN MARIANNE Nov- Nov Feb
557
06 -07 -10
20- 22- 4-
US20100029
Peptide inhibitors of c-jun dimerization and uses thereof Phylogica Limited Aug- Aug Feb
552
04 -05 -10
25- 2- 4-
US20100028
OPTICAL DETERMINATION OF LIVING VS. NON LIVING CELLS Not Available Oct- Nov Feb
853
05 -06 -10
19- 18- 4-
US20100028
FORMULATION FOR DELIVERY OF IMMUNE RESPONSE MODIFIERS 3M INNOVATIVE PROPERTIES COMPANY Jun- Jun Feb
381
06 -07 -10
28- 4-
US20100028 Hazardous substance removing material and method for removing 29-
FUJIFILM Corporation Jul- Feb
369 hazardous substance Jul-08
09 -10
18- 21-
US20100015 18-
METHODS AND KIT FOR ANALYTE DETECTION GENERAL ELECTRIC COMPANY Jul- Jan-
633 Jul-08
08 10
23- 22- 21-
US20100015 NANOREPORTERS AND METHODS OF MANUFACTURING AND USE
INSTITUTE FOR SYSTEMS BIOLOGY Dec- Dec Jan-
607 THEREOF
05 -06 10
HUMAN PAPILLOMA VIRUS (HPV) DETECTION USING NUCLEIC ACID 10- 9- 21-
US20100015
PROBES, MICROBEADS AND FLUORESCENT-ACTIVATED CELL GOULD TOBY Dec- Dec Jan-
594
SORTER (FACS) 04 -05 10
10- 10- 7-
US20100003 RNA-DEPENDENT DNA POLYMERASE FROM GEOBACILLUS
LAMPSON BERT C Mar- Mar Jan-
723 STEAROTHERMOPHILUS
04 -04 10
13- 12- 7-
US20100003 VACCINES AND IMMUNOTHERAPEUTICS USING CODON OPTIMIZED
KUTZLER MICHELE Jan- Jan Jan-
277 IL-15 AND METHODS FOR USING THE SAME
06 -07 10
28- 7-
US20100003 METHODS AND USES OF CAULIFLOWER AND COLLARD FOR 11-
THOMAS JEFFERSON UNIVERSITY Jun Jan-
269 RECOMBINANT PROTEIN PRODUCTION Jul-06
-07 10
3- 8- 24-
US20090318
PYRAZOLOPYRIDINES AND ANALOGS THEREOF BONK JASON D Oct- Jun Dec
435
03 -09 -09
22- 22- 24-
US20090318 Compositions and methods for activating innate and allergic
ID Biomedical Corporation of Quebec Oct- Oct Dec
337 immunity
03 -04 -09
18- 18- 24-
US20090317 COMPOSITIONS AND METHODS RELATED TO STAPHYLOCOCCAL
BURTS MONICA Jan- Jan Dec
421 BACTERIUM PROTEINS
06 -07 -09
28- 27- 24-
US20090317 Modified AAV Vectors Having Reduced Capsid Immunogenicity and
The Trustees of the University of Pennsylvania Apr- Apr Dec
417 Use Thereof
06 -07 -09
1- 1- 17-
US20090312 BIOLOGICAL SPECIMEN COLLECTION AND TRANSPORT SYSTEM
Longhorn Vaccines & Diagnostics, LLC Oct- Oct Dec
285 AND METHODS OF USE
07 -08 -09
6- 6- 17-
US20090311
COMPOSITIONS FOR THE USE IN IDENTIFICATION OF FUNGI IBIS BIOSCIENCES, INC. Apr- Apr Dec
683
06 -07 -09
13- 27- 17-
US20090311 MUCOSAL IMMUNOGENIC SUBSTANCES COMPRISING A
LI LIE TAO VICTOR Jan- Jun Dec
334 POLYINOSINIC ACID - POLYCYTIDILIC ACID BASED ADJUVANT
06 -06 -09
23- 23- 17-
US20090311
IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS Novartis AG Mar- Mar Dec
288
06 -07 -09
29- 29- 10-
US20090306 ANTIBODY PRODUCED USING OSTRICH AND METHOD FOR
JAPAN SCIENCE AND TECHNOLOGY AGENCY Aug- Aug Dec
347 PRODUCTION THEREOF
05 -06 -09
20- 13- 10-
US20090306 HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA
Xenon Pharmaceuticals Inc. Sep- Aug Dec
090 DESATURASE INHIBITORS
04 -09 -09
12- 10- 10-
US20090306
Novel Compounds 010 CAGE PETER ALAN Dec- Dec Dec
042
07 -08 -09
1- 10-
US20090305 NOVEL HUMAN VIRUS CAUSING RESPIRATORY TRACT INFECTION 21-
CHAN KWOK HUNG Jun Dec
282 AND USES THEREOF Jul-04
-09 -09
15- 15- 10-
US20090304
Composition and Methods for Immunisation Using CD1D Ligands GALLI GRAZIA Mar- Mar Dec
743
06 -07 -09
4- 6- 10-
US20090304 INFLUENZA VACCINES WITH REDUCED AMOUNT OF EMULSION
Novartis Vaccines and Diagnostics SRL Nov- Nov Dec
742 ADJUVANT
05 -06 -09
4- 6- 10-
US20090304 INFLUENZA VACCINES INCLUDING COMBINATIONS OF
NOVARTIS VACCINES AND DIAGNOSTICS SRL Nov- Nov Dec
739 PARTICULATE ADJUVANTS AND IMMUNOPOTENTIATORS
05 -06 -09
1- 1- 10-
US20090304 CELL-DERIVED VIRAL VACCINES WITH LOW LEVELS OF RESIDUAL
NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO KG Nov- Nov Dec
729 CELL DNA
05 -06 -09
19- 19- 10-
US20090304
Soluble Fragments of The Sars-Cov Spike Glycoprotein DIMITROV DIMITER S Jan- Jan Dec
683
07 -07 -09
27- 10-
US20090304 Methods for the treatment and prevention of infection using anti- 29-
Not Available Jul- Dec
681 selectin agents Jul-04
05 -09
15- 14- 3-
US20090298 HYDROXY AND ALKOXY SUBSTITUTED IH-
Pfizer Inc. Mar- Mar Dec
821 IMIDAZONAPHTHYRIDINES AND METHODS
06 -07 -09
6- 4- 3-
US20090298
Compounds ALCARAZ LILIAN Feb- Feb Dec
807
08 -09 -09
25- 30- 3-
US20090297 RECOMBINANT HUMAN CYTOMEGALOVIRUS AND VACCINES
MEDIMMUNE, LLC Jun- Jun Dec
555 COMPRISING HETEROLOGOUS ANTIGENS
04 -09 -09
4- 3- 19-
US20090286
NOVEL COMPOUNDS AstraZeneca AB Oct- Oct Nov
835
07 -08 -09
13- 12- 19-
US20090286
Thioxanthine Derivatives and Their Use as Inhibitors of MPO ASTRAZENECA AB Apr- Apr Nov
813
06 -07 -09
10- 28- 19-
US20090286 USE OF THE LONG PENTRAXIN PTX3 FOR THE PREVENTION OR
TECNOGEN S.P.A. Mar- Feb Nov
726 TREATMENT OF VIRAL DISEASES
06 -07 -09
24- 16- 19-
US20090286 Mixed Cell Diagnostic Systems For Detection Of Respiratory, Herpes
GOODRUM PATRICIA GAIL RAY Apr- Oct Nov
222 And Enteric Viruses
98 -08 -09
16- 1- 19-
US20090285
PLANT EXTRACT AND ITS THERAPEUTIC USE Veritron Limited May- Dec Nov
921
08 -08 -09
20- 27- 19-
US20090285
Polyamino acid for use as adjuvant AKASHI MITSURU Apr- Jul- Nov
901
05 09 -09
20- 19-
US20090285 20-
FROZEN STOCKPILING OF INFLUENZA VACCINES Novartis AG Jul- Nov
854 Jul-06
07 -09
8- 10- 12-
US20090281 COMPOSITIONS AND METHODS USING SAME FOR THE DETECTION
ARAD DORIT Sep- Sep Nov
042 OF VIRUSES
05 -06 -09
6- 5- 12-
US20090281
ANTIVIRAL CELL-PENETRATING PEPTIDES CURRELI FRANCESCA May- May Nov
041
08 -09 -09
13- 13- 5-
US20090275
ANTIVIRAL COMPOUNDS AND USE THEREOF Myriad Genetics, Incorporated Oct- Apr Nov
583
06 -09 -09
2- 1- 5-
US20090275 ARRAYED DETECTOR SYSTEM FOR MEASUREMENT OF INFLUENZA
UNIVERSITY OF ROCHESTER May- May Nov
016 IMMUNE RESPONSE
08 -09 -09
2- 2- 29-
US20090270
1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS Not Available Sep- Sep Oct-
443
04 -05 09
19- 19- 29-
US20090270 Cyclopentenol Nucleoside Compounds Intermediates for their
THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION Oct- Oct Oct-
431 Synthesis and Methods of Treating Viral Infections
05 -06 09
23- 23- 29-
US20090269 METHODS AND COMPOUNDS FOR MITIGATING PATHOGENIC
BOGOCH ELENORE S Apr- Apr Oct-
367 OUTBREAKS USING REPLIKIN COUNT CYCLES
08 -09 09
16- 18- 22-
US20090264
USEFUL INDOLE COMPOUNDS BARDEN TIMOTHY Dec- Dec Oct-
653
05 -06 09
10- 8- 22-
US20090264
Adenoviral vector-based foot-and-mouth disease vaccine GENVEC, INC. Nov- May Oct-
509
05 -08 09
20- 20- 22-
US20090264
Organic compounds CHOWDHURY SULTAN Feb- Feb Oct-
444
08 -09 09
Alkyl Esters Of Cyclic Amino Alcohols With Muscarinic M3 Receptor 24- 23- 17-
US20090233
Antagonist Activity, Useful For Treating E.G. Chronic Bronchial ASTRAZENECA AB Apr- Apr Sep
965
Obstruction, Asthma And Overactive Bladder 06 -07 -09
29- 28- 3-
US20090221 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-
AstraZeneca AB Aug- Aug Sep
653 derivatives as beta2 adrenoreceptor agonists
05 -06 -09
16- 15- 3-
US20090221
Novel Crystal Modifications ASTRAZENECA AB Mar- Mar Sep
640
06 -07 -09
3- 15- 3-
US20090221
IMIDAZOPYRIDINONES Not Available Aug- May Sep
631
07 -09 -09
6- 4- 3-
US20090221 4-AMINOQUINOLINE COMPOUNDS FOR TREATING VIRUS-RELATED
BUSCHER BENJAMIN A May- May Sep
624 CONDITIONS
05 -06 -09
21- 23- 3-
US20090221 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-
AURIGENE DISCOVERY TECHNOLOGIES LIMITED Jun- Jun Sep
583 CoA DESATURASE
07 -08 -09
4- 3- 3-
US20090221 HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES
Pfizer Inc. Nov- Nov Sep
556 AND METHODS
05 -06 -09
15- 14- 3-
US20090221 SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND
Pfizer Inc. Mar- Mar Sep
551 METHODS
06 -07 -09
10- 11- 3-
US20090221 Institute of Pharmacology and Toxicology Academy of
POLYETHLENE GLYCOL MODIFICATIONS OF THYMOSIN ALPHA-1 Nov- Nov Sep
487 Military Medical Sciences P.L.A. China
05 -06 -09
25- 25- 3-
US20090220 COMPOSITIONS FOR- DETECTING OF INFLUENZA VIRUSES AND
MND DIAGNOSTIC LTD Oct- Oct Sep
941 KITS AND METHODS USING SAME
05 -06 -09
3- 3- 3-
US20090220
Compositions for Use in Identification of Adventitious Viruses IBIS BIOSCIENCES, INC. Mar- Mar Sep
937
05 -06 -09
2- 2- 3-
US20090220 Reducing interference between oil-containing adjuvants and
NOVARTIS VACCINES AND DIAGNOSTICS SRL Aug- Aug Sep
547 surfactant-containing antigens
05 -06 -09
22- 20- 3-
US20090220
Adjuvanted influenza vaccines for pediatric use GROTH NICOLA Feb- Feb Sep
546
08 -09 -09
15- 15- 3-
US20090220
Adjuvant-Sparing Multi-Dose Influenza Vaccination Regimen NOVARTIS AG Jun- Jun Sep
545
06 -07 -09
4- 6- 3-
US20090220 ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED
NOVARTIS VACCINES AND DIAGNOSTICS SRL Nov- Nov Sep
544 FROM INFLUENZA VIRUSES GROWN IN CELL CULTURE
05 -06 -09
4- 6- 3-
US20090220 EMULSIONS WITH FREE AQUEOUS-PHASE SURFACTANT FOR
NOVARTIS VACCINES AND DIAGNOSTICS SRL Nov- Nov Sep
541 ADJUVANTING SPLIT INFLUENZA VACCINES
05 -06 -09
27- 3-
US20090220 DEFECTIVE RIBOSOMAL PRODUCTS IN BLEBS (DRIBBLES) AND 29-
HU HONG-MING Jul- Sep
530 METHODS OF USE TO STIMULATE AN IMMUNE RESPONSE Jul-05
06 -09
13- 16- 3-
US20090220
ADAM10 and its Uses Related to Infection HODGE THOMAS Jan- Jan Sep
514
06 -07 -09
28- 11- 3-
US20090220
USES OF INTERFERONS WITH ALTERED SPATIAL STRUCTURE Not Available Aug- Feb Sep
456
03 -09 -09
4- 3- 13-
US20090203
VERO CELL LINE WHICH IS ADAPTED TO GROW IN SUSPENSION Ricardo Kratje Oct- Oct Aug
112
05 -06 -09
26- 28- 13-
US20090202
MOLECULAR CARDIOTOXICOLOGY MODELING JOHNSON KORY R Aug- Aug Aug
995
05 -06 -09
4- 6- 13-
US20090202 INFLUENZA VACCINES EXTEMPORANEOUSLY ADSORBED TO
NOVARTIS VACCINES AND DIGNOSTICS SRL Nov- Nov Aug
590 ALUMINIUM ADJUVANTS
05 -06 -09
21- 14- 6-
US20090197 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC
XENON PHARMACEUTICALS INC. Dec- Apr Aug
894 AGENTS
01 -09 -09
20- 6-
US20090197 PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC 30-
XENON PHARMACEUTICALS INC. Feb Aug
890 AGENTS Jul-03
-09 -09
7- 7- 6-
US20090197
Method of Increasing the Function of an AAV Vector The Trustees of teh University of Pennsylvania Apr- Apr Aug
338
05 -06 -09
6- 6- 6-
US20090196 Compositions Methods and Kits For Enhancing Immune Response To
The Procter & Gamble Company Feb- Feb Aug
921 A Respiratory Condition
08 -09 -09
5- 5- 30-
US20090192
Method for cryospray ablation Reset Medical, Inc. Dec- Dec Jul-
505
07 -08 09
6- 5- 30-
US20090192
Novel Compounds ASTRAZENECA AB Oct- Oct Jul-
163
05 -06 09
22- 21- 30-
US20090192
NOVEL ADENINE COMPOUND AstraZeneca Aktiebolag A corporation of Sweden Sep- Sep Jul-
153
05 -06 09
20- 30- 30-
US20090192
PRODRUGS OF HETEROARYL COMPOUNDS Koronis Pharmaceuticals, Incorporated Jun- Mar Jul-
099
03 -09 09
1- 31- 30-
US20090192
Casein derived peptides and uses thereof SIDELMAN ZVI Mar- Oct Jul-
081
00 -07 09
10- 9- 23-
US20090186
METHOD FOR TREATMENT OF PANCREATITIS Ore Pharmaceuticals Inc. Oct- Oct Jul-
014
07 -08 09
29- 15- 16-
US20090182 BENZOPYRANONE DERIVATIVES AND THEIR USE AS ANTI-VIRAL Shanghai Institute of Materia Medica Chinese Academy of
Dec- Dec Jul-
133 AGENTS Sciences
05 -06 09
8- 5- 16-
US20090181 Novel Inhibitors of Cysteine Proteases, the Pharmaceutical
BOISSY GUILLAUNE Dec- Dec Jul-
972 Compositions Thereof and their Therapeutic Applications
05 -06 09
14- 14- 16-
US20090181
Rapid test for detecting infection KUMAR ARUN Jan- Jan Jul-
361
08 -08 09
16- 9-
US20090176 Novel Tricyclic Spiropiperidine Compounds, Their Synthesis and 19-
ERIKSSON TOMAS Jan Jul-
815 Their Uses as Modulators of Chemokine Receptor Activity Jul-06
-09 09
6- 9-
US20090176 Inhibitors Based on Fusion, Hr1 and Hr2 Sequences in Bacterial 6-Jul-
CHIRON SRL Jul- Jul-
699 Adhesin 04
05 09
30- 26- 9-
US20090175 AEROSOL METHOD FOR NANO SILVER-SILICA COMPOSITE ANTI-
BRINKER C JEFFREY Nov- Nov Jul-
948 MICROBIAL AGENT
07 -08 09
13- 27- 9-
US20090175 Immunogenic Substances Comprising A Polyinosinic Acid-
Not Available Jan- Jun Jul-
902 Polycytidilic Acid Based Adjuvant
06 -06 09
10- 2-
US20090170 The Government of the United States of America, as 2-Jul-
RE-SEQUENCING PATHOGEN MICROARRAY Apr Jul-
717 represented by the Secretary of the Air Force 04
-08 09
24- 24- 2-
US20090169 Microparticles containing biodegradable polymer and cationic
Not Available Feb- Feb Jul-
636 polysaccharide for use in immunogenic compositions
06 -07 09
27- 4- 25-
US20090163
Novel Compounds BONNERT ROGER May- Mar Jun-
518
03 -09 09
24- 24- 25-
US20090162
HUMAN PARVOVIRUS DELWART ERIC L May- May Jun-
831
04 -05 09
21- 19- 25-
US20090162
MUTANT FORMS OF STREPTOLYSIN O NOVARTIS AG Dec- Dec Jun-
392
07 -08 09
25- 25- 25-
US20090162
Novel siRNAS and methods of use thereof FEINSTEIN ELENA Oct- Oct Jun-
365
06 -07 09
GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING 28- 27- 25-
US20090162
LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA DNAVEC Corporation Oct- Oct Jun-
320
VIRUS SPIKE PROTEIN 05 -06 09
5- 4- 21-
US20090131
2-Thioxanthine Derivatives Acting as MPO-Inhibitors ASTRAZENECA AB Jun- Jun May
459
06 -07 -09
Compositions with Modified Nucleases Targeted to Viral Nucleic 14- 14- 19-
US20090047
Acids and Methods of Use for Prevention and Treatment of Viral APPELBAUM JACOB G Apr- Apr Feb
272
Diseases 04 -05 -09
18- 30- 8-
US20090011
INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES MAXYGEN, INC. Nov- Oct Jan-
465
02 -06 09
26- 17- 8-
US20090011 MICROPOROUS MATERIALS, METHODS OF MAKING, USING, AND
UNIVERSITY OF UTAH RESEARCH FOUNDATION May- May Jan-
403 ARTICLES THEREOF
04 -05 09
2- 1- 1-
US20090005
1-Alkoxy 1H-Imidazo Ring Systems and Methods 3M Innovative Properties Company Sep- Sep Jan-
376
04 -05 09
11- 10- 1-
US20090005 Substituted Fused [1,2]Imidazo[4,5-C] Ring Compounds and
HEPPNER PHILIP D Feb- Feb Jan-
371 Methods
05 -06 09
18- 17- 1-
US20090004 METHODS FOR CONCURRENT IDENTIFICATION AND
ISIS Pharmaceuticals, Inc. Feb- Feb Jan-
643 QUANTIFICATION OF AN UNKNOWN BIOAGENT
04 -05 09
12- 13- 25-
US20080319
Methods and Uses of Antibodies in the Purification of Interferon ViraNative AB Feb- Feb Dec
170
05 -06 -08
9- 8- 25-
US20080318
Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines COLEY PHARMACEUTICAL GROUP, INC. Feb- Feb Dec
998
05 -06 -08
19- 19- 25-
US20080317 METHOD FOR TREATING MICROORGANISMS AND/OR INFECTIOUS
EDGINGTON GARRY Jun- Jun Dec
702 AGENTS
07 -08 -08
13- 13- 18-
US20080311
Adjuvant Activity of Gastrointestinal Peptides Not Available Dec- Dec Dec
138
04 -05 -08
25- 24- 18-
US20080311
Scytovirin Domain 1 Related Polypeptides Office of Technology Transfer May- May Dec
125
05 -06 -08
5- 4- 18-
US20080311 Loop-Variant Pdz Domains as Biotherapeutics, Diagnostics and
DELAGRAVE SIMON Dec- Dec Dec
042 Research Reagents
05 -06 -08
29- 17- 18-
US20080310
APPARATUS AND METHOD FOR USING OZONE AS A DISINFECTANT VIROFORCE SYSTEMS INC. Nov- Jun Dec
992
06 -08 -08
17- 16- 11-
US20080305
Immunogenic Compositions Comprising Hmgb 1 Polypeptides MEDIMMUNE, INC. Jun- Jun Dec
120
04 -05 -08
29- 5- 11-
US20080305
Modified Bacteriophage Vectors and Uses Thereof UNIVERSITY OF ROCHESTER Oct- Oct Dec
119
04 -05 -08
9- 3- 4-
US20080300
Novel Benzothiazolone Derivatives ASTRAZENECA AB Aug- Aug Dec
275
05 -06 -08
14- 13- 4-
US20080300
NOVEL COMPOUNDS AstraZeneca AB Dec- Dec Dec
244
06 -07 -08
6- 6- 4-
US20080300 PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND
CAI SUI XIONG May- May Dec
191 THE USE THEREOF
03 -04 -08
6- 6- 4-
US20080299 CHROMATOGRAPHIC METHODS FOR ASSESSING ADENOVIRUS
CLARKE PETER Mar- Mar Dec
545 PURITY
07 -08 -08
1- 29- 4-
US20080299
METHODS AND FORMULATIONS FOR TOPICAL GENE THERAPY ONISHI ERIC Mar- Feb Dec
182
07 -08 -08
30- 30- 4-
US20080299
Antiviral Compounds ENGEL ROBERT May- May Dec
070
07 -08 -08
1- 1- 4-
US20080295
SELF SANITIZING FACE MASKS AND METHOD OF MANUFACTURE HAAS MARCI B Jun- Jun Dec
843
07 -07 -08
15- 12- 27-
US20080293 Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for
ASTRAZENECA AB Dec- Dec Nov
775 the Treatment of Respiratory Disease
05 -06 -08
12- 11- 27-
US20080293 Novel N-(Fluoro-Pyrazinyl)-Phenylsulfonamides as Modulators of
CHESHIRE DAVID Dec- Dec Nov
742 Chemokine Receptor Ccr4
05 -06 -08
21- 24- 27-
US20080292
PRIMATE T-LYMPHOTROPIC VIRUSES Centers for Disease Control and Prevention Feb- Feb Nov
657
05 -07 -08
8- 8- 27-
US20080292
Antigenic GM-CSF peptides and antibodies to GM-CSF Morphotek, Inc. Feb- Feb Nov
641
06 -07 -08
3- 20-
US20080286 COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING 29-
THE CHINESE UNIVERSITY OF HONG KONG Apr Nov
756 SEVERE ACUTE RESPIRATORY SYNDROME (SARS) Jul-03
-08 -08
2- 31- 13-
US20080280
Salt Il ASTRAZENECA AB Aug- Jul- Nov
951
05 06 -08
5- 4- 13-
US20080279
Compositions For Treating Respiratory Viral Infections and Their Use Intradigm Corporation Nov- Nov Nov
920
04 -05 -08
8- 13-
US20080279 9-Jul-
Viral Adjuvants JOHNSTON ROBERT E Jul- Nov
891 04
05 -08
5- 19- 13-
US20080279
Disease Prevention and Vaccination Prior to Thymic Reactivation Monash University Dec- Apr Nov
812
03 -04 -08
6- 20- 13-
US20080279 TRANSPORTABLE DECONTAMINATION UNIT AND
BACIK MICHAEL A Mar- Feb Nov
722 DECONTAMINATION PROCESS
07 -08 -08
6- 20- 13-
US20080279
DECONTAMINATION UNIT AND PROCESS CENTANNI MICHAEL A Mar- Feb Nov
721
07 -08 -08
6- 20- 13-
US20080279 DECONTAMINATION UNIT WITH COLLAPSIBLE DECONTAMINATION
CENTANNI MICHAEL A Mar- Feb Nov
720 ENCLOSURE AND DECONTAMINATION PROCESS
07 -08 -08
27- 24- 6-
US20080275
Piperidines for the Treatment of Chemokine Mediated Diseases ASTRAZENECA AB May- May Nov
084
05 -06 -08
19- 18- 6-
US20080274
Vaccines and Methods for Using the Same KUTZLER MICHELE Nov- Nov Nov
140
04 -05 -08
22- 21- 30-
US20080269
Novel Adenine Compound AstraZeneca Aktiebolag A Corporation of Sweden Sep- Sep Oct-
240
05 -06 08
30- 29- 30-
US20080269
Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds Coley Pharmaceutical Group, Inc. Dec- Dec Oct-
192
04 -05 08
26- 26- 30-
US20080269
Inhibitors of RTP801 and their use in disease treament FEINSTEIN ELENA Feb- Feb Oct-
156
07 -08 08
1- 30- 30-
US20080269
Modified Small Interfering Rna Molecules and Methods of Use HAN JANG Oct- Sep Oct-
148
04 -05 08
17- 16- 30-
US20080269
Immunogenic Sars Domain BEADENKOPF ROBERT J Jun- Jun Oct-
115
04 -05 08
29- 9- 30-
US20080267 Modified Viral Particles with Immunogenic Properties and Reduced
Lipid Sciences, Inc. Jun- May Oct-
997 Lipid Content Useful for Treating and Preventing Infectious Diseases
00 -08 08
4- 4- 30-
US20080267 Sars Virus Vaccine with Adenovirus Carrier and Preparation Method
Cancer Center, Sun Yat-Sun University Jun- Jun Oct-
992 Thereof, and Use of Sars Virus S Gene for Preparation of Vaccine
04 -04 08
6- 20- 30-
US20080267 TRANSPORTABLE DECONTAMINATION UNIT AND
BACIK MICHAEL A Mar- Feb Oct-
819 DECONTAMINATION PROCESS
07 -08 08
11- 23-
US20080261 9-Jul-
Immune Cell Biosensors and Methods of Using Same Amaox, Inc. Jul- Oct-
258 04
05 08
20- 20- 23-
US20080261
Fluorescent Proteins and Related Methods and Compounds UNIVERSITY OF MASSACHUSETTS Sep- Sep Oct-
257
04 -05 08
15- 15- 23-
US20080260
New Live Virus Vaccines JOHNSON PHILIP R Feb- Feb Oct-
775
05 -06 08
24- 23- 23-
US20080260
Saccharide Conjugate Vaccines Not Available Dec- Dec Oct-
773
04 -05 08
22- 23-
US20080260 23-
Polypeptides for Oligomeric Assembly of Antigens CAPECCHI BARBARA Jul- Oct-
769 Jul-04
05 08
30- 30- 23-
US20080260
REPLIKIN PEPTIDES AND USES THEREOF BOGOCH ELENORE S May- May Oct-
764
06 -07 08
5- 1- 16-
US20080255
Novel Compounds ASTRAZENECA AB Nov- Nov Oct-
150
05 -06 08
29- 29- 16-
US20080255
Steroid-Derived Pharmaceutical Compositions JadoLabs GmbH Jun- Jun Oct-
076
04 -05 08
31- 29- 16-
US20080254 Anti-Sars Virus Antibody, Hybridoma Producing the Antibody and
FUJII NOBUYUKI Oct- Oct Oct-
440 Immunoassay Reagent Using the Antibody
03 -04 08
PCR PRIMER SET DETECTING SEVERE ACUTE RESPIRATORY 12- 21- 14-
US20080194
SYNDROME (SARS)-CORONAVIRUS, METHOD AND KIT FOR SAMSUNG ELECTRONICS CO., LTD. Dec- Apr Aug
422
DETECTING SARS-CORONAVIRUS USING THE SAME 03 -08 -08
20- 20- 7-
US20080188 Heterocyclic Derivatives and Their Use as Stearoyl-Coa Desaturase
XENON PHARMACEUTICALS INC. Sep- Sep Aug
488 Inhibitors
04 -05 -08
3- 18- 7-
US20080187 Methods and apparatus to prevent, treat, and cure the symptoms of
VAIL MARILYN L Apr- Mar Aug
609 nausea caused by chemotherapy treatments of human cancers
00 -08 -08
6- 6- 17-
US20080172 Method to Decrease the Risk of a Vaccine-Induced Chronic Immune
CLASSEN IMMUNOTHERAPIES Apr- Apr Jul-
247 Mediated Disorder in Humans With a Family History of the Disorder
04 -05 08
Reagents, Devices, and Methods For Proteomic Analysis With 21- 19- 17-
US20080171
Applications Including Diagnostics, Vaccines, Quality Control and NETWORK IMMUNOLOGY INC. Apr- Apr Jul-
057
Research 04 -05 08
30- 17-
US20080170 28-
Compositions and Methods for Stimulation of Lung Innate Immunity The Board of Regents of the University of Texas System Jul- Jul-
996 Jul-06
07 08
18- 10-
US20080167 19-
Novel Compounds 243 ELKINS BARRY Jul- Jul-
332 Jul-06
07 08
20- 20- 10-
US20080167
Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase XENON PHARMACEUTICALS INC. Sep- Sep Jul-
321
04 -05 08
4- 4- 10-
US20080167
Filter based detection system COONEY CHRISTOPHER GERARD Jan- Jan Jul-
198
07 -07 08
4- 4- 10-
US20080166 Sorting, amplification, detection, and identification of nucleic acid
The Regents of the University of California Jan- Jan Jul-
793 subsequences in a complex mixture
07 -07 08
24- 10-
US20080166 25-
Immunoassay Method and Immunoassay Kit to Be Used Therein ARKRAY, Inc. Jul- Jul-
701 Jul-05
06 08
26- 25- 10-
US20080166 Immunogenic Compositions Comprising Multiple Gonococcal
CHIRON SRL Jun- Jun Jul-
370 Antigens
03 -04 08
9- 11- 3-
US20080160 Peptide That Elicits Neutralizing Antibodies Targeting the Hiv Co-
The Government of the United States of America as Apr- Apr Jul-
010 Receptor
04 -05 08
19- 19- 3-
US20080159 Use of Inhibitors of the Renin-Angiotensin System for the Treatment IMBA-INSTITUTE FUR MOLEKULARE BIOTECHNOLOGIE
May- May Jul-
962 of Lung Injuries GMBH
05 -06 08
27- 27- 3-
US20080156 HAZARDOUS SUBSTANCE REMOVING MATERIAL, METHOD FOR
FUJIFILM Corporation Dec- Dec Jul-
743 REMOVING HAZARDOUS SUBSTANCES, AND NONWOVEN FABRIC
06 -07 08
20- 20- 8-
US20080108 Heterocyclic Derivatives for the Treatment of Diseases Mediated by
XENON PHARMACEUTICALS INC. Sep- Sep May
629 Stearoyl-Coa Desaturase Enzymes
04 -05 -08
8- 7- 8-
US20080107 METHOD FOR TREATING INFLAMMATORY DISEASES OF THE
Gene Logic Inc. Sep- Sep May
650 DIGESTIVE TRACT
06 -07 -08
30- 11- 1-
US20080103
Systems and methods for pathogen detection and response Searete LLC, a limited liability corporation Nov- Sep May
746
05 -07 -08
15- 1-
US20080102 6-Jul-
METHODS AND COMPOSITIONS FOR DETECTING RHINOVIRUSES Focus Technologies, Inc. Oct May
444 04
-07 -08
5- 24-
US20080096 7-Jul-
Durable Biocides and Disinfectants MITSUI NORIN CO., LTD. Jul- Apr-
959 04
05 08
PCR PRIMER SET FOR DETECTING SEVERE ACUTE RESPIRATORY 12- 24- 24-
US20080096
SYNDROME (SARS)-CORONAVIRUS, METHOD AND KIT FOR HWANG JUNG-JOO Dec- Nov Apr-
186
DETECTING SARS-CORONAVIRUS USING THE SAME 03 -04 08
16- 17-
US20080015 17-
QUERCETIN-CONTAINING COMPOSITIONS LINES THOMAS C Jul- Jan-
247 Jul-06
07 08
20- 20- 17-
US20080015 HETEROCYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC
XENON PHARMACEUTICALS INC. Sep- Sep Jan-
230 AGENTS
04 -05 08
23- 23- 17-
US20080015 METHODS AND COMPOSITIONS OF TARGETED DRUG
Joseph Errico Jan- Jan Jan-
194 DEVELOPMENT
06 -07 08
14- 14- 17-
US20080015 Urea Substituted Imidazopyridines, Imidazoquinolines, and
3M INNOVATIVE PROPERTIES COMPANY Jun- Jun Jan-
184 Imidazonaphthyridines
04 -05 08
11- 10- 17-
US20080014
Compositions Against Sars-Coronavirus and Uses Thereof DE KRUIF CORNELIS A Nov- Nov Jan-
204
04 -05 08
24- 28- 17-
US20080014 Anticancer Agent Containing Dendritic Cell Having Rna Virus
DNAVEC RESEARCH INC. Jun- Apr Jan-
183 Transferred Thereinto
04 -05 08
19- 27- 10-
US20080009
MUTAGENIC HETEROCYCLES Koronis Pharmaceuticals, Inc. Dec- Dec Jan-
496
03 -06 08
29- 20- 10-
US20080009
ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS Baxter Healthcare Corporation Oct- Sep Jan-
040
04 -07 08
6- 7- 3-
US20080004 High Dose, Short Interval Use of Sulfated Polysaccharides for
COMPER WAYNE D Feb- Feb Jan-
236 Treatment of Infections
04 -05 08
9- 25- 3-
US20080004
New Expression Tools for Multiprotein Applications BERGER IMRE Mar- Nov Jan-
228
04 -04 08
Rna Interference Mediated Inhibition of Severe Acute Respiratory 15- 13- 22-
US20070270
Syndrome (Sars) Gene Expression Using Short Interfering Nucleic SIRNA THERAPEUTICS, INC. Apr- Apr Nov
360
Acid 03 -04 -07
8- 8- 9-
US20070185
Modulation of ace2 expression BENNETT C F Mar- Mar Aug
044
05 -05 -07
28- 9- 9-
US20070185 ANTIVIRAL AGENTS FOR THE TREATMENT, CONTROL AND
SEQUOIA PHARMACEUTICALS, INC. Apr- Nov Aug
027 PREVENTION OF INFECTIONS BY CORONAVIRUSES
03 -06 -07
17- 17- 9-
US20070184
Compositions for use in identification of influenza viruses ESHOO MARK W Oct- Oct Aug
434
05 -06 -07
5- 5- 2-
US20070178 Method and diagnostic tests based on flow cytometric analysis of
AGRATI CHIARA Aug- Aug Aug
533 antigen-specific t lymphocytes
03 -04 -07
3- 3- 2-
US20070178
Promoter engineering and genetic control ALPER HAL S Jan- Jan Aug
505
06 -07 -07
12- 2- 2-
US20070178
Antiviral composition comprising p-menthane-3,8-diol CLARKE PAUL D Mar- Mar Aug
048
04 -05 -07
20- 22- 26-
US20070173 Methods of treating or preventing peritonitis with oxidative
Oculus Innovative Sciences, Inc. Jan- Jan Jul-
755 reductive potential water solution
06 -07 07
20- 11- 26-
US20070173
Compositions and methods for preventing infection JOLLA BIOSCIENCES LLC Sep- Dec Jul-
481
02 -06 07
22- 26-
US20070172 8-Jul-
Methods of Producing Antibodies for Diagnostics and Therapeutics CHANG XIAO-JIA Nov Jul-
817 03
-06 07
8- 7- 26-
US20070172
Method for detecting the specificity of activated lymphocyte HU JUN Dec- Dec Jul-
448
03 -04 07
29- 22- 19-
US20070167 Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane
CELEBI AZIM A Dec- Dec Jul-
476 fused imidazo ring compounds
03 -04 07
19- 19- 19-
US20070167 NOVEL ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED
ZENTARIS GmbH Dec- Dec Jul-
408 CYTOTOXICITY AND USES THEREOF
05 -06 07
5- 5- 19-
US20070166
Methods for detecting parvovirous infections BLUTH MARTIN H May- May Jul-
823
03 -04 07
15- 15- 19-
US20070166
Combination approaches for generating immune responses BARNETT SUSAN W Sep- Sep Jul-
784
03 -04 07
9- 8- 19-
US20070166 Methods , composition and preparations for delivery of immune
ZARRAGA ISIDRO ANGELO E Apr- Apr Jul-
384 response modifiers
04 -05 07
21- 22- 19-
US20070166 Chloroquine coupled antibodies and other proteins with methods for
KOSAK KENNETH M Aug- Feb Jul-
281 their synthesis
04 -07 07
24- 23- 12-
US20070160
VIRAL PROTEASE CHEN XIN Oct- Oct Jul-
981
05 -06 07
4- 3- 5-
US20070155
Sulfone substituted imidazo ring ethers DELLARIA JOSEPH F JR Dec- Dec Jul-
767
03 -04 07
30- 16- 5-
US20070155
Boron-containing small molecules Anacor Pharmaceuticals Dec- Aug Jul-
699
05 -06 07
26- 5-
US20070155 Artificial cpg single-stranded oligodeoxynucleotide and antiviral use 25-
WANG LIYING Jul- Jul-
683 thereof Jul-03
04 07
29- 7- 5-
US20070154 Supports for assaying analytes and methods of making and using
FRUTOS ANTHONY G Dec- Jun Jul-
348 thereof
05 -06 07
8- 7- 28-
US20070149 MAYO FOUNDATION FOR MEDICAL EDUCATION AND
Antiviral Compositions and Methods Nov- Nov Jun-
487 RESEARCH
05 -06 07
28- 25- 28-
US20070148
Methods for detecting conformational changes in bioentities O'MALLEY SHAWN M Dec- Oct Jun-
670
05 -06 07
25- 25- 21-
US20070141 Biomimetic Biodetector of Toxins, Viruses, Bacteria, and Biological
HARMON H J Oct- Oct Jun-
597 Factors
05 -06 07
16- 26- 21-
US20070141
Treating severe acute respiratory syndrome HEMISPHERx BIOPHARMA May- Jan Jun-
080
03 -07 07
9- 7- 21-
US20070141
Treatment of inflammatory respiratory diseases Schering Aktiengesellschaft May- May Jun-
053
03 -04 07
2- 14-
US20070136 3-Jul-
Expression of a recombinant transgene Board of Trustees Operating Michigan State University Jul- Jun-
890 03
04 07
8- 8- 14-
US20070135 Novel inhibitors of cysteine proteases, the pharmaceutical
BOISSY GUILLAUME Dec- Dec Jun-
439 compositions thereof and their therapeutic applications
05 -05 07
Isoflavone derivatives of tectoridin, the preparation thereof and the 15- 14- 31-
US20070123
anti-virus medicines containing the same as an effective CHENGDU DIKANG PHARMACEUTICAL INSTITUTE May- May May
566
constituents 03 -04 -07
29- 10- 8-
US20070031 Modified viral particles with immunogenic properties and reduced
CHAM BILL E Jun- Apr Feb
923 lipid content useful for treating and preventing infectious diseases
00 -06 -07
5- 20- 8-
US20070031 Methods of constructing biodiverse gene fragment libraries and
Phylogica Limited May- Feb Feb
832 biological modulators isolated therefrom
99 -04 -07
23- 23- 8-
US20070031
Assay cartridges and methods for point of care instruments BLANKFARD MARTIN Jun- Jun Feb
283
05 -06 -07
9- 8- 1-
US20070027
Albumin fusion proteins HASELTINE WILLIAM A Feb- Aug Feb
306
04 -06 -07
11- 6- 1-
US20070026 Methods and compositions for identifying chemical or biological
GHC TECHNOLOGIES INC Apr- Apr Feb
391 agents using multiplexed labeling and colocalization detection
05 -06 -07
16- 31- 1-
US20070026
Anti-coronavirus agent Toagosei Co., Ltd. Oct- Oct Feb
087
03 -03 -07
17- 6- 1-
US20070026
Interferon beta in severe acute respiratory syndrome (sars) ARES TRADING S.A. Apr- Apr Feb
014
03 -04 -07
27- 16- 1-
US20070026 Systems and methods for identifying replikin scaffolds and uses of
BOGOCH ELENORE S Mar- Feb Feb
009 said replikin scaffolds
01 -06 -07
19- 13- 1-
US20070025
INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES MAXYGEN, INC. May- Sep Feb
966
04 -06 -07
25- 25-
US20070021 Methods of reducing risk of infection from pathogens with soluble 25-
PARION SCIENCES INC Jul- Jan-
439 amide and ester pyrazinoylguanidine sodium channel blockers Jul-05
05 07
9- 25- 25-
US20070021
Composition and its Therapeutic Use INSIGNION HOLDINGS LTD AND VER Aug- Sep Jan-
326
02 -06 07
19- 13- 25-
US20070020
INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES MAXYGEN, INC. May- Sep Jan-
734
04 -06 07
19- 13- 25-
US20070020
INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES MAXYGEN, INC. May- Sep Jan-
235
04 -06 07
19- 2- 18-
US20070015
System and methods for nucleic acid and polypeptide selection WILLIAMS RICHARD B May- May Jan-
181
00 -06 07
Integration of fluids and reagents into self-contained cartridges 27- 22- 16-
US20060257
containing particle-based sensor elements and membrane-based ANSLYN ERIC Feb- Dec Nov
991
sensor elements 04 -04 -06
6- 7- 16-
US20060257 Methods and kits for propagating and evolving nucleic acids and
RNA LINE OY Jun- Jun Nov
976 proteins
03 -04 -06
2- 2- 16-
US20060257 Methods and apparatus for detecting cardiac injury markers using
BioScale, Inc. May- May Nov
945 an acoustic device
05 -06 -06
27- 22- 16-
US20060257 Integration of fluids and reagents into self-contained cartridges
ANSLYN ERIC Feb- Dec Nov
941 containing particle and membrane sensor elements
04 -04 -06
21- 21- 16-
US20060257 Method for isolating intracellular antibodies able to neutralize
LINE GENOMICS S.P.A. Nov- Nov Nov
925 protein interactions
02 -03 -06
24- 16-
US20060257 Methods for identifying small molecules that modulate premature 24-
ALMSTEAD NEIL G Jul- Nov
866 translation termination and nonsense mediated mrna decay Jul-02
03 -06
12- 12- 16-
US20060257 Screening assay for inhibitors of severe acute respiratory syndrome
Wright State University May- May Nov
861 (SARS) using SELDI-TOF Mass Spectrometry
05 -06 -06
27- 22- 16-
US20060257
Membrane assay system including preloaded particles BALLARD KARRI L Feb- Dec Nov
854
04 -04 -06
10- 9- 16-
US20060257
Severe acute respiratory syndrome coronavirus Chiron Corporation Apr- Apr Nov
852
03 -04 -06
Reagents, devices and methods for proteomic analysis with 21- 16- 24-
US20060190
applications including diagnostics, vaccines, quality control and HOFFMANN GEOFFREY W Apr- Mar Aug
189
research 04 -06 -06
Nucleic acid primer set, nucleic acid probe set and method for 23- 23- 10-
US20060177
detecting respiratory disease virus using the primer set and probe HUH NAM Dec- Dec Aug
849
set 04 -05 -06
Synthetic peptide targeting critical sites on the SARS-associated 22- 28- 25-
US20060110
coronavirus spike protein responsible for viral infection and method UNIV HONG KONG Nov- Oct May
758
of use thereof 04 -05 -06
Method of removing hazardous substance, and hazardous substance 28- 26- 27-
US20060088
removing material using the same such as air cleaning filter, mask DAIKIN IND LTD Mar- Mar Apr-
926
and wipping sheet, and method of storing the same 03 -04 06
30- 28- 9-
US20060051 Feline infectious peritonitis (FIP) and systemic multi-organ
AUSTIN KIMBERLY M Jun- Jun Mar
744 coronavirus biomarkers and screening methods
04 -05 -06
28- 28- 9-
US20060051
Compositions and methods for mucosal vaccination 3M Innovative Properties Company Apr- Apr Mar
374
04 -05 -06
13- 15- 16-
US20060035
Benzothiazolium compounds LEE SHIOW-JU Aug- Aug Feb
926
04 -05 -06
16- 6- 16-
US20060035
Treating severe and acute viral infections HEMISPHERx BIOPHARMA May- Oct Feb
859
03 -05 -06
7- 7- 16-
US20060035 Methods for tailoring the immune response to an antigen or
Biomedical Research Models, Inc. Jan- Jan Feb
853 immunogen
04 -05 -06
26- 10- 16-
US20060035
Recombinant super-compound interferon and uses thereof WEI GUANGWEN Aug- Mar Feb
327
04 -05 -06
16- 16-
US20060034 Novel human virus causing respiratory tract infection and uses 21-
CHAN KWOK H May Feb
853 thereof Jul-04
-05 -06
7- 18- 2-
US20060024 Coronavirus, nucleic acid, protein, and methods for the generation
HOEK CORNELIA V D Jan- Aug Feb
668 of vaccine, medicaments and diagnostics
04 -04 -06
15- 13- 2-
US20060024 Treatments for viral infections using IFN cytokines and ribavirin,
ALIBEK KEN Jan- Jan Feb
271 alone or in combination
04 -05 -06
14- 26-
US20060019 22-
Methods for treating Hepatitis C CHEN GUANGMING Jul- Jan-
976 Jul-04
05 06
20- 26-
US20060019 21-
SARS CoV main protease inhibitors HSIEH HSING-PANG Jul- Jan-
967 Jul-04
05 06
14- 14- 26-
US20060019
Anti-viral uses of borinic acid complexes BELLINGER-KAWAHARA CAROLYN Jun- Jun Jan-
927
04 -05 06
18- 26-
US20060019 18-
Methods and compositions for inducing innate immune responses Coley Pharmaceutical Group, Ltd. Jul- Jan-
923 Jul-04
05 06
21- 26-
US20060018 Novel human virus causing respiratory tract infection and uses 21-
CHAN KWOK H Jul- Jan-
923 thereof Jul-04
04 06
29- 29- 26-
US20060018
Intradermal delivery of vacccines and therapeutic agents ALARCON JASON B Jun- Apr Jan-
877
01 -05 06
22- 7- 19-
US20060014
Albumin fusion proteins Human Genome Sciences, Inc. Jan- Jul- Jan-
254
03 05 06
16- 9- 12-
US20060009
Pyridazine derivatives and their use as therapeutic agents ABREO MELWYN Mar- Feb Jan-
459
04 -05 06
6- 12-
US20060008 6-Jul-
Methods and compositions for detecting rhinoviruses Focus Technologies, Inc. Jul- Jan-
810 04
04 06
8- 12-
US20060008 8-Jul-
Room decontamination with hydrogen peroxide vapor STERIS INC. Jul- Jan-
379 04
04 06
27- 26- 12-
US20060006
Door handle cover HERRON ROY H JR May- May Jan-
678
04 -05 06
25- 25- 5-
US20060003 Peptides and peptidomimetics having immune-modulating, anti-
KAWABE TAKUMI Jun- Jun Jan-
941 inflammatory, and anti-viral activity
03 -04 06
29- 28- 5-
US20060003
Mass tag PCR for mutliplex diagnostics BRIESE THOMAS Apr- Apr Jan-
352
04 -05 06
30- 29- 5-
US20060003 Methods and kits for identifying target nucleotides in mixed
Applera Corporation Apr- Apr Jan-
351 populations
04 -05 06
Reagents, devices and methods for proteomic analysis with 21- 4- 27-
US20050240
applications including diagnostics, vaccines, quality control and Apr- Feb Oct-
353
research 04 -05 05
8- 27- 21-
US20050158 Methods and apparatus to prevent, treat, and cure the symptoms of
VAIL MARILYN L. Dec- Nov Jul-
411 nauea caused by chemotherapy treatments of human cancers
03 -04 05
2- 26-
US20050114 Transgenic mice having a human major histocompatibility complex 30-
AURIAULT CLAUDE Jul- May
910 (MHC) phenotype, experimental uses and applications Jul-03
04 -05
3- 3- 26-
US20050112 Cytidine deaminase activators, deoxycytidine deaminase activators,
DEWHURST STEPHEN Sep- Sep May
555 Vif antagonists, and methods of screening for molecules thereof
03 -04 -05
9- 26-
US20050112 Characterization of the earliest stages of the severe acute 9-Jul-
HENG XU RUI Jul- May
554 respiratory syndrome (SARS) virus and uses thereof 04
04 -05
12- 19-
US20050107 12-
Modulation of CEACAM1 expression BENNETT C. F. Jul- May
324 Jul-03
04 -05
8- 8- 19-
US20050106
Epitope profiles of SARS coronavirus Sep- Sep May
563
03 -04 -05
28- 5- 12-
US20050101
Therapeutic treatment methods 2 AHLEM CLARENCE N. Aug- Dec May
581
02 -03 -05
28- 26- 12-
US20050100 Compositions and methods for the treatment of severe acute
BAKER BRENDA F. Apr- Apr May
885 respiratory syndrome (SARS)
03 -04 -05
12- 12- 12-
US20050100
Peptide-based diagnostic reagents for SARS CHANG TSENG Y. Nov- Nov May
883
03 -03 -05
7- 10- 12-
US20050100
Virucidal activities of cetylpyridinium chloride ViraTox, L.L.C. Nov- Sep May
612
03 -04 -05
31- 1- 5-
US20050096
Neutrophil activation by immune response modifier compounds Oct- Nov May
259
03 -04 -05
28- 5-
US20050095 Compositions and methods for diagnosing and treating severe acute 29-
The Chinese University of Hong Kong Jul- May
618 respiratory syndrome (SARS) Jul-03
04 -05
3- 3- 5-
US20050095 Compositions and methods for detecting severe acute respiratory
Diagnostic Hybrids, Inc. Nov- Nov May
582 syndrome coronavirus
03 -03 -05
25- 25- 3-
US20050048
Immunostimulatory combinations and treatments 3M Innovative Properties Company Aug- Aug Mar
072
04 -04 -05
27- 27- 17-
US20050039
Imageable animal model of SARS infection XU MINGXU May- May Feb
220
04 -04 -05
14- 14- 17-
US20050037 Method and means for detection of severe acute respiratory
TSENG KUO-TANG Aug- Aug Feb
338 syndrome
03 -03 -05
9- 9- 17-
US20050036
Methods of treating lung diseases Arizeke Pharmaceuticals, Inc. Jan- Jan Feb
951
04 -04 -05
19- 19- 6-
US20050004 Inhibition of SARS-associated coronavirus (SCoV) infection and
GUAN YI May- May Jan-
063 replication by RNA interference
04 -04 05
1- 6-
US20050003 1-Jul-
Assay system and methods for detecting SARS-CV AsiaGEN Corporation Jul- Jan-
340 03
03 05
4- 4- 6-
US20050002
SARS-coronavirus virus-like particles and methods of use HEROLD JENS May- May Jan-
953
04 -04 05
15- 15- 6-
US20050002 Combinations and kits for cancer treatment using selected
Board of Regents, The University of Texas System Aug- Aug Jan-
941 antibodies to aminophospholipids
03 -03 05
15- 18- 6-
US20050002
Hematopoietic stem cell gene therapy Monash University Apr- Apr Jan-
913
99 -03 05
30- 30- 6-
US20050002 Compositions and methods for treating coronavirus infection and
BLATT LAWRENCE M. Mar- Mar Jan-
901 SARS
04 -04 05
29- 29- 30-
US20040265
Compositions for enhancing transport of molecules into cells IVERSEN PATRICK L. Apr- Apr Dec
879
04 -04 -04
23- 23- 30-
US20040265
Methods and kits for detecting SARS-associated coronavirus BRIESE THOMAS Jan- Jan Dec
796
04 -04 -04
15- 15- 30-
US20040265 Liposomes coated with selected antibodies that bind to
HUANG XIANMING Aug- Aug Dec
367 aminophospholipids
03 -03 -04
9- 9- 30-
US20040265
Methods and compositions for enhancing immune response KEDL ROSS M. Apr- Apr Dec
351
04 -04 -04
27- 27- 23-
US20040259 Inhibiting Coronaviridae viral replication and treating Coronaviridae
CARROLL STEVEN S. Apr- Apr Dec
934 viral infection with nucleoside compounds
04 -04 -04
15- 30- 23-
US20040259
Disease prevention by reactivation of the thymus Monash University Apr- Dec Dec
803
99 -03 -04
9- 9- 23-
US20040258
Delivery of immune response modifier compounds JING NAIYONG Apr- Apr Dec
698
04 -04 -04
26- 26- 16-
US20040253 Microporous materials, methods of making, using, and articles
DURTSCHI JACOB May- May Dec
624 thereof
04 -04 -04
13- 21- 16-
US20040253
Anti-atypical pneumonia decoction HU XIN YUAN Jun- Jul- Dec
328
03 03 -04
15- 30- 2-
US20040241
Stimulation of thymus for vaccination development Monash University Apr- Dec Dec
842
99 -03 -04
2- 2- 2-
US20040237 Protecting shield for performing the insertion of a tube during
YANG JUI KUANG Jun- Jun Dec
198 emergency rescuing or anesthesia
03 -03 -04
27- 27- 25-
US20040235 Inhibitors of severe acute respiratory syndrome (SARS) 3C-like
Agouron Pharmaceuticals, Inc. Apr- Apr Nov
952 proteinase
04 -04 -04
Sensitive diagnostic testing methodology using multiplex real time 22- 22- 18-
US20040229
PCR with one dye (MOD) and its use as in severe acute respiratory YEUNG WAH HIN ALEX Aug- Aug Nov
211
syndrome (SARS) 03 -03 -04
5- 5- 4-
US20040220
Inhibiting viral infections SCEUSA NICHOLAS A. Nov- Nov Nov
139
03 -03 -04
15- 15- 4-
US20040219
Selected immunoconjugates for binding to aminophospholipids RAN SOPHIA Aug- Aug Nov
155
03 -03 -04
9- 9- 28-
US20040214 Surface sanitizing compositions with improved antimicrobial
Xantech Pharmaceuticals, Inc. Mar- Mar Oct-
785 performance
04 -04 04
15- 15- 28-
US20040214 Anti-viral treatment methods using phosphatidylethanolamine-
HE JIN Aug- Aug Oct-
764 binding peptide derivatives
03 -03 04
15- 15- 28-
US20040213 Methods for treating viral infections using immunoconjugates to
RAN SOPHIA Aug- Aug Oct-
779 aminophospholipids
03 -03 04
22- 22- 21-
US20040209
Compositions and methods for preventing infection HILDRETH JAMES E. Sep- Sep Oct-
844
03 -03 04
16- 16- 21-
US20040208
Human monoclonal antibodies against interleukin 8 (IL-8) GENMAB A/S Dec- Dec Oct-
873
03 -03 04
15- 15- 21-
US20040208
Selected antibody CDRs for binding to aminophospholipids Board of Regents, The University of Texas System Aug- Aug Oct-
868
03 -03 04
5- 5- 14-
US20040204
Compounds for modulating RNA interference RANA TARIQ M. Aug- Aug Oct-
420
03 -03 04
9- 9- 14-
US20040202 Delivery of immune response modifier compounds using metal-
3M Innovative Properties Company Apr- Apr Oct-
720 containing particulate support materials
04 -04 04
24- 24- 30-
US20040191 Selective activation of cellular activities mediated through a
3M Innovative Properties Company Mar- Mar Sep
833 common toll-like receptor
04 -04 -04
29- 29- 23-
US20040184
Building decontamination with vaporous hydrogen peroxide STERIS INC. Jan- Jan Sep
950
04 -04 -04
13- 13- 16-
US20040180 Proteome epitope tags and methods of use thereof in protein
engeneOS, Inc. Nov- Nov Sep
380 modification analysis
03 -03 -04
5- 5- 9-
US20040176
1-Amino 1H-imidazoquinolines 3M Innovative Properties Company Mar- Mar Sep
367
04 -04 -04
15- 9-
US20040175 Selected antibody compositions and methods for binding to 15-
Board of Regents, The University of Texas System Jul- Sep
378 aminophospholipids Jul-03
03 -04
12- 12- 2-
US20040171
Antiviral oligonucleotides targeting HIV Replicor, Inc. Sep- Sep Sep
568
03 -03 -04
27- 27- 2-
US20040171
Selective modulation of TLR-mediated biological activity 3M Innovative Properties Company Feb- Feb Sep
086
04 -04 -04
30- 30- 2-
US20040170
Mixed cell diagnostic systems GOODRUM PATRICIA GAIL RAY Mar- Mar Sep
965
04 -04 -04
11- 12- 2-
US20040170
Methods for identifying antiviral oligonucleotides Replicor, Inc. Sep- Sep Sep
959
03 -03 -04
29- 20- 2-
US20040170 Method of treating and preventing infectious diseases via creation of
CHAM BILL E. Jun- Jun Sep
649 a modified viral particle with immunogenic properties
00 -03 -04
15- 2-
US20040170 15-
Selected antibody compositions for binding to aminophospholipids RAN SOPHIA Jul- Sep
620 Jul-03
03 -04
20- 26- 26-
US20040167 Method of treating or inhibiting the development of brain
NOZAKI MASAKO May- Nov Aug
161 inflammation and sepsis
03 -03 -04
Methods and apparatus to prevent, treat and cure infections of the 2- 2- 15-
US20040009
human respiratory system by pathogens causing severe acute VAIL MARILYN L. May- May Jan-
245
respiratory syndrome (SARS) 03 -03 04
24- 24- 4-
US20030224 Antisense antiviral agent and method for treating ssRNA viral
IVERSEN PATRICK L. Apr- Apr Dec
353 infection
03 -03 -03
24- 19- 2-
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-
US10669245 ASTRAZENECA AB Jan- Mar Jun-
carboxamides dipeptidyl peptidase 1 inhibitors
14 -19 20
1- 1- 19-
US10655108 Cell-derived viral vaccines with low levels of residual cell DNA Seqirus UK Limited Nov- Nov May
05 -06 -20
29- 29- 19-
US10655099 Animal protein-free media for cultivation of cells Baxalta GmbH Oct- Oct May
04 -18 -20
20- 20- 19-
Recombinant human/bovine parainfluenza virus 3 (B/HPIV3) The United States of America, as represented by the
US10654898 Jan- Jan May
expressing a chimeric RSV/BPIV3 F protein and uses thereof Secretary, Department of Health and Human Serices
15 -16 -20
29- 20- 12-
Tissue preferential codon modified expression cassettes, vectors
US10647998 The Trustees of the University of Pennsylvania Apr- Jun May
containing same, and uses thereof
13 -17 -20
26- 22- 12-
US10647781 Generation of binding molecules Merus N.V. Sep- Nov May
11 -17 -20
13- 2- 12-
Compositions comprising AAV expressing dual antibody constructs
US10647758 THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA May- Jul- May
and uses thereof
14 19 -20
4- 11- 12-
Vaccines and immunotherapeutics using IL-28 and compositions and
US10646563 THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Apr- Sep May
methods of using
08 -18 -20
10- 12-
Methods for inducing an immune response via buccal and/or 26-
US10646438 BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM May May
sublingual administration of a vaccine Jul-10
-17 -20
24- 21- 5-
Systems and methods for distinguishing optical signals of different
US10641707 Gen-Probe Incorporated Feb- Mar May
modulation frequencies in an optical signal detector
11 -14 -20
7- 24- 5-
US10640788 CRISPR-related methods and compositions with governing gRNAs Editas Medicine, Inc. Nov- Jan May
13 -19 -20
22- 21- 5-
US10640785 Virus vectors for highly efficient transgene delivery The Children's Hospital of Philadelphia Nov- Nov May
11 -12 -20
10- 7- 5-
Method for propagating adenoviral vectors encoding inhibitory gene
US10640776 GenVec, Inc. Nov- Sep May
products
05 -17 -20
31- 16- 5-
US10640763 Molecular indexing of internal sequences Cellular Research, Inc. May- May May
16 -17 -20
16- 9- 28-
The United States of America, as represented by the
US10633447 Soluble engineered monomeric Fc Mar- May Apr-
Secretary, Department of Health and Human Services
12 -17 20
7- 28-
28-
US10632133 Anti-viral azide containing compounds LIFE TECHNOLOGIES CORPORATION Dec Apr-
Jul-10
-17 20
7- 27- 21-
US10626415 Method of increasing the function of an AAV vector The Trustees of the University of Pennsylvania Apr- Oct Apr-
05 -17 20
24- 25- 21-
Commonwealth Scientific and Industrial Research
US10626379 Production of viruses in cell culture Nov- Jan Apr-
Organisation
15 -19 20
11- 8- 14-
US10619186 Methods and compositions for library normalization Cellular Research, Inc. Sep- Sep Apr-
15 -16 20
10- 5- 14-
US10619153 TAL effector-mediated DNA modification Iowa State University Research Foundation, Inc. Dec- Oct Apr-
09 -17 20
9- 17- 14-
US10617677 Nuclear transport modulators and uses thereof Biogen MA Inc. May- Jul- Apr-
12 18 20
26- 21- 7-
Descriptive measurements and quantification of staining artifacts for
US10614284 Ventana Medical Systems, Inc. May- Nov Apr-
in situ hybridization
15 -17 20
28- 27- 7-
Non-human primate-derived pan-ebola and pan-filovirus monoclonal
US10611827 INTEGRATED BIOTHERAPEUTICS, INC. Oct- Oct Apr-
antibodies directed against envelope glycoproteins
14 -15 20
16- 7-
31-
US10610584 Reverse genetics systems Seqirus UK Limited Oct Apr-
Jul-09
-17 20
3- 7- 7-
Cytokine conjugates for the treatment of proliferative and infectious
US10610571 SYNTHORX, INC. Aug- Jun Apr-
diseases
17 -19 20
27- 27- 31-
US10605808 Antibody producing non-human animals Merus N.V. Jun- Apr Mar
08 -16 -20
8- 21- 31-
US10604729 Liquid loading composition, method of making and use thereof DEVMAR PRODUCTS, LLC Sep- May Mar
16 -18 -20
30- 25- 31-
US10604574 Oncolytic viral delivery of therapeutic polypeptides ONCORUS, INC. Jun- Oct Mar
16 -18 -20
16- 15- 31-
Anti-dengue virus antibodies, polypeptides containing variant Fc
US10604561 Agency for Science, Technology and Research Sep- Sep Mar
regions, and methods of use
16 -17 -20
30- 30- 31-
FUNDACIÓ INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE
US10604549 Adenovirus comprising an albumin-binding moiety Apr- Apr Mar
BELLVITGE (IDIBELL)
14 -15 -20
29- 29- 4-
US10548971 MERS-CoV vaccine INOVIO PHARMACEUTICALS, INC. Nov- Jun Feb
13 -18 -20
23- 23- 4-
Compositions and methods for modified dendrimer nanoparticle
US10548959 Massachusetts Institute of Technology Sep- Sep Feb
delivery
16 -16 -20
29- 20- 7-
Dendrimer like amino amides possessing sodium channel blocker
US10526292 Parion Sciences, Inc. May- Dec Jan-
activity for the treatment of dry eye and other mucosal diseases
12 -17 20
30- 2- 7-
US10526283 Prodrugs of dithiol mucolytic agents PARION SCIENCES, INC. Apr- May Jan-
15 -16 20
6- 22- 7-
US10525120 Methods and compositions for live attenuated viruses TAKEDA VACCINES, INC. Apr- Jul- Jan-
07 16 20
15- 20- 7-
US10525049 Specific Akt3 inhibitor and uses thereof Augusta University Research Institute, Inc. Jan- May Jan-
16 -19 20
5- 2- 31-
Quinazolinones and azaquinazolinones as ubiquitin-specific protease
US10519130 FORMA Therapeutics, Inc. Feb- Nov Dec
7 inhibitors
15 -18 -19
5- 2- 31-
Quinazolinones and azaquinazolinones as ubiquitin-specific protease
US10519129 FORMA Therapeutics, Inc. Feb- Nov Dec
7 inhibitors
15 -18 -19
5- 2- 31-
Quinazolinones and azaquinazolinones as ubiquitin-specific protease
US10519128 FORMA Therapeutics, Inc. Feb- Nov Dec
7 inhibitors
15 -18 -19
5- 2- 31-
Quinazolinones and azaquinazolinones as ubiquitin-specific protease
US10519127 FORMA Therapeutics, Inc. Feb- Nov Dec
7 inhibitors
15 -18 -19
12- 14- 31-
US10517947 Methods for preparing squalene NOVARTIS AG May- Dec Dec
10 -17 -19
6- 6- 31-
US10517923 Immunosuppressive agents and their use in therapy Norwegian University of Science and Technology Nov- Nov Dec
13 -14 -19
3- 8- 31-
US10517881 Pharmaceutical compositions and methods POP TEST ONCOLOGY LLC Aug- Jan Dec
15 -19 -19
5- 2- 24-
Quinazolinones and azaquinazolinones as ubiquitin-specific protease
US10513508 FORMA Therapeutics, Inc. Feb- Nov Dec
7 inhibitors
15 -18 -19
4- 4- 29-
Liquid immunity induction-promoting composition and vaccine
US10456464 NITTO DENKO CORPORATION Aug- Aug Oct-
pharmaceutical composition that include thrombosis treatment drug
14 -15 19
7- 7- 22-
Cell-free nucleic acids for the analysis of the human microbiome and The Board of Trustees of the Leland Stanford Junior
US10450620 Nov- Nov Oct-
components thereof University
13 -14 19
2- 9- 22-
Carbonic anhydrase IX (G250) antibodies and methods of use
US10450383 DANA-FARBER CANCER INSTITUTE, INC. Dec- May Oct-
thereof
05 -17 19
24- 24- 15-
Active low molecular weight variants of angiotensin converting
US10443049 Northwestern University Jan- Jan Oct-
enzyme 2 (ACE2)
17 -18 19
16- 23- 15-
US10442853 Antibodies and processes for preparing the same TAIGA BIOTECHNOLOGIES, INC. May- Aug Oct-
08 -16 19
22- 7- 8-
US10434158 Combination of vaccination and inhibition of the PD-1 pathway CureVac AG Feb- Feb Oct-
13 -18 19
7- 7- 8-
United States Government as represented by the
US10434116 Methods of treating coronavirus infection Apr- Apr Oct-
Secretary, Department of Health and Human Services
14 -15 19
7- 9- 1-
Helix-grafted proteins as inhibitors of disease-relevant protein-
US10428128 Colorodo State University Research Foundation Nov- Nov Oct-
protein interactions
14 -15 19
4- 7- 1-
Glycolipids and pharmaceutical compositions thereof for use in
US10428102 THE UNIVERSITY OF NOTTINGHAM Apr- Apr Oct-
therapy
14 -15 19
26- 21- 1-
Heterocyclylmethyl-thienouracile as antagonists of the adenosine-
US10428083 BAYER PHARMA AKTIENGESELLSCHAFT Mar- Mar Oct-
A2B-receptor
15 -16 19
17- 8- 1-
US10428027 Sulfinylphenyl or sulfonimidoylphenyl benzazepines Hoffmann La-Roche Inc. Sep- Mar Oct-
15 -18 19
19- 17- 1-
US10426737 Lipids and lipid compositions for the delivery of active agents Novartis AG Dec- Dec Oct-
13 -14 19
19- 11- 24-
US10421991 Rapid epidemiologic typing of bacteria BioFire Diagnostics, LLC May- Nov Sep
08 -15 -19
12- 15- 24-
Double-stranded oligonucleotide molecules to DDIT4 and methods
US10421962 Quark Pharmaceuticals, Inc. Sep- Feb Sep
of use thereof
12 -17 -19
2- 1- 24-
US10420837 Vaccine pharmaceutical composition for transdermal administration NITTO DENKO CORPORATION Oct- Oct Sep
14 -15 -19
12- 11- 24-
US10420685 Mobile clinics Baylor College of Medicine Nov- Nov Sep
14 -15 -19
7- 17-
7-Jul-
US10416171 Influenza potency assays Seqirus UK Limited Jul- Sep
15
16 -19
6- 20- 17-
Exosome-mediated diagnosis of hepatitis virus infections and
US10416161 MOREHOUSE SCHOOL OF MEDICINE Oct- Sep Sep
diseases
08 -16 -19
Amino acid sequences directed against envelope proteins of a virus 5- 17- 10-
US10407492 and polypeptides comprising the same for the treatment of viral Ablynx N.V. Jun- Oct Sep
diseases 08 -17 -19
6- 5- 3-
Cleavage and exchange of major histocompatibility complex ligands
US10400024 SANQUIN REAGENTS B.V. Jun- Jun Sep
employing azobenzene-containing peptides
14 -15 -19
4- 3-
Substituted benzofuranyl and benzoxazolyl compounds and uses 3-Jul-
US10399963 Karyopharm Therapeutics Inc. Dec Sep
thereof 13
-17 -19
16- 3-
12-
US10399941 Conjugates of cell binding molecules with cytotoxic agents HANGZHOU DAC BIOTECH CO., LTD. Apr Sep
Jul-12
-14 -19
29- 29- 3-
US10398795 Decontamination device and method using ultrasonic cavitation TOMI ENVIRONMENTAL SOLUTIONS, INC. Dec- Dec Sep
17 -17 -19
1- 30- 27-
US10393633 Sample fixation and stabilisation RNASSIST LTD. Mar- May Aug
13 -17 -19
13- 27-
14-
US10392613 Purification of nucleic acids using copper-titanium oxides ABBOTT MOLECULAR INC. Jul- Aug
Jul-15
16 -19
29- 11- 27-
US10391188 Decontamination device and method using ultrasonic cavitation TOMI ENVIRONMENTAL SOLUTIONS, INC. Dec- Sep Aug
17 -18 -19
3- 2- 27-
US10391167 Mucosal vaccine composition NITTO DENKO CORPORATION Oct- Oct Aug
13 -14 -19
14- 13- 27-
US10391160 Dimethyl fumarate and vaccination regimens Biogen MA Inc. Mar- Mar Aug
14 -15 -19
2- 2- 20-
Recombinant adeno-associated virus capsids with enhanced human The Board of Trustees of the Leland Stanford Junior
US10385320 Dec- Dec Aug
skeletal muscle tropism University
15 -16 -19
13- 15- 20-
Compositions comprising AAV expressing dual antibody constructs
US10385119 Trustees of the University of Pennsylvania May- Oct Aug
and uses thereof
14 -18 -19
17- 24- 20-
Lipidated immune response modifier compound compositions,
US10383938 3M Innovative Properties Company Aug- Jul- Aug
formulations, and methods
10 18 -19
23- 31- 20-
US10383935 Methods of making and using live attenuated viruses Regents of the University of Minnesota Sep- Oct Aug
15 -17 -19
2- 27- 20-
US10383852 Prevention and treatment of viral infections Not Available Jun- Nov Aug
16 -18 -19
6- 5- 13-
US10378008 Method and apparatus for automated processing of pooled samples GFE BLUT MBH Aug- Aug Aug
14 -15 -19
17- 6- 13-
US10378002 Replication conditional virus that specifically kills senescent cells Kythera Biopharmaceuticals, Inc. Apr- Jul- Aug
12 18 -19
5- 27- 13-
Isothiazolopyrimidinones, pyrazolopyrimidinones, and
US10377773 FORMA Therapeutics, Inc. Feb- Feb Aug
pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
15 -18 -19
5- 1- 13-
US10377767 Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors FORMA Therapeutics, Inc. Feb- Mar Aug
15 -18 -19
5- 7- 6-
Identification of VSIG8 as the putative VISTA receptor (V-R) and
US10370455 IMMUNEXT, INC. Dec- Dec Aug
use thereof to produce VISTA/VSIG8 agonists and antagonists
14 -15 -19
23- 13- 6-
US10370338 Benzazepine dicarboxamide compounds with tertiary amide function Hoffmann-La Roche Inc. May- Nov Aug
16 -18 -19
4- 4- 6-
Composition for enhancing induction of humoral immunity, and
US10369219 NITTO DENKO CORPORATION Aug- Aug Aug
vaccine pharmaceutical composition
14 -15 -19
1- 1- 6-
Polymeric carrier cargo complex for use as an immunostimulating
US10369216 CureVac AG Apr- Apr Aug
agent or as an adjuvant
14 -15 -19
7- 7- 6-
US10369205 Immunomodulatory compositions and methods of use thereof Not Available Jan- Jan Aug
14 -15 -19
2- 2- 6-
US10369204 Molecular vaccines for infectious disease Dako Denmark A/S Oct- Oct Aug
08 -09 -19
11- 11- 30-
US10363303 Microneedle compositions and methods of using same VERNDARI, INC. Jan- Jul- Jul-
16 18 19
29- 12- 30-
US10363282 Analogs of C5a and methods of using same Board of Regents of The University of Nebraska Jun- Jan Jul-
10 -18 19
31- 2- 23-
The United States of America, as represented by the
US10358481 Engineered antibody constant domain molecules Jan- Dec Jul-
Secretary, Department of Health and Human Services
08 -16 19
24- 23- 23-
US10357568 Adjuvant nanoemulsions with phospholipids GLAXOSMITHKLINE BIOLOGICALS S.A. Mar- Mar Jul-
11 -12 19
14- 17- 23-
US10357562 Immunoprotective primary mesenchymal stem cells and methods Autoimmune Technologies, LLC Mar- Jul- Jul-
13 15 19
7- 7- 23-
US10357510 Metal nanoclusters and uses thereof THE REGENTS OF THE UNIVERSITY OF MICHIGAN Aug- Aug Jul-
14 -15 19
30- 24- 16-
Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific
US10351571 FORMA Therapeutics, Inc. Dec- May Jul-
protease 7 inhibitors
14 -18 19
1- 30- 16-
US10350255 Polygonum cuspidatum extracts PhotoDynamic Inc. Oct- Sep Jul-
15 -16 19
6- 5- 9-
US10344320 Capacitive liquid crystal biosensors The Johns Hopkins University May- May Jul-
15 -16 19
18- 29- 9-
US10344263 Synthetic membrane-receiver complexes RUBIUS THERAPEUTICS, INC. Nov- Mar Jul-
13 -17 19
9- 9- 9-
US10344261 Immunomodulatory conjugates ASCEND BIOPHARMACEUTICALS LTD Nov- Nov Jul-
11 -12 19
23- 24- 9-
US10344027 Compositions and methods for inhibiting kinases Inhibikase Therapeutics, Inc. Apr- Oct Jul-
15 -18 19
15- 17- 9-
US10342868 Methods and compositions for inhibiting Akt3 Augusta University Research Institute, Inc. Jan- Jan Jul-
16 -17 19
15- 15- 9-
US10342825 Solution containing hypochlorous acid and methods of using same Sonoma Pharmaceuticals, Inc. Jun- Jun Jul-
09 -10 19
18- 13- 2-
US10336725 Chemical compounds AstraZeneca AB Mar- Dec Jul-
14 -17 19
8- 8- 2-
US10335484 Methods of generating robust passive and active immune responses HUMABS BIOMED SA Jan- Jan Jul-
13 -14 19
9- 4- 2-
US10335393 Nuclear transport modulators and uses thereof Biogen MA Inc. May- Dec Jul-
12 -17 19
14- 10- 2-
Compositions with modified nucleases targeted to viral nucleic acids
US10335372 Jacob G. Appelbaum Apr- Mar Jul-
and methods of use for prevention and treatment of viral diseases
04 -17 19
2- 3- 4-
Chimeric viruses presenting non-native surface proteins and uses
US10308913 Icahn School of Medicine at Mount Sinai Dec- Mar Jun-
thereof
05 -16 19
6- 5- 4-
Optimized human clotting factor VIII gene expression cassettes and
US10308705 The University of North Carolina at Chapel Hill Feb- Feb Jun-
their use
15 -16 19
25- 4-
17-
US10308685 Inhibitory peptides of viral infection UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION May Jun-
Jul-14
-17 19
27- 18- 4-
US10307475 Methods and compositions for immunization against virus Academia Sinica Mar- Feb Jun-
09 -14 19
12- 12- 4-
US10307472 Combination of vaccination and OX40 agonists CureVac AG Mar- Mar Jun-
14 -14 19
24- 2- 4-
US10307439 Substituted nucleosides, nucleotides and analogs thereof Alios Biopharma, Inc. Jun- Feb Jun-
14 -17 19
27- 4-
6-Jul-
US10307434 Nucleic acid prodrugs and methods of use thereof WAVE LIFE SCIENCES LTD. May Jun-
09
-16 19
5- 4-
15-
US10307391 Disulfur bridge linkers for conjugation of a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD. Apr Jun-
Jul-15
-17 19
24- 4-
6-Jul-
US10307374 Oil-in-water emulsions that contain nucleic acids GLAXOSMITHKLINE BIOLOGICALS S.A. Apr Jun-
11
-17 19
17- 1- 28-
Adeno-associated virus (AAV) serotype 8 sequences, vectors
US10301650 The Trustees of the University of Pennsylvania Dec- May May
containing same, and uses therefor
01 -17 -19
7- 18- 28-
US10301648 Method of increasing the function of an AAV vector The Trustees of the University of Pennsylvania Apr- Feb May
05 -15 -19
18- 19- 28-
US10301594 Synthetic membrane-receiver complexes RUBIUS THERAPEUTICS, INC Nov- Nov May
13 -18 -19
18- 19- 28-
US10301593 Synthetic membrane-receiver complexes RUBIUS THERAPEUTICS, INC. Nov- Mar May
13 -18 -19
24- 24- 28-
Middle east respiratory syndrome coronavirus immunogens, The United States of America, as Represented by the
US10301377 Feb- Feb May
antibodies, and their use Secretary, Department of Health and Human Services
15 -16 -19
29- 10- 28-
US10300149 Compositions for enhancing transport of molecules into cells SAREPTA THERAPEUTICS, INC. Apr- Jan May
03 -17 -19
14- 28-
Synthetic nanoparticles for delivery of immunomodulatory 15-
US10300145 Massachusetts Institute of Technology Jul- May
compounds Jul-16
17 -19
20- 21- 28-
US10300127 Immune complex The Rockefeller University Mar- Mar May
15 -16 -19
15- 14- 28-
US10300124 Rodent hepadnavirus cores with reduced carrier-specific antigenicity VLP BIOTECH, INC. Mar- Mar May
13 -14 -19
9- 10- 21-
US10294534 Respiratory infection assay THE SECRETARY OF STATE FOR HEALTH Dec- Dec May
11 -12 -19
14- 1- 21-
Human monoclonal antibody with specificity for dengue virus
US10294293 DSO National Laboratories Dec- Jun May
serotype 1 E protein and uses thereof
10 -16 -19
21- 21-
21-
US10294280 Constrained proteins and uses therefor Monash University Jul- May
Jul-14
15 -19
21- 19- 21-
US10293060 Method for increasing expression of RNA-encoded proteins CureVac AG Aug- Feb May
14 -16 -19
3- 21-
Acetylenedicarboxyl linkers and their uses in specific conjugation of 15-
US10293055 HANGZHOU DAC BIOTECH CO., LTD. Mar May
a cell-binding molecule Jul-15
-17 -19
5- 4- 14-
Substituted pyrimidines containing acidic groups as TLR7
US10287253 APROS THERAPEUTICS, INC. Dec- Dec May
modulators
16 -17 -19
4- 4- 14-
Composition for enhancing induction of humoral immunity, and
US10286067 NITTO DENKO CORPORATION Aug- Aug May
vaccine pharmaceutical composition
14 -15 -19
27- 27- 14-
US10286056 Adjuvant nanoemulsions with crystallisation inhibitors GLAXOSMITHKLINE BIOLOGICALS S.A. Jan- Jan May
11 -12 -19
7- 4- 7-
US10280199 Coronavirus proteins and antigens Phibro Animal Health Corporation Feb- Aug May
14 -16 -19
25- 27- 7-
US10279029 Immunogenic compositions and uses thereof BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Mar- Feb May
15 -18 -19
24- 14- 7-
Compositions and methods for treating and preventing porcine
US10279028 Ohio State Innovation Foundation Apr- Dec May
reproductive and respiratory syndrome
12 -17 -19
2- 6- 7-
US10279027 Transgenic Vero-CD4/CCR5 cell line INTERNATIONAL AIDS VACCINE INITIATIVE Oct- Apr May
15 -17 -19
9- 2- 30-
Means and methods for influencing the stability of antibody ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT
US10273454 Dec- Jun Apr-
producing cells VAN AMSTERDAM
05 -17 19
18- 21- 30-
Hydrocarbon double-stapled stabilized HIV-1 GP41 heptad repeat
US10273290 DANA-FARBER CANCER INSTITUTE, INC. Jun- Sep Apr-
domain peptides
09 -17 19
22- 20- 30-
US10272150 Combination PIV3/hMPV RNA vaccines ModernaTX, Inc. Oct- Jul- Apr-
15 18 19
5- 4- 30-
US10272149 Modified bat influenza viruses and their uses J. CRAIG VENTER INSTITUTE Sep- Sep Apr-
14 -15 19
9- 9- 23-
US10266887 CRISPR effector system based diagnostics MASSACHUSETTS INSTITUTE OF TECHNOLOGY Dec- Mar Apr-
16 -18 19
9- 9- 23-
US10266886 CRISPR effector system based diagnostics MASSACHUSETTS INSTITUTED OF TECHNOLOGY Dec- Mar Apr-
16 -18 19
17- 20- 23-
Adeno-associated virus (AAV) serotype 8 sequences, vectors
US10266846 The Trustees of the University of Pennsylvania Dec- Oct Apr-
containing same, and uses therefor
01 -16 19
2- 2- 23-
Coumarin derivative as antiviral agent, pharmaceutical composition
US10266545 I-NOVA MEDICINSKA ISTRAZIVANJA D.O.O. Feb- Feb Apr-
thereof, its preparation and use
16 -16 19
30- 3- 23-
Adeno-associated virus (AAV) clades, sequences, vectors containing
US10265417 The Trustees of the University of Pennsylvania Sep- Aug Apr-
same, and uses therefor
03 -16 19
15- 10- 23-
US10265407 Modular nanodevices for smart adaptable vaccines Yale University Feb- Nov Apr-
07 -14 19
24- 23- 23-
US10265395 Adjuvant compositions and related methods Not Available Mar- Mar Apr-
15 -17 19
CENTRO DE INVESTIGACION BIOMEDICA EN RED EN 13- 10- 23-
Methods and reagents for efficient and targeted delivery of
US10265371 BIOINGENIERIA BIOMATERIALES Y NANOMEDICINA (CIBER Jan- Jan Apr-
therapeutic molecules to CXCR4 cells
BBN) 11 -17 19
13- 23-
15-
US10265291 Disulfur bridge linkers for conjugation of a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD. Feb Apr-
Jul-15
-17 19
27- 26- 16-
CpG oligonucleotide analogs containing hydrophobic T analogs with
US10260071 COLEY PHARMACEUTICAL GMBH Sep- May Apr-
enhanced immunostimulatory activity
06 -16 19
15- 15- 16-
Anti-pneumococcal hyperimmune globulin for the treatment and
US10259865 ADMA Biologics, Inc. Mar- Mar Apr-
prevention of pneumococcal infection
17 -17 19
23- 4- 16-
Compositions and methods comprising hydrocarbon-stapled
US10259848 DANA-FARBER CANCER INSTITUTE, INC. Jan- May Apr-
polypeptides
08 -16 19
7- 27- 19-
Hand, foot, and mouth vaccines and methods of manufacture and
US10233429 Takeda Vaccines, Inc. Nov- Oct Mar
use thereof
14 -17 -19
16- 16- 19-
CD137 enrichment for efficient tumor infiltrating lymphocyte
US10233425 The Trustees of the University of Pennsylvania Sep- Sep Mar
selection
13 -14 -19
21- 21- 19-
US10233237 Heterodimeric immunoglobulins AMGEN INC. Nov- Nov Mar
12 -13 -19
13- 4- 19-
Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel
US10233158 Parion Sciences, Inc. Dec- Apr Mar
blocking compounds
13 -18 -19
3- 19-
Acetylenedicarboxyl linkers and their uses in specific conjugation of 15-
US10232051 HANGZHOU DAC BIOTECH CO., LTD. Mar Mar
a cell-binding molecule Jul-15
-17 -19
22- 19- 12-
US10227376 Radiolabeled cationic steroid antimicrobials and diagnostic methods BRIGHAM YOUNG UNIVERSITY Aug- Aug Mar
14 -15 -19
4- 17- 12-
US10227373 Enantiomers of the 1′,6′-isomer of neplanocin A Auburn University Aug- May Mar
14 -17 -19
20- 19- 12-
US10226449 Heterocyclic modulators of lipid synthesis and combinations thereof 3-V Biosciences, Inc. Dec- Dec Mar
13 -14 -19
30- 2- 12-
Design, synthesis and methods of use of acyclic fleximer nucleoside Katholieke Universiteit Leuven/Lieden University Medical
US10226434 Jan- Jul- Mar
analogues having anti-coronavirus activity Center, RC Leiden
15 18 -19
8- 9- 5-
Univeersity of Pittsburgh—Of the Commonwealth System
US10222374 B-cell antigen presenting cell assay Apr- Aug Mar
of Higher Education
10 -17 -19
21- 3- 5-
US10221446 Signal propagation biomolecules, devices and methods STC.UNM May- Oct Mar
13 -16 -19
2- 30- 5-
US10220002 Controlled-release peptide compositions and uses thereof BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA Dec- Nov Mar
11 -12 -19
3- 3- 26-
US10213383 Hydrophilic filtration during manufacture of vaccine adjuvants NOVARTIS AG Dec- Dec Feb
09 -10 -19
9- 9- 19-
Chips, detection systems, and methods for multiplex pneumococcus
US10209254 The UAB Research Foundation Oct- Oct Feb
serology
13 -14 -19
4- 19- 19-
US10209248 Multiplex immuno screening assay Institut Pasteur May- Jul- Feb
12 17 -19
28- 28- 19-
RNA virus attenuation by alteration of mutational robustness and
US10206994 INSTITUT PASTEUR Jan- Jan Feb
sequence space
15 -16 -19
Protective masks with coating comprising different electrospun 23- 10- 12-
US10201198 fibers interweaved with each other, formulations forming the same, Profit Royal Pharmaceutical Limited Dec- Dec Feb
and method of producing thereof 14 -15 -19
Nucleic acid comprising or coding for a histone stem-loop and a 15- 21- 1-
US10166283 poly(A) sequence or a polyadenylation signal for increasing the CureVac AG Feb- Mar Jan-
expression of an encoded pathogenic antigen 12 -17 19
29- 1-
31-
US10166255 Intracellular genomic transplant and methods of therapy INTIMA BIOSCIENCE, INC. Jul- Jan-
Jul-15
16 19
8- 17- 25-
Mast cell stabilizers for treatment of hypercytokinemia and viral
US10160796 Emergo Therapeutics, Inc. Sep- Nov Dec
infection
16 -17 -18
15- 20- 25-
US10159731 Methods and compositions for inhibiting Akt3 Augusta University Research Institute, Inc. Jan- Feb Dec
16 -18 -18
13- 12- 25-
US10159729 Antigen and method for production thereof Sallpro Biotech AB Sep- Sep Dec
13 -14 -18
27- 15- 25-
Chemically and metabolically stable dipeptide possessing potent
US10159672 PARION SCIENCES, INC. Jun- Dec Dec
sodium channel blocker activity
11 -17 -18
16- 15- 18-
US10156562 Assay for detecting Th1 and Th2 cell populations AMGEN INC. May- May Dec
14 -15 -18
15- 1- 18-
US10155980 Compositions and methods for detecting rare sequence variants ACCURAGEN HOLDINGS LIMITED Aug- Nov Dec
16 -17 -18
25- 9- 18-
US10155946 Particle-nucleic acid conjugates and therapeutic uses related thereto Emory University Jun- Oct Dec
12 -17 -18
9- 9- 18-
Decreasing potential iatrogenic risks associated with influenza
US10155932 Novartis AG Sep- May Dec
vaccines
04 -16 -18
Human respiratory syncytial virus consensus antigens, nucleic acid 10- 10- 7-
US10040828 constructs and vaccines made therefrom, and methods of using THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Apr- Apr Aug
same 12 -13 -18